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Genome Wide Association Studies (GWAS) have uncovered many genetic regions
which are associated with autoimmune disease risk. In this thesis, I present methods
which I have developed to build upon these studies and enable the analysis of the causal
variants of these diseases.
Colocalization methods disentangle whether potential causal variants are shared or
distinct in related diseases, and enable the discovery of novel associations below the
single-trait significance threshold. However, existing approaches require independent
datasets to accomplish this. I extended two methods to allow for the shared-control
design; one of these extensions also enables fine mapping in the case of shared variants.
My analysis of four autoimmune diseases identified 90 regions associated with at least
one disease, 33 of which were associated with 2 or more disorders; 14 of these had
evidence of distinct causal variants.
Once associated variants have been identified, we may wish to test some aggregate
property, such as enrichment within an annotation of interest. However, the null
distribution of GWAS signals showing association with a trait and preserving expected
correlation due to linkage disequilibrium is complicated. I present an algorithm which
computes the expected output of a GWAS, given any arbitrary definition of “null”, and
hence can be used to simulate the null distribution required for such a test.
Commonly, GWAS report only summary data, and determining which genetic
variants are causal is more difficult; the strongest signal may merely be correlated with
the true causal variant. I have developed a statistical method for fine mapping a
region, requiring only GWAS p-values and publicly available reference datasets. I
sample from the space of potential causal models, rejecting those leading to expected
summary data excessively different from that observed. This removes the need for the
assumption of a single causal variant. In contrast to other summary statistic methods
which allow for multiple causal variants, it does not depend upon availability of effect
size estimates, or the allelic direction of effect and it can infer whether the pattern of
association is likely caused by a non-genotyped SNP without requiring imputation. I
discuss the effect of choice of reference dataset, and the implications for other
summary statistics techniques.
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Chapter 1
Introduction
An increasing focus in medicine is the integration of genetic information, from early
prediction of disease risk to making more informed treatment choices. As genetic
mechanisms are becoming better understood, and technology is being developed to
enable increasingly larger scale and cheaper molecular phenotyping of patients, we are
coming to understand the heterogeneity of genetics in complex diseases. As the volume
of biological data increases, the challenges to be solved in understanding disease
aetiology have progressively become statistical rather than biological.
The biological datasets available are often incomplete, and contain structures which
are not fully understood, making analysis more difficult. In order to increase our power
to detect disease causing genetic variants, it is necessary to develop methodologies which
enable the integration of several datasets, be they cross-disease analysis or incorporating
epigenetic information. In this thesis I address the statistical methods required for fine
mapping causal variants and for examining whether causal variants are shared between
two diseases, applying my methods to the area of autoimmune disease.
2 Introduction
1.1 Autoimmune Diseases
Autoimmune diseases are caused by the immune system being reactive to self-tissue,
resulting in damage to the organs or structures being targeted. Many autoimmune
diseases are known, but my research focuses upon four in particular: Type 1 Diabetes;
Rheumatoid Arthritis; Celiac Disease and Multiple Sclerosis.
1.1.1 Individual Diseases
1.1.1.1 Type 1 Diabetes
Type 1 Diabetes (T1D, formerly known as insulin-dependent diabetes mellitus) is caused
by the autoimmune destruction of the insulin-producing β-cells within the pancreatic
islets. Insulin is a peptide hormone which promotes the absorption of glucose by cells.
In its absence, the body is unable to regulate blood glucose levels; this leads to both
hyperglycemia and ketoacidosis, as cells are starved of glucose. These are potentially
fatal if the underlying condition is not recognised and treated.
There is no cure for T1D, and, although there is some evidence that
immunosuppressive agents can slow progression in newly diagnosed patients [Bluestone
et al, 2010], the side effects of these drugs mean that they are not used; since age of
onset is typically young, with the peak age of diagnosis around 14, long term safety of
therapies is a particular concern. Instead, a life-long regime of insulin-replacement is
required, and those whose disease is not well-controlled are at risk of complications
such as cardiomyopathy, renal failure and retinopathy. Glucose intake must be
carefully monitored so that the correct insulin dose can be given; hypoglycemia can
have a swift onset, and is fatal if not corrected. T1D is associated with a significantly
increased mortality rate [Soedamah-Muthu et al, 2006].
A symptomatically related disease is Type 2 Diabetes; however this is not thought
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to be immune-related, but rather a metabolic disease in which the host cells become
resistant to insulin.
1.1.1.2 Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is caused by inflammation of the synovial membrane, the
connective tissue lining the inner surface of many joints. The inflammatory environment
in the synovium of patients with RA can damage the cartilage of the joint, which leads
in turn to erosion of the bone. RA is a polyarthritis, typically initially presenting with
pain and swelling in small joints, such as those in the hands, before progressing to larger
joints. In addition, there are many extra-articular manifestations of the disease; it is
associated with ischaemic heart disease and pulmonary fibrosis, leading to increased
mortality.
The joint damage done is irreversible, and RA is frequently disabling. However,
disease-modifying drugs, such as TNF -inhibitors, are sometimes able to slow disease
progression; and, together with analgesia, are the primary treatments used.
1.1.1.3 Celiac Disease
Celiac Disease (CEL, also known as Coeliac Disease) is caused by an autoinflammatory
reaction to small bowel tissue in the presence of gliadin, a gluten protein found in wheat
and similar cereals. As well as causing pain, this inflammation results in atrophy of
the villi lining the small intestine and consequent inability to properly absorb food.
CEL is a pre-malignant condition, leading to an increased risk of both lymphoma and
adenocarcinoma of the small bowel.
Since the autoantibodies in CEL are produced only in the presence of gliadin, the
most effective treatment for this condition is a lifelong gluten-free diet.
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1.1.1.4 Multiple Sclerosis
In Multiple Sclerosis (MS) the immune system targets antigens within the brain and
spinal cord, resulting in the destruction of the myelin sheaths insulating neurons and
the formation of lesions within the central nervous system. This results in a wide range
of neurological symptoms, depending upon the location of the lesions, including sensory,
motor and cognitive defects.
The disease has several distinct clinical manifestations. Patients with the relapsing-
remitting form have a pattern of periods of increased disease activity followed by fading
of symptoms, as demyelination occurs and then heals poorly. By contrast, other patients
present a progressive pattern of the disease, leading to prolonged demyelination of the
neurons and eventually to axiol loss. These patients experience a steady worsening over
time. While the majority of those with the disease present with the relapsing-remitting
phenotype, this typically converts to the progressive form.
Although there is currently no cure for MS, recently monoclonal antibodies such as
alemtuzumab, which targets CD52, a protein expressed on the surface of lymphocytes,
have shown promise in reducing the rate of relapses [Coles, 2012].
1.1.2 Biology of Autoimmune Diseases
The immune system is a collection of structures and processes in the body which
protect against invading pathogens and promote host tissue integrity. An important
constituent of the immune system are the white blood cells (leukocytes), which are
produced in the bone marrow but found throughout the circulatory system and body
tissues. Leukocytes encompass a variety of functionally-distinct cell types, which are
characterised by a remarkable plasticity to recognise and respond to virtually any type
of pathogen. However, two types are of particular interest for the study of autoimmune
disease.
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Many autoimmune diseases, including the four discussed above, occur when
T-lymphocytes target self-antigens. There are several types of T-cells. Prior to
differentiation, they undergo several rounds of selection; in the last round, “negative
selection”, they are presented with self-antigens on the Major Histocompatibility
Complex (MHC) of medullary thymic epithelial cells. Those which react too strongly
have the potential to cause autoimmune disease; these are generally induced to undergo
apoptosis, however, some differentiate into regulatory T-cells (TREGs). Although the
mechanisms by which they do so are not fully understood, these suppress the responses
of other T-cells, reducing reactions to self-antigens; increasing TREG function has been
suggested as a therapy strategy for autoimmune disease [Waldron-Lynch et al, 2014].
Other types of T-cells include cytotoxic T-cells (TCs) and helper T-cells (THs). When
they first differentiate, both TCs and THs are “naive”, and require specific antigen
stimulation in the context of the MHC to promote their activation and clonal selection.
TCs directly kill cells which express their target antigen on its class 1 MHC molecule
by releasing cytokines and inducing apoptosis. In contrast, when THs encounters a cell
which expresses their target antigen on its class 2 MHC molecule, they release
cytokines, which assist in the immune response. After an immune response has
occurred, some antigen-experienced T-cells remain as long-lived memory T-cells, to
enable a quicker response to be mounted against the same pathogen in the future.
B-lymphocytes secrete antibodies, proteins which bind to antigens on the pathogen
and either impede their target or signal in order to mark their target out for destruction
by other immune cells. B-cells play a role in some autoimmune diseases, although to a
lesser extent than T-cells; rheumatoid factor is an auto-antibody which is often found
in patients with RA. As with T-cells, B-cells go through a negative selection step in
development, in order to prevent the differentiation of mature B cells, with the capacity
to produce autoreactive antibodies, that can recognise self-antigens.
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1.1.3 Genetics of Autoimmune Diseases
From looking at how disease prevalence clusters within families, there is strong
evidence that autoimmune disease propensity is heritable. A standard estimate of
familial aggregation is the sibling recurrence risk, how much more likely is it that a
sibling of someone affected also has the disease than we would expect by random
chance. This is high in autoimmune diseases; it has been reported that T1D has a
sibling recurrence risk ratio as high as 12 [Risch, 1987]. This is highly suggestive of a
significant genetic component to disease risk.
The strongest genetic association with autoimmune diseases (and the first to be
discovered, via linkage studies in the 1970s) is the HLA region on chromosome 6. This
region encodes the MHC, which is vital in immune system regulation and presents the
key molecules that allow T-cells to recognise self and foreign antigens. However, common
autoimmune diseases are strongly polygenic and, especially with the advent of genome-
wide association studies (GWAS), a great many new disease-associated regions have
been discovered. Figure 1.1 shows the location of all 51 currently known T1D-associated
regions; these are distributed throughout the genome.
Genetic factors are known to play a role in all aspects of autoimmune disease: from
susceptibility to self-reactive immune responses, determining the targets of autoimmune
destruction and disease progression. However, there are also non-genetic factors at play.
By examining disease concordance between pairs of monozygotic twins [Selmi et al,
2012] produce estimates of what proportion of autoimmune disease risk is attributable to
genetic factors; these are significantly below one. The remainder is due to environmental
factors.
Although autoimmune diseases are not modern diseases (we have records of some
dating back to antiquity), in recent years their prevalence has been increasing at too
great a rate to be explicable by genetic factors. There is also marked geographical
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Figure 1.1 The distribution of known T1D-associated regions across the genome,
taken from T1D base (www.t1dbase.org ).
variation in prevalence, even when accounting for confounders such as prosperity,
climate and exposure to pathogens. The hygiene hypothesis posits that a lack of early
exposure to pathogens leads to an inappropriate education of the immune system and
the generation of an immune repertoire that is more biased to autoimmune responses;
Vitamin D deficiency has also been implicated in autoimmune disease development and
has been proposed as a cause for the increased incidence of autoimmune diseases in
Northern countries. It is thought that, though both genetic and environmental factors
contribute to disease susceptibility, a trigger such as a viral infection is necessary for
onset [Rodriguez-Calvo et al, 2016].
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1.2 Genome Wide Association Studies
The first regions associated with autoimmune disease, such as HLA and the chr11 region
containing the gene INS (associated with T1D), were found by linkage studies. These
studies look at large families where members are affected by the disease over several
generations, and try to find a region where shared inheritance patterns correspond to
disease status. However, the erosion of LD is slow, and so given data from only a couple
of generations, disease associations can only be narrowed down to a large genetic region
(typically millions of base pairs). In addition, although linkage studies can work very
well on traits which follow a Mendelian pattern of inheritance, if a disease is complex,
with many variants having less than fully penetrant influence on disease susceptibility,
only very strong associations will show in a linkage study.
The vast majority of the human genome, which contains around three billion base
pairs, is conserved across humans. However, there is genetic variation across the
population; any two individuals differ in about 0.5% of their DNA. The most common
form of human genetic variation is the single nucleotide polymorphism (SNP). SNPs
occur when there is a difference at a single nucleotide; in humans, these are estimated
to occur about once every 300 base pairs. They vary from very common with no
clinical implications to rare yet highly pathogenic; for instance, a SNP within the
coding region of a gene may lead to an incorrect amino acid being used to form a
protein, and hence changed function. The minor allele frequency (MAF) of a SNP is
the frequency at which the less common allele occurs; this may vary considerably
between populations (indeed, the alleles carried by an individual can be used to infer
ancestry).
SNPs do not occur independently from each other; two alleles at different positions
are in linkage disequilibrium (LD) if they occur together more frequently than would
be expected by random chance. This has several causes. Most commonly, during the
1.2 Genome Wide Association Studies 9
chromosomal crossover phase of meiosis, alleles which are close together are more likely
to be on the same chromatid, and hence be inherited together. A particular combination
of SNP alleles may also confer some selective advantage and hence be frequently found
together. A benign SNP may therefore appear to be associated with a disease if it is in
high LD with a pathogenic SNP; such effects are very difficult to disentangle.
An advantage of linkage studies is that they enable discovery of genetic association
without the requirement for knowledge about and determining of the specific causes
of genetic variation in disease risk. More recent technology, however, has enabled the
fast and cheap genotyping by microarray of large numbers of SNPs across the genome,
and it is now possible to do genome wide association studies (GWAS). In these studies,
independent univariate analysis of SNPs against some phenotype (such as disease status)
are done for a genome-wide set of SNPs. The most common design, which is the one
discussed in the rest of this thesis, is a case/control comparison, with SNP association
with the disease being measured by means of a score test to determine whether allelic
frequencies are significantly different between cases and controls. Typically only the
summary statistics, such as unsigned p-values, are reported from a GWAS; these are
often presented on a Manhattan plot, which plots position on the chromosome against
− log10 p-value, enabling the strongest associations to be easily visible as peaks (for an
example of an autoimmune disease Manhattan plot, see Figure 1.2).
As with any method which uses p-values to determine the significance of the effect
found, a threshold must be chosen. By standard custom, p < 0.05 is used for a test of
a single hypothesis. However, the number of tests being performed in a GWAS (not all
of which are independent, due to the effect of LD) means that multiple testing must be
corrected for. A threshold of 5× 10−8 has been widely accepted by the field [Dudbridge
and Gusnanto, 2008]. However, the true number of independent tests is population
dependent, with an African cohort having more genetic variation than a European one;
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Figure 1.2 Manhattan plots of RA associations, from a meta-analysis of GWAS for
trans-ethnic, European and Asian populations, coloured by chromosome. The high
peak in chromosome 6 corresponds to HLA. Figure taken from [Okada et al, 2014].
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the “correct” threshold for an African population is likely to be lower than 5×10−8, and
this is the subject of ongoing research.
Note that, in Figure 1.2, there are differences in the heights of the peaks of the
European and Asian Manhattan plots. Many signals in the European analysis fail to
reach genome-wide significance in the Asian analysis (mainly due to the European study
having higher power). Due to genetic drift, allele frequency of SNPs varies between
populations; a causal SNP which accounts for much disease-variation in one population
may not be present in another. Since GWAS analysis is fundamentally about determining
whether allele frequency differs between cases and controls, it is important to stratify
by population, and ensure the use of an appropriate control dataset, to ensure any
differences we detect are truly caused by disease-status. Typically a GWAS will analyse
a single (often European) population in order to reduce this effect.
The first GWAS [Haines et al, 2005] used only 50 controls and 96 cases, however, as
genotyping has become cheaper, the desire to increase the power to detect associations at
SNPs with lower odds ratios, or greater rarity, has driven up the sample sizes, which are
now typically in the tens of thousands. Rigorous quality control measures, many of them
introduced by the Wellcome Trust Case Control Consortium [Burton et al, 2007] (at the
time the largest GWAS ever performed, this analysed seven diseases for SNP association
and found 21 significant loci, the vast majority of which have since been replicated), and
an honesty about the number of hypotheses being considered are required to provide
meaningful results. SNPs with low call rates are removed, since this may be indicative
of DNA sample quality. Similarly, SNPs not being in Hardy-Weinberg equilibrium is
suggestive of a genotyping or genotype calling error at this position, and so they are
removed. In addition, the effects of population stratification must be controlled for in
order to reduce the chance of systemic differences other than disease status between
cases and controls.
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Figure 1.3 Number of published autoimmune disease associations found by GWAS,
including the number of disease implicated. Figure produced by C Wallace, using data
from www.immunobase.org.
Over the course of the past decade, the number of GWAS performed has exploded.
Figure 1.3 shows the number of autoimmune disease associated variants reported by
year, with increasing numbers being implicated in multiple diseases. The development
of the GWAS methodology has enabled the analysis of complex polygenetic traits, and
greatly improved our understanding of autoimmune disease aetiology.
1.2.1 Limitations of GWAS
Although called “genome wide”, GWAS by no means test all known variants. They
genotype a subset of common SNPs thought to explain a large proportion of genetic
variation, but relatively few rare SNPs (indeed, for very rare SNPs, the sample sizes
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required to obtain statistical power would be prohibitive). Coverage is not even across
the genome; some regions of the genome have no coverage at all (see, for instance, the
gaps in coverage within chromosome 1 and chromosome 9 corresponding to centromeres
in Figure 1.2). Although SNPs are the most common form of genetic variation, and the
easiest to analyse, others do exist; structural variations such as copy number variations
and translocations may also be important in disease aetiology (though often tagged by
SNPs).
For the purposes of determining whether a genetic region contains a trait-associated
variant, such incomplete coverage often suffices. GWAS are able to explain significant
proportions of the estimated autoimmune disease hereditary However, some heredity
is unavoidably “missing”; for example, [Barrett et al, 2009b] estimate that the 32 loci
identified as associated with Crohn’s disease through GWAS explain only 20% of the
genetic risk. Even if the true causal variant is not included, if it is in high LD with a
sequenced SNP (that is, if it is “tagged” by one of the GWAS SNPs), we will still be able
to see its effect upon disease status. It has also been suggested that GWAS will reveal
the influence of very rare SNPs via a “synthetic association”, by occurring more often in
association with one of the alleles of a common GWAS SNP. However, for this signal to
be statistically significant, the effect size of the rare SNP would have to be very large;
in autoimmune disease, effect sizes tend to be modest, and it is unlikely that a GWAS
would be powered to detect a rare causal variant of this form. Indeed, a well-powered
study which searched directly for rare autoimmune associated variants found that they
explained only 3% of the heritability explained by common variants [Hunt et al, 2013].
This reliance on tag-SNPs to find disease associations, however, makes the use of
GWAS data for fine mapping the causal variants themselves difficult; from reported
p-values alone, how do we determine whether a SNP is causal for a disease, or merely
in high LD with the (possibly not genotyped) true causal variant? Fine mapping the
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variants which underlie disease association is vital to understanding aetiology.
Association to a region does not necessarily correspond to any given gene within that
region being implicated in the disease process; it may be that the causal variant is, for
instance, in a regulatory element which acts upon some distant gene. Identifying the
causal variant can enable discovery of common aetiology between autoimmune
diseases, and may also suggest novel treatment strategies. Fine mapping from GWAS
data is a thread which runs throughout my thesis.
1.3 ImmunoChip
One solution to the problem of the true causal variants not being genotyped, especially
if you have a prior belief about the identities or locations of these variants, is to create
a custom genotyping platform specifically for the analysis of your disease of interest.
The ImmunoChip [Cortes and Brown, 2011] is one such platform, designed to aid in the
fine mapping of autoimmune disease associated signals. It contains all SNPs which had
previously been associated with one of the 11 autoimmune diseases being studied, as
well as all known SNPs at the time (February 2010) from the 1000 Genomes Project
and European data in LD blocks surrounding these SNPs for which probes could be
designed. In addition, for each disease, 3000 “wild-card” SNPs were included; these
were typically either SNPs which had failed to reach genome-wide significance yet were
deemed to be potentially interesting, or else further SNPs within a region believed to
be disease-associated. In total, 186 loci believed to be associated with an autoimmune
disease are densely covered by the ImmunoChip SNPs. In addition, to aid fine mapping
of the true causal variants, SNPs were not filtered by LD or by spacing (in a GWAS,
such filtering increases the number of independent signals which can be analysed, but
at a cost of greatly complicating any fine mapping efforts).
Although autoimmune disease associated regions are well covered, ImmunoChip
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contains only ∼ 200, 000 SNPs, much fewer than a typical GWAS. This, together with
the bulk numbers in which the chips were produced, reduced the price of analysis,
making running an autoimmune GWAS more attractive and enabling an increase in
sample size and therefore power. The fact that analysis was done for so many diseases
upon broadly the same set of SNPs makes discovering shared causal variants
logistically much easier; this is also aided by the ImmunoChip Consortium providing
common control data.
The ImmunoChip, however, does not completely negate the issues with use of
GWAS data for fine mapping discussed in Section 1.2.1. While common variants are
systematically accounted for, due to the inclusion of 1000 Genomes SNPs, the only
rare variants included are those which had already been identified in an existing
autoimmune disease GWAS, or which happen to have been chosen due to lying within
a densely genotyped regions. This focus upon known regions means that the rest of the
genome is sparsely covered; if a novel association happens to exist outside these regions
(say for a different autoimmune disease), it is unlikely to be identified by a study using
the ImmunoChip unless it happens to be one with a low p-value in an existing GWAS
of one of the 11 diseases.
ImmunoChip contains probes for 195, 806 SNPs; the remaining 718 variants are small
insertion-deletions. These variants are both the most common types and the easiest to
genotype. However, this means that the effect of large structural variants is missing
from discovery unless they happen to be tagged by a SNP or detectable from raw SNP
intensity signals [Cooper et al, 2015].
In addition, the SNPs selected were chosen due to their association in European-
only GWAS. Disease-causal variants which are found only in non-European populations
will be under-represented upon the ImmunoChip, which may have implications for the
analysis of such populations.
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GWAS to analyse autoimmune disease genetics, including those using the
ImmunoChip, are curated within ImmunoBase (http://www.immunobase.org/), and it
is from here that I have sourced the majority of the summary data analysed in this
thesis.
1.4 Statistical Methods for Assessing Shared
Aetiology
Clinical studies have shown that having one autoimmune disease is a strong risk factor
for developing others; for instance, many patients with ankylosing spondylitis go on to
develop inflammatory bowel disorder, and vice versa [Laukens et al, 2010]. Further,
family studies show clustering of multiple autoimmune diseases between relations. Some
therapies, such as anti-TNF drugs, are effective against a wide range of autoimmune
diseases. Together with the commonality of the mechanisms of the diseases, this is
strong evidence for the presence of shared aetiology, and much of this sharing is likely
to be genetic.
Many autoimmune-related genetic regions, including the most strongly associated,
HLA, are associated with several diseases. In databases such as ImmunoBase
(http://www.immunobase.org/), known association with one disease is considered
grounds for lowering the threshold required for a genetic variant to be considered
significantly associated with another. Figure 1.4 shows the proportion of risk
associated variants which are shared between diseases. However, finding shared disease
association to a genetic region does not automatically correspond to shared aetiology;
instead, different variants within the region may lead to different disease processes.
One method of quantifying the shared aetiology between two traits is the genetic
correlation, the correlation between the vectors of effect sizes [Bulik-Sullivan et al, 2015].
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Figure 1.4 For each pair of diseases, the arrows show the proportion of variants
identified as being causal for the first disease which are shared with the second disease.
Figure taken from [Cotsapas and Hafler, 2013].
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Let Y1 and Y2 denote phenotypes for disease 1 and disease 2 respectivly, and let X
be the matrix of sample genotypes. Consider a set of SNPs of interest, S (typically,
S contains all SNPs under study). Let γ be the zero-centred vector which satisfies
argmaxαCor(Y1,Xα) (that is, the projection of Y1 onto the space of X), and let β be
this value for disease 2. Then the genetic correlation between phenotypes at SNPs in S
is computed as:
rS =
∑
i∈S γiβi√
(∑i∈S γ2i ) (∑i∈S β2i )
However, although this provides a good measure for the amount of sharing between
traits, it assesses this at a global level, and does not reveal whether causal variants are
shared within a specific region, nor does it enable a fine mapping to determine which
causal variants are shared. For this, we require colocalization techniques.
In this section, I summarise existing colocalization methods as published. By looking
for colocalisation between trait-associated SNPs, these methods can be used to perform
an analysis of association between two traits such as disease status. They can also be used
to find colocalisation between trait-associated SNPs and gene expression Quantitative
Trait Loci (eQTLs) in a cell type of interest. However, they require that for each of the
trait datasets we have an independent control dataset.
1.4.1 Bayesian Approach
Here, I summarise a Bayesian approach to colocalization, which is given
in [Giambartolomei et al, 2014].
1.4.1.1 Framework
Consider the case when each trait is influenced by at most one variant in a
pre-specified region. Let there be Q ≥ 2 SNPs in a region and let a configuration
describe which SNP(s) in the region are causal for which trait, if any. Then there are
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(Q + 1)2 configurations of possible causal SNPs, each of which can be assigned to one
of five possible hypotheses:
H0: No SNP is associated with either trait.
H1: There is a SNP associated with trait 1, but no SNP is associated with trait 2.
H2: There is a SNP associated with trait 2, but no SNP is associated with trait 1.
H3: There is a SNP associated with trait 1, and a different SNP associated with
trait 2.
H4: A single SNP is associated with both trait 1 and trait 2.
Colocalization is equivalent to hypothesis H4; a large posterior probability for this
hypothesis provides evidence for colocalization.
1.4.1.2 Choice of Priors
In a Bayesian approach, we begin by defining our prior expectation of each of these
hypotheses.
For each SNP in the region, we can define p0, p1, p2 and p12 as:
p0, the prior probability that the SNP is associated with neither disease
p1, the prior probability that it is associated with the first disease only
p2, the prior probability that it is associated with the second disease only
p12, the prior probability that it is associated with both diseases.
In the absence of additional information about the SNPs, assume that all are
equivalently likely a priori. p1 and p2 were assigned to be 10−4, an estimate of the
proportion of all SNPs expected to be associated with a given trait and equivalent to
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expecting 50 detectable causal variants in a GWAS with 500,000 SNPs. p12 was
assigned to be 10−6; this was tested with a sensitivity analysis, comparing the results
given when p12 = 10−5, 2 × 10−6, 10−6 with the original analysis of the blood lipid
dataset given in [Teslovich, T. Musunuru, K. Smith, 2010]. As p0 = 1 − p1 − p2 − p12,
p0 ≃ 1.
Then, the prior for a configurationM, Π(M), is dependent only upon the hypothesis
it corresponds to:
M∈ H0: Π(M) = pQ0 = p20(pQ−20 ) ≃ 1
M∈ H1: Π(M) = pQ−10 p1 = p0p1(pQ−20 ) ≃ 10−4
M∈ H2: Π(M) = pQ−10 p2 = p0p2(pQ−20 ) ≃ 10−4
M∈ H3: Π(M) = pQ−20 p1p2 = p1p2(pQ−20 ) ≃ 10−8
M∈ H4: Π(M) = pQ−10 p12 = p0p12(pQ−20 ) ≃ 10−6
1.4.1.3 Computation of Posterior Probabilities
In order to compare two models under a Bayesian framework, the Bayes Factor (BF) is
frequently used; this is the ratio of how well two models predict D, the data observed.
In the case of colocalization, the BF for each model M against the null hypothesis of
no association (H0) is:
BF (M) = P(D|M)
P(D|H0)
Let BF 1i be the BF derived for the model {SNP i is causal for trait 1} and BF 2j be
the BF derived for the model {SNP j is causal for trait 2}. Since there is an independent
control dataset for each trait, the regression models are independent and hence the term
P(D|M) can be split into two independent terms, one for each trait, giving:
M∈ H0: BF (M) = 1
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M∈ H1: BF (M) = P(D|SNP i is causal for trait 1)P(D|no SNP is causal for trait 2)P(D|no SNP is causal for trait 1)P(D|no SNP is causal for trait 2) = BF 1i
M∈ H2: BF (M) = P(D|no SNP is causal for trait 1)P(D|SNP j is causal for trait 2)P(D|no SNP is causal for trait 1)P(D|no SNP is causal for trait 2) = BF 2j
M ∈ H3:
BF (M) = P(D|SNP i is causal for trait 1)P(D|SNP j is causal for trait 2)P(D|no SNP is causal for trait 1)P(D|no SNP is causal for trait 2) = BF 1i BF 2j
M ∈ H4:
BF (M) = P(D|SNP i is causal for trait 1)P(D|SNP i is causal for trait 2)P(D|no SNP is causal for trait 1)P(D|no SNP is causal for trait 2) = BF 1i BF 2i
for any SNPs i and j, i ̸= j.
In practice, these Bayes Factors can be expensive to compute, and instead the
Approximate Bayes Factors (ABF) are calculated, using the method described in
[Wakefield, 2009], which enables the computation of an ABF from only summary
statistics. Since often in GWAS only the summary statistics are reported, it is valuable
to be able to perform colocalization on such data.
For each hypothesis Hi, given data D, we have:
P(Hi|D) ∝
∑
M∈Hi
P(D|M)Π(M)
and hence:
P(Hi|D)
P(H0|D) =
Π(M|M ∈ Hi)
Π(H0)
∑
M∈Hi
P(D|M)
P(D|H0)
= Π(M|M ∈ Hi)Π(H0)
∑
M∈Hi
BF (M)
Defining ABF 1i to be the ABF derived for the model {SNP i is causal for trait 1}
and ABF 2j to be the ABF derived for the model {SNP j is causal for trait 2} as before,
and using the priors defined in Section 1.4.1.2, we can write:
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P(H0|D)
P(H0|D) = 1
P(H1|D)
P(H0|D) = p1
∑Q
i=1ABF1i
P(H2|D)
P(H0|D) = p2
∑Q
i=1ABF2i
P(H3|D)
P(H0|D) = p1p2
∑
i ̸=j ABF1iABF2j
P(H4|D)
P(H0|D) = p12
∑Q
i=1ABF1iABF2i
1.4.2 Proportional Approach
Here, I describe the proportional approach to colocalization, as given in [Wallace et al,
2012] and [Wallace, 2013].
1.4.2.1 Test for Colocalization
Write Y1 and Y2 for the response vectors of the two traits of interest (for instance,
disease status for two diseases with believed shared aetiology or disease status and gene
expression data). Let βˆ1 and βˆ2 be the maximum likelihood estimators for β1 and β2,
the coefficients obtained when the Ys are individually regressed upon genotype data
for a set of Q explanatory SNPs. Let β1 and β2 have covariance matrices V1 and V2
respectively.
The null hypothesis of colocalization is expressed as proportionality between the
coefficient vectors; that is, there exists some constant η such that β1 = β2η . By Fieller’s
theorem [Fieller, 1954], under this null hypothesis, if η is known:
βˆ1 − βˆ2
η
T (V1 + V2
η2
)−1βˆ1 − βˆ2
η
 ∼ χ2Q (1.1)
However, η is unknown. Instead, under a profile likelihood approach, the maximum
likelihood estimator, ηˆ, is used and the distribution in Equation 1.1 cannot be assumed.
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One option would be to assume a χ2Q−1 distribution, but discontinuities in the likelihood
also pose a problem. Instead, a posterior predictive p-value is computed [Rubin, 1984].
Writing η = tan(θ), the test statistic at a given value of θ is:
T (θ) =
(
sin(θ)βˆ1 − cos(θ)βˆ2
)T (
sin2(θ)V1 + cos2(θ)V2
)−1 (
sin(θ)βˆ1 − cos(θ)βˆ2
)
∼ χ2Q
Write P(θ) for the posterior distribution of θ given βˆ1 and βˆ2. Write T ∗(θ) for the
p-value derived at a specific value of θ. Then the posterior predictive p-value for testing
the null hypothesis of colocalization is given by:
∫ π
0
T ∗(θ)P(θ)dθ
1.4.2.2 Computation of P(θ), the Posterior Distribution of the
Proportionality Constant
In the absence of any additional information, non-informative priors π(θ) ∼ 1 and
π(β) ∼ 1 are used.
Let M =
(
cos2(θ)V −11 + sin2(θ)V −12
)−1
and µ =
(
cos(θ)βˆ1V −11 + sin(θ)βˆ2V −12
)
M
The likelihood of βˆ1, βˆ2 given θ, β, is given by:
L(βˆ1, βˆ2|β, θ) = 1
(2π)
Q
2 (|V1||V2|)
1
2
×exp
−
[
(βˆ1 − cos(θ)β)TV −11 (βˆ1 − cos(θ)β) + (βˆ2 − sin(θ)β)TV −12 (βˆ2 − sin(θ)β)
]
2

= 1
(2π)
Q
2 (|V1||V2|)
1
2
×exp
−
[
(β − µ)TM−1(β − µ)− µTM−1µ+ bT1 V −11 βˆ1 + bT2 V −12 βˆ2
]
2

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and the posterior distribution of θ is:
P(θ) ∝
∫ ∞
−∞
L(βˆ1, βˆ2|β, θ)π(θ)π(β)dβ
∝ |M |
1
2
(2π)
Q
2 (|V1||V2|)
1
2
exp
−
[
bT1 V
−1
1 βˆ1 + bT2 V −12 βˆ2 − µTM−1µ
]
2

This posterior distribution can also be used to compute a (possibly disjoint) 95% credible
interval for η.
1.4.2.3 Selection of Appropriate SNPs for the Proportional Approach
We expect that only a small proportion of the SNPs in the region are actually associated with
the traits. Each additional SNP analyzed adds a degree of freedom, leading to a loss of power
in our test; due to linkage disequilibrium, these SNPs are highly correlated, and hence an
appropiately chosen much smaller subset of SNPs can capture almost the same information as
the complete set of SNPs. In addition, this algorithm requires the computation of the inverses
of the Q by Q matrices V1 and V2; it is seldomly computationally feasible to analyse all SNPs
within a genetic locus. We therefore wish to choose a subset of these to examine.
One suggestion would be to choose the top SNPs based upon their relation to the traits
being studied. However, due to theWinner’s Curse effect [Ioannidis, 2008], these apparent top
SNPs are likely to have inflated effect sizes compared to their true values: while asymptotically
the expectation of the Maximum Likelihood Estimator, βˆ, is β, once we condition upon having
passed some significance threshold γ, E
(
βˆ
∣∣∣∣{∣∣∣∣ βˆSE(βˆ)
∣∣∣∣ > γ}) ̸= β. Instead, there are several
selection strategies which do not result in biased estimators being passed to the colocalization
analysis.
The first is Bayesian Model Averaging. In this technique, we treat the choice of SNPs in
the model itself as a nuisance parameter. We consider all regression models of traits against
two SNPs, considering each equally likely a priori, and for each compute a Bayes factor (and
thus a posterior probability). In practice, in order to speed up computation, an Approximate
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Bayes Factor is computed, using a Laplace approximation [Raftery, 1996]. For each model,
we also compute the posterior predictive p-value (calculated as in 1.4.2.2). By summing over
these posterior predictive p-values, weighted by the posterior probability of the model they
correspond to, we are able to compute an overall posterior predictive p-value for testing the
hypothesis of proportional effects for the two traits in the region.
Alternatively, Principal Component Analysis can be used. This procedure transforms the
SNP data into an orthogonal set of linear sums of the original variables, in such a way that the
first component explains the largest possible amount of the variance, the second component
explains the largest possible amount of the remaining variance, and so on. By taking the
first few principle components, we are able to run the analysis on a much reduced dataset
which still explains the majority of variance in disease status. This has the advantage that
the algorithm need only be run once. However, the principle components are linear sums,
potentially involving all SNPs; this makes the results hard to interpret in the context of the
effect of individual SNPs.
1.5 Statistical Methods for Fine Mapping
Ideally, full genotype data would be used to identify causal variants. However, this is often
unavailable, and many fine mapping studies have been done in order to identify causal variants
from GWAS summary data, such as p-values, SNP odds ratios and standard errors [Maller
et al, 2012]. Frequently these methods assume that each genetic region contains a single
causal variant, an assumption known to be false in many autoimmune-associated regions. A
common strategy for dealing with multiple causal SNPs is to adopt a conditional approach, at
each iteration finding the strongest signal remaining. However, this approach can lead to us
discounting what could turn out to be the strongest model. In the IL2RA region, for instance,
the best 2 SNP model for MS does not contain the top performing single SNP, and hence is
not found by a forward stepwise search [Wallace et al, 2015].
In this section, I summarise two existing techniques which infer causal variants from GWAS
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summary data without making assumptions about the number of causal variants. They do,
however, require as input the direction of effects at each SNP, and are only able to analyse
potential causal variants which have been genotyped.
1.5.1 PAINTOR
PAINTOR ( Kichaev et al [2014]) assumes multiple causal variants are possible and allows
for the integration of functional genomic annotation data such as transcription factor binding
sites; these can be found from sources including ENCODE [ENCODE Project Consortium
et al, 2012].
1.5.1.1 The Model
Let L be the number of fine-mapping loci under analysis. Let locus j contain Nj SNPs, have
Z-Score vector Zj and R2 matrix Σj , where Σj is estimated from a reference dataset such
as 1000 Genomes [Auton et al, 2015] if necessary. For SNP i within locus j, let Cij be the
indicator that i is causal, and let λij be the non-centrality parameter of the standardised effect
size of i.
Let K be the number of functional genomic annotations obtained for these loci. Define
vectors Aij with:
Aijk =

0 k = 0 (the baseline)
1 SNP i in locus j is part of annotation k
0 SNP i in locus j is not part of annotation k
and let γk be the effect size of a causal SNP having annotation k.
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Then the likelihood of observing Z is
L(Z|γ,λ,A) =
∑
C∈C
P(Z ∩C|γ,λ,A))
=
∏
j
∑
Cj∈Cj
P(Zj |Cjλj)P(Cj |γA∗j)
The effect of γ on causality is modelled as a logistic regression:
P(Cj |γ) =
∏
i
(
1
1 + exp(γTAij)
)Cij ( 1
1 + exp(−γTAij)
)1−Cij
and Z is modelled as a multivariate normal:
Z|λjCj ∼ N(Zj ,Σj(λj ◦ Cj)Σj) (1.2)
where the vector (λj ◦ Cj) gives the elemental pairwise multiplication between λj and Cj .
1.5.1.2 Model Fitting
Since the model includes latent variables Cj , it is not possible to simply maximise the likelihood
in order to fit data to the model. Instead, a Expectation Maximisation (EM) algorithm is used
to maximise the likelihood over γ. This involves two steps, iterated until convergence is
achieved. In the first step (the ‘E Step’), the expected value of the log-likelihood of C given
the current values of γ is computed. In the second step (the ‘M Step’), the equation computed
in the previous E Step is maximised to update the estimate of γ.
In order to prevent the model from being over-specified, the non-centrality parameters λ
are fixed, and only γ is optimised over. The value of λ used is:
λj =

Zj |Zj | > 3.7
3.7× sign(Zj) else
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(Note that a Z-Score of 3.7 corresponds to a p-value of 10−4).
1.5.2 CAVIAR
CAVIAR ( Hormozdiari et al [2014]) allows for multiple causal variants (although, for
computational reasons, in practice we assume at most 6). As output, it generates a set of
SNPs that with high probability contains all causal variants.
1.5.2.1 Single Causal Variant
Let n be the number of individuals and m be the number of SNPs genotyped, with SNP c
being the sole causal SNP.
Write y for the vector of phenotypes and xi for the vector of genotypes at SNP i. Without
loss of generality, let xi be normalised such that 1Txi = 0 and xTi xi = n.
Assume that the phenotypes can be modelled by a linear model:
y = µ1+ βcxc + ϵ ϵ ∼ Nn(0, σ2I)
Then the likelihood function is:
L(y|µ, βc, σ2) = |2πσ2I|exp
(
− 12σ2 (y− µ1− βcxc)
T (y− µ1− βcxc)
)
and maximising this gives:
 µˆ
βˆc
 = 1
n
1Ty
xTc y

 µˆ
βˆc
 ∼ N

µ
βc
 , σ2
n
1 0
0 1


ϵˆ = y− µˆ1− βˆcxc ϵˆT ϵˆ ∼ σ2χ2n independent of µˆ, βˆc
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Then, the association statistics for SNP c, Sc = sˆc,
sˆc =
√
nβˆc
σ√
1
n
√
ϵˆT ϵˆ
σ
= nβˆc√
ϵˆT ϵˆ
has a tλc,n distribution, with non-centrality parameter λc = βˆcσ
√
n. For sufficiently large n,
approximate Sc ∼ N(λc, 1).
Now consider some other SNP, i, and let r = 1nxTi xc. Now:
βˆi =
xTi y
n
λi = rλc
βˆi
σ
√
n ∼ N
(
r
βˆc
σ
√
n, 1
)
Cov
(
βˆc
σ
√
n,
βˆi
σ
√
n
)
= 1
nσ2
xTc σ2Ixi = r
Hence, for any two SNPs i and j
Si
Sj
 ∼ N

λi
λj
 ,
 1 rij
rij 1


and SNP i is causal at the α-significance level if:
|sˆi| > Φ−1(1− α2 )
where Φ−1 is the quantile function of the standard normal distribution.
1.5.2.2 Multiple Causal Variants - Identical Non-Centrality Parameters
Now assume that there may be multiple causal SNPs. Write c for the vector which indicates
signed the causal status for each SNP: ci = 1 if SNP i has positive effect; ci = −1 if SNP i
has negative effect and ci = 0 if SNP i has no effect. Assume that all causal SNPs share the
same non-centrality parameter, λc.
Write Σ for the matrix of pairwise correlations between SNPs. Then, as in the previous
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single variant case:
S ∼ N(λcΣc,Σ)
Let γ be the probability that any given SNP is causal and has a positive effect; under the
assumption that positive and negative effects are equally likely, this is also the probability that
any given SNP is causal and has a negative effect. Then the prior probability that a particular
vector c∗ occurs is:
P(c∗) =
n∏
i=1
γ|c
∗
i |(1− 2γ)(1−|c∗i |)
and hence the posterior probability of c∗ given association statistics sˆ is:
P(c∗|sˆ) = P(sˆ|c
∗)P(c∗)∑
c P(sˆ|c)P(c)
Functional data can be incorporated by using a variant-specific probability, γi.
Now consider a set of SNPs K, and write CK for the set of configurations with all causal
SNPs being from K (including the null configuration). Then let ρ, the confidence level that K
captures the true causal SNPs, be:
ρ = P(CK|sˆ) =
∑
c∈CK
P(c|sˆ)
K is called a ρ-confidence-set of causal SNPs.
For a given minimum confidence threshold ρ∗, the best estimate of the causal model is then
given by the smallest set K∗ such that P(CK∗ |sˆ) ≥ ρ∗.
1.5.2.3 Multiple Causal Variants - Different Non-Centrality Parameters
Now, allow causal SNPs to have different non-centrality parameters. Use the prior probability:
λc|c ∼ N(0,Σc) Σc =

0 i ̸= j
σ icausal
ϵ inot causal
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Write f(λc, 0,Σc) for the probability density function of λc|c.
The prior then becomes:
P(c,λc) = P(c)P(λc|c)
=
(
n∏
i=1
γ|ci|(1− 2γ)(1−|ci|)
)
f(λc, 0,Σc)
Since the vector of non-centrality parameters for all SNPs, λ, is given by Σλc, the association
statistics must follow a multivariate distribution:
S ∼ N(0,ΣΣcΣ) (1.3)
and one can proceed as before.
Since the denominator of the posterior probability of causal status is computationally
intractable in the generalised case, it is assumed that the total number of causal SNPs in
a region is at most 6. A greedy algorithm is used: at each iteration, the SNP which most
increases the posterior probability is selected as causal, until the posterior probability of the
causal set is at least ρ times the total posterior probability of the data.
1.6 Structure of Thesis
In this chapter, I have introduced the diseases and data-types I will analyse in my thesis, and
summarised some of the existing techniques developed for the analysis of such data.
In Chapter 2, I extend the colocalization techniques discussed in Section 1.4 to the case
where there is a single common control dataset, a common approach for GWAS of related
diseases, since it provides a more efficient use of samples, and hence increases the power
avaliable, and use them to better understand causal structure within regions, and to find novel
disease associations. By extending the Bayesian approach, I also show how multinomial models
can be used to fine map variants shared between two diseases using full genotype data and
under the assumption of a common single causal variant.
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Chapter 3 describes a method which simulates the summary data from a GWAS. I discuss
the theory behind my approach, and suggest its use for estimating the null distribution in a
SNP set enrichment analysis.
Full genotype data of the sort used in Chapter 2 is often unavailable. In Chapter 4, I
propose a method which, by simulating the output from GWAS under different causal models,
enables the inference of causal models from summary data consisting only of p-values and
which avoids the single causal variant assumption.
Finally, in Chapter 5, I discuss the future relevance of the methods presented in this
thesis, and outline my thoughts regarding future directions for the genomic analysis of complex
disease.
Chapter 2
Colocalization for Common Controls
2.1 Author Contributions
Work in this chapter has been published [Fortune et al, 2015], and parts of the text in the
Results and Discussion sections closely mirror those in the published paper, which was jointly
edited by Chris Wallace and myself. All development, coding and analysis described is entirely
my own.
2.2 Motivation
As discussed in Section 1.4, there is substantial overlap in genetic regions showing association
with autoimmune disease; this is strongly indicative of shared aetiology. I wanted to find
out whether these overlaps correspond to truly shared variants, or whether they are due to
the action of distinct variants which happen to be in physical proximity. Knowing that two
diseases share a common causal variant is indicative of shared causal mechanism, and might
also suggest investigation of similar treatment strategies, particularly if a known treatment
for one of the diseases targets a gene product in this region related to the causal variant.
Conversely, evidence of distinct causal variants may indicate that the region is associated with
a divergence in pathological processes.
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It may also be possible to leverage the knowledge that certain diseases have shared genetic
association in order to identify novel causal variants. A known association with other related
diseases gives us prior plausibility when assessing the evidence that a variant is causal for a
disease of interest, even if the signal falls below the usual significance threshold in a single-
disease analysis.
However, showing that a variant is associated with two traits does not demonstrate that it
is causal for both, as this effect may be due to distinct causal variants in linkage disequilibrium
with each other. Instead, a more formal framework which takes into account this possibility is
required; this is the task of colocalization.
2.3 Application of Method: Association of FADS2
with Crohn’s Disease
I start with an example of an application of existing colocalization method to find a causal
gene for Crohn’s Disease (CD).
Inflammatory Bowel Disease (IBD) is a group of autoimmune diseases characterised by
inflammation of the colon and small intestine. The two most common types of IBD are CD
and Ulcerative Colitis (UC). eQTLs are genetic variants which affect the expression of genes.
These effects are often cell-type specific, and understanding them can help us understand
disease aetiology.
My collaborators, [Peters et al, 2016], mapped eQTLs in five primary immune cell types:
CD4+; CD8+; CD14+; CD16+ and CD19+, for patients with various autoimmune disease
including IBD. They found that rs102275 appears to both be associated with CD and an
eQTL for FADS2, a gene with known prior plausibility from mouse studies to be associated
with IBD. However, this association is not sufficient to demonstrate causality, and so I carried
out a colocalization test upon this region, comparing the results from the eQTL mapping to the
IBD association. My results are shown in Table 2.1. In all of the immune cell types analysed,
for both the CD and IBD datasets, my posterior probability of colocalization was > 0.98. By
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contrast, for the UC-only dataset, my posterior probability of colocalization was < 0.005 for
all cell types. This provides strong evidence that this eQTL is also causal for CD, and supports
a causal role for FADS2 in CD.
Cell Type
CD4+ CD8+ CD14+ CD16+ CD19+
Disease
CD 0.982 0.982 0.989 0.992 0.991
IBD 0.993 0.993 0.987 0.991 0.992
UC 0.00247 0.00471 0.00419 0.00145 0.000983
Table 2.1 Posterior probabilities of colocalization (H4) between eQTL data for given
immune cell types and association with IBD for the FADS2 region, containing
candidate causal SNP rs102275. These strongly suggest causality for CD.
2.4 The Complication of a Common Control
Dataset
Both the techniques described in Section 1.4 require that it be possible to model each trait
using an independent regression. In order to do this, for each of our datasets, we need an
independent control dataset to perform this regression upon. However, due to the cost of
genotyping, it is common for GWAS of multiple diseases to maximise their power by using a
single common control dataset, against which each disease dataset is compared. The Wellcome
Trust Case Control Consortium [Burton et al, 2007], for instance, analysed ∼ 2000 individuals
with each of seven major diseases with a shared set of ∼ 3000 controls. The use of a common
control dataset introduces dependency between the results of each regression analysis and
hence violates the underlying assumptions. One possibility is to split the controls into several
independent but smaller datasets; however, this sacrifices power.
In the next section, I describe how I extended both colocalization methods to allow for
the use of a common control dataset, as presented in [Fortune et al, 2015]. The code used is
given in the colocCommonControl R package, which can be found at
https://github.com/mdfortune/colocCommonControl. I then applied my colocalization
36 Colocalization for Common Controls
method to four autoimmune diseases: T1D; RA; CEL and MS, using data from the
ImmunoChip, which provides dense coverage of 188 regions associated with at least one
autoimmune disease.
2.5 Extending Methods to the Case of a Common
Control
2.5.1 Common Control Extension to the Bayesian Approach
2.5.1.1 Framework
As in [Giambartolomei et al, 2014] (see Section 1.4.1), I consider the case when each trait is
caused by at most one variant. Let there be Q ≥ 2 SNPs in a region. Then there are (Q+1)2
configurations of possible causal SNPs, each of which can be assigned to one of five possible
hypotheses (Figure 2.1).
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H0 ×1
. . .
H1 ×Q
. . .
H2 ×Q
. . .
H3 ×Q(Q− 1)
. . .
H4 ×Q
Figure 2.1 The hypotheses being tested by the Bayesian approach are represented as
collections of configurations. Each configuration is represented by a line, and each
circle represents one of the Q SNPs in a region under consideration. Yellow circles
represent SNPs that are causal for disease 1; blue circles represent SNPs that are causal
for disease 2 and yellow/blue circles represent SNPs that are causal for both diseases.
We assume that at most one SNP within the region can be causal for each disease.
2.5.1.2 Choice of Priors
In the absence of any other information about a region, I considered that a prior of the same
form as that in [Giambartolomei et al, 2014] should be used. Write p1 and p2 for the probability
that a SNP is associated exclusivly with each one of the two traits. Write p12 for the probability
that one SNP is associated with both traits and p0 = 1− p1 − p2 − p12 be the probability that
a SNP is not associated with any trait. Then our prior for each model, M, is as in Section
1.4.1.
Following [Giambartolomei et al, 2014], I set p1 = p2 = 10−4, which implies, conservatively,
that ImmunoChip contains around 20 causal variants for any autoimmune disease. Consider a
region withQ SNPs. Then, since the number of models |M ∈ H3| = Q(Q−1)2 and |M ∈ H4| = Q,
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we have:
τ = P(H4|H3 or H4)
= Qp0p12
Qp0p12 + Q(Q−1)2 p1p2
= 2p0p122p0p12 + (Q− 1)p1p2
Since colocalization requires association with two diseases, the probability of
colocalization must be less than the probability of one of the two diseases being associated
(p1). However, since autoimmune diseases are known to share genetics, colocalization must
occur more frequently than random chance would predict from two independent diseases
(p1p2). Hence, I require p1 = 10−4 > p12 > p1p2 = 10−8. Note that the above also highlights
that τ decreases with increasing Q. This makes sense because with more SNPs, there is more
chance for close but distinct causal variants to occur by random chance.
Of the 416 regions associated to two traits analysed in [Parkes et al, 2013], 45% were
concordant (that is, H4 with the same direction of effect), 14% discordant (that is, H4 with
opposite directions of effect) and 42% were not correlated (that is, H3). This agrees with the
result of surveying colleagues, where the median suggestion was 0.5. Hence, I concluded that
a sensible estimate of τ is around 0.5.
Figure 2.2 plots the value of τ generated for each of p12 = 10−5, p12 = 10−6 and p12 = 10−7,
together with the distribution of Q for the 126 regions studied. From this, we can see that
p12 = 10−6 comes closest to achieving my desired value of τ , and so it is this I chose to use in
my analysis. Hence, my prior becomes:
P(M) = (1, 10−4, 10−4, 10−8, 10−6)
Changing Priors to Reflect Information from External Publications The
prior above was computed to be an appropriate choice for an arbitary region present in the
ImmunoBase. It is a good default prior, allowing for comparative analysis of many regions,
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Figure 2.2 τ , the probability of colocalization, given that both traits are associated
with a region. τ can be expressed as a function of Q, the number of SNPs in the
region, and p12, the probability of any given SNP being associated to two traits (we
assume that the probability of a SNP being associated to the first trait only is held
constant at 10−4). The top plot gives a histogram showing the distribution of Q over
all regions analysed. The lower plot shows τ plotted against Qfor each of
p12 = 10−5, p12 = 10−6, p12 = 10−7. The dotted line shows τ = 0.50, which I believe to
be a reasonable average value. From this, I conclude that p12 = 10−6 is the most
appropriate value to use.
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however, it may be improved upon, particularly for the analysis of a single, well studied,
region. If a region contains only a few SNPs of interest (that is, Q is small) then we would
expect P(H4|H3 or H4) to be inflated, and this could be reflected in the prior. Alternativly
we could have additional information, independent from the data to be analysed, regarding
the likelihood of disease association with the region, which we may wish to incorporate into
our prior.
For instance, my analysis was restricted to UK samples only, enabling me to assume equal
linkage disequilibrium between different case cohorts (a requirement of the simple multinomial
model I will use in Section 2.5.1.3). However, in the case of RA and MS, this meant that I
analysed only a fraction of samples originally used; for these two traits, the published results
curated in ImmunoBase, http://www.immunobase.org, give important additional information
about the regions which I wish to incorporate into our priors. Denote this information by A.
I write P(A|M) as a function of q− = P(The region is considered associated by ImmunoBase
when it is not) and q+ = P(The region is not considered associated by ImmunoBase when it
is). Then, I can adjust Π′, the original prior for M, in light of A according to:
P(M|A) ∝ P(A|M)Π′(M)
For instance, if in a region where Trait 1 is considered to be associated by ImmunoBase, and
Trait 2 is not considered associated by ImmunoBase then the following priors are appropriate:
M∈ H0: P(M|A) ∝ q−(1− q−)Π′(M)
M∈ H1: P(M|A) ∝ (1− q+)(1− q−)Π′(M)
M∈ H2: P(M|A) ∝ q−q+Π′(M)
M∈ H3: P(M|A) ∝ (1− q+)q+Π′(M)
M∈ H4: P(M|A) ∝ (1− q+)q+Π′(M)
and, if in a region where Trait 1 is considered to be associated by ImmunoBase, and nothing
is known about Trait 2, then the following priors are appropriate:
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M∈ H0: P(M|A) ∝ q−Π′(M)
M∈ H1: P(M|A) ∝ (1− q+)Π′(M)
M∈ H2: P(M|A) ∝ q−Π′(M)
M∈ H3: P(M|A) ∝ (1− q+)Π′(M)
M∈ H4: P(M|A) ∝ (1− q+)Π′(M)
In my analysis, additional information exists in ImmunoBase for RA and MS, whereas
nothing is known for T1D and CEL. The criteria for inclusion of a region in ImmunoBase is
quite stringent; either it has to reach genome-wide significance in a study of the trait (p <
5 × 10−8) or be strongly associated with the trait (p < 10−5) and already be included for
another autoimmune disease. Hence, the chance of a false positive is small, and I shall use
q− = 0.01. By contrast, all ImmunoBase regions were selected to have some autoimmune
association. Hence, even if a region is not currently considered associated with a specific trait,
due to the colocalization between diseases, the chance that there is association is quite high.
Hence, I shall use q+ = 0.5. Substituting these values into the equations above, I used the
following priors for the RA-MS analysis:
If A = {No association with either trait}, then:
P(M|A) = (1, 5.05× 10−5, 5.05× 10−5, 1.02× 10−12, 1.02× 10−10)
If A = {Association with only one trait (Trait 1)}, then:
P(M|A) = (0.995, 4.98× 10−3, 5.03× 10−5, 2.51× 10−7, 2.51× 10−5)
If A = {Association with both traits}, then:
P(M|A) = (0.988, 4.94× 10−3, 4.94× 10−3, 2.47× 10−5, 2.47× 10−3)
And the following priors for, for instance, the T1D-RA analysis:
If A = {No association with RA}, then:
P(M|A) = (1.00, 1.00× 10−4, 5.05× 10−5, 5.05× 10−9, 5.05× 10−7)
If A = {Association with RA}, then:
P(M|A) = (0.995, 9.95× 10−5, 4.98× 10−3, 4.98× 10−7, 4.98× 10−5)
Similar adjustments are made for comparison of RA or MS with either T1D or CEL.
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2.5.1.3 Computation of Posterior Probabilities
Since there is a shared control dataset, I cannot model the two traits with independent logistic
regression models. Instead, let n be the total number of samples. Let S be the n by Q genotype
matrix. Let Y be the vector of length n giving the disease association for each sample, (with
Yk = 0 corresponding to individual k being from the control group, Yk = 1 corresponding to
trait 1, and Yk = 2 corresponding to trait 2. Then I model the configuration corresponding to
SNP i being causal for disease 1 and SNP j being causal for disease 2 using the multinomial
model:
ln(P(Yk = 1))
ln(P(Yk = 0))
= β10 + β11Ski
ln(P(Yk = 2))
ln(P(Yk = 0))
= β20 + β21Skj ∀k
Using the Begg and Gray approximation [Begg and Gray, 1984], this can be converted
into a binary logistic regression, as implemented in the R package mlogitBMA
(http://cran.r-project.org/web/packages/mlogitBMA/index.html). I then use a
Laplace approximation to compute approximate Bayes Factors for each
configuration [Raftery, 1996], using the implementation in the R package BMA
(https://cran.r-project.org/web/packages/BMA/BMA.pdf).
Let Ci be a configuration, and let C0 denote the configuration in which no SNP is causal
for either trait. Let D denote the entire dataset, and let Di denote the dataset restricted to
only those SNPS in Ci. Note that the Bayes Factor for Ci is computed using only Di. However,
following the technique used in [Maller et al, 2012], we have that BFi, the Bayes Factor for Ci
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is:
BFi (as computed) =
P(Di|Ci)
P(Di|C0)
= P(Di|Ci)P(D|C0)
P(D|C0)P(Di|C0)
= P(Di|Ci)P(D−i|Di, C0)P(Di|C0)
P(D|C0)P(Di|C0)
= P(Di|Ci)P(D−i|Di, C0)
P(D|C0)
= P(Di|Ci)P(D−i|Di, Ci)
P(D|C0)
= P(D|Ci)
P(D|C0)
And hence, the Bayes Factor computed using the restricted dataset is identical to that
computed using the entire dataset.
I then compute the posterior probabilities of a hypothesisHmade of configurations C1, ..., Cn
as follows:
P(H|D) =
n∑
i=1
P(Ci|D)
∝
n∑
i=1
P(D|Ci)Π(Ci) (Bayes’ Theorem)
∝ Π(C|C ∈ H)
n∑
i=1
BF (Ci)
(since each configuration within the Hypothesis has an identical prior)
Use of Different Priors By computing the Bayes factors for each configuration, and
then multiplying by the prior, I am able to apply many different priors without increasing the
computational time of the algorithm, enabling exploration of sensitivity to prior.
The results presented here reflect my prior beliefs about the relative hypotheses in the case
of autoimmune disease; these may not be appropriate for a different set of traits. However,
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so long as each configuration within a hypothesis has an equal prior probability, it is simple
to derive posterior probabilities for alternative priors without re-computing the Bayes Factors.
Write Π for the original prior, and Πa for the alternative prior. If the original posterior
probabilities are P(H|D), then we can compute the alternative posterior probabilities using:
Pa(H|D) ∝ Πa(C|C ∈ H)
n∑
i=1
BF (Ci)
∝ Π
a(C|C ∈ H)Π(C|C ∈ H)
Π(C|C ∈ H)
n∑
i=1
BF (Ci)
∝ Π
a(C|C ∈ H)
Π(C|C ∈ H) P(H|D)
and hence
Pa(H|D) =
Πa(C|C∈H)
Π(C|C∈H) P(H|D)∑
H′
(
Πa(C|C∈H′)
Π(C|C∈H′) P(H′|D)
)
Use of this Method for Fine Mapping To find evidence of genetic association between
the SNPs at a region and a trait is suggestive that one of the genes near the SNP is causal.
However, this need not be the case. Even if the locus contains a causal SNP, it could be,
for instance, in a regulatory element which modifies the expression of a gene some distance
away. However, if we know the identity of the causal variants in the region, we can incorporate
information from other datasets to make inferences about the causal genes. For instance, a
chromosome conformation capture analysis of a causal variant enables us to map the genetic
regions it interacts with [Davison et al, 2012; Martin et al, 2015]. Hence, we are interested in
fine mapping any region which shows evidence of disease association in search of likely causal
SNPs. The Bayesian approach enables such analysis with minimal additional computational
time and borrows power by using information from both traits. Since:
P(Ci|H) ∝ BF (Ci|H)
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the probability of an individual SNP being causal given a hypothesis being true is proportional
to the contribution of the corresponding configuration to the summed Bayes factor.
2.5.1.4 The Use of Tagging to Speed Computational Time
To speed computation, I used tagging; SNPs are represented by others with which they have
r2 > 0.99.
Write {SNPi, SNPj} for the model where trait 1 is caused by SNPi and trait 2 is caused
by SNPj . Write {SNPi, 0} for the model where trait 1 is caused by SNPi and trait 2 is
not caused by any SNP. If SNP1 and SNP2 are in the same tag set, I need only compute
the Bayes factor for model {SNP1, SNP1}, B11, and I assume that the Bayes Factors for
models {SNP1, SNP2}, {SNP2, SNP1} and {SNP2, SNP2} can be approximated by B11.
Although this decreases the number of models we need to analyze, it increases the complexity
of associating models with hypotheses. If Tagi is of size ni, then the model {Tagi, Tagi}
corresponds to ni models in H4 and ni(ni − 1) models in H3.
2.5.1.5 Extension to More than Two Traits
Conceptually, the framework of the Bayesian analysis is easy to extend to more than two traits,
or to allowing multiple causal variants. However, this greatly increases the hypothesis space,
making computation and interpretation significantly more complex. For instance, in the case
of three traits, there are fifteen possible hypotheses to consider:
H0: No SNP is associated with any trait.
H1: Only trait 1 is associated with any SNP.
H2: Only trait 2 is associated with any SNP.
H3: Only trait 3 is associated with any SNP.
H4: Trait 1 and trait 2 are associated with different SNPs; trait 3 is not associated with any
SNP.
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H5: Trait 1 and trait 3 are associated with different SNPs; trait 2 is not associated with any
SNP.
H6: Trait 2 and trait 3 are associated with different SNPs; trait 1 is not associated with any
SNP.
H7: Trait 1 and trait 2 are colocated; trait 3 is not associated with any SNP.
H8: Trait 1 and trait 3 are colocated; trait 2 is not associated with any SNP.
H9: Trait 2 and trait 3 are colocated; trait 1 is not associated with any SNP.
H10: All traits are associated, but with different SNPs.
H11: Trait 1 and trait 2 are colocated; trait 3 is not, but is associated with a different SNP.
H12: Trait 1 and trait 3 are colocated; trait 2 is not, but is associated with a different SNP.
H13: Trait 2 and trait 3 are colocated; trait 1 is not, but is associated with a different SNP.
H14: All traits are colocated.
In practice, I used pairwise analysis of traits.
2.5.1.6 Conditional Extension to the Bayesian Approach
The Bayesian method assumes that each trait is caused by at most one variant; in some regions,
this is not a realistic assumption. Hence, I developed an extension of the Bayesian approach
which allows us to analyse a region where some SNPs are already known to be associated with
the traits. The multinomial model is used as before, however each configuration analysed now
contains all the known causal SNPs, and we investigate the effect of including at most one
additional causal SNP for each trait. Hence, using the notation above, if SNPs a1, ...aA are
already (or assumed) known to be causal for trait 1, and SNPs b1, ..., bB are already known
(or assumed) to be causal for trait 2, then we test the configuration that SNPi is additionally
causal for trait 1, and SNPj is additionally causal for trait 2, using the model:
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ln(P(Yk = 1))
ln(P(Yk = 0))
= β10 + β11Ski + γ11Ska1 + ...+ γ1ASkaA
ln(P(Yk = 2))
ln(P(Yk = 0))
= β20 + β21Skj + γ21Skb1 + ...+ γ2BSkbB
∀k
This method is run iteratively for each region until the configuration containing no
additional SNPs (i.e. H0) is the configuration preferred.
2.5.2 Common Control Extension to the Proportional
Approach
2.5.2.1 Test for Colocalization
As in the case of independent controls (Section 1.4.2), I write Y1 and Y2 for the phenotypes of
the two traits and βˆ1, βˆ2 for the maximum likelihood estimators of β1 and β2, the coefficients
obtained when the Ys are regressed upon Q explanatory SNPs. Let β1 and β2 have covariance
matrices V11 and V22 respectively.
The null hypothesis of proportionality can be expressed as:
β1 =
β2
η
⇔ β1 − β2
η
= 0
Since there is a shared control, the regressions of the two traits are no longer independent
and so β1 and β2 have some non-zero covariance matrix V12. Write V21=VT12. By asymptotic
normality of maximum likelihood estimators:
 βˆ1
βˆ2
 ∼ N

 β1
β2
 ,
 V11 V12
V21 V22


A linear transformation gives:
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βˆ1 − βˆ2
η
∼ N
(
β1 − 1
η
β2, V11 − 1
η
V12 − 1
η
V21 +
1
η2
V22
)
Hence, under the null hypothesis:
(
βˆ1 − 1
η
βˆ2
)T (
V11 − 1
η
V12 − 1
η
V21 +
1
η2
V22
)−1 (
βˆ1 − 1
η
βˆ2
)
∼ χ2Q
Or, writing η = tan(θ):
T (θ) =
(
sin(θ)βˆ1 − cos(θ)βˆ2
)T
(
sin2(θ)V11 − sin(θ) cos(θ)V12 − sin(θ) cos(θ)V21 + cos2(θ)V22
)−1
(
sin(θ)βˆ1 − cos(θ)βˆ2
)
∼ χ2Q
giving us a test statistic for a given value of θ.
Since the true value of θ is unknown, I am unable to directly compute a p-value for this
test statistic. Instead, write P(θ) for the posterior distribution of θ given βˆ1 and βˆ2. Write
T ∗(θ) for the p-value derived at a specific value of θ. Then the posterior predictive p-value for
testing the null hypothesis of colocalization is given by:
∫ π
0
T ∗(θ)P(θ)dθ
2.5.2.2 Computation of P(θ), the Posterior Distribution of the
Proportionality Constant
In the absence of any additional information, uninformative priors π(θ) ∼ 1 and π(β) ∼ 1 are
used.
Let V =
 V11 V12
V21 V22
 and let W =
 W11 W12
W21 W22
 = V −1.
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Under proportionality, there exists β such that β1 = β cos(θ) and β2 = β sin(θ), and hence
I can write the likelihood of βˆ1, βˆ2, given θ, β, as:
L(βˆ1, βˆ2|β, θ) = 1
(2π)
Q
2 (|V |) 12
exp
−12
 βˆ1 − β cos(θ)
βˆ2 − β sin(θ)

T  W11 W12
W21 W22

 βˆ1 − β cos(θ)
βˆ2 − β sin(θ)


Write:
x = cos(θ)W11βˆ1 + cos(θ)W12βˆ2 + sin(θ)W21βˆ1 + sin(θ)W22βˆ2
X = cos2(θ)W11 + sin(θ) cos(θ)W12 + sin(θ) cos(θ)W21 + sin2(θ)W22
µ = X−1x
Then:
L(βˆ1, βˆ2|β, θ) = 1
(2π)
Q
2 (|V |) 12
exp
−12

 βˆ1
βˆ2

T
W
 βˆ1
βˆ2
− βTx− xTβ + βTXβ


= 1
(2π)
Q
2 (|V |) 12
exp
−12

 βˆ1
βˆ2

T
W
 βˆ1
βˆ2
+ (β − µ)TX(β − µ)− µTXµ


And so we can compute:
P(θ) ∝
∫
β
L(βˆ1, βˆ2|β, θ)π(θ)π(β)dβ
∝ π(θ)
(2π)
Q
2 (|V |) 12
exp
−12

 βˆ1
βˆ2

T
W
 βˆ1
βˆ2
− µTXµ


×
∫
β
exp
[
−12
(
(β − µ)TX(β − µ)
)]
dβ
∝ π(θ)
(2π)
Q
2 (|V |) 12
exp
−12

 βˆ1
βˆ2

T
W
 βˆ1
βˆ2
− µTXµ


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2.5.2.3 Test Statistic Used
Hence, the posterior predictive p-value to test the null hypothesis of proportionality is given
by: ∫ π
0
T ∗(θ) π(θ)
(2π)
Q
2 (|V |) 12
exp
−12

 βˆ1
βˆ2

T
W
 βˆ1
βˆ2
− µTXµ

 dθ
where T ∗(θ) is the p-value obtained when
(
sin(θ)βˆ1 − cos(θ)βˆ2
)T (
sin2(θ)V11 − sin(θ) cos(θ)V12 − sin(θ) cos(θ)V21 + cos2(θ)V22
)−1 (
sin(θ)βˆ1 − cos(θ)βˆ2
)
is compared to a χ2Q distribution.
2.5.3 Comparison of the Bayesian and Proportional
Approaches
A limitation of the Bayesian approach is its assumption of single causal variants for each
trait. By contrast, the proportional approach allows the assumption of an arbitrary number of
causal variants (although in practice this is restricted, as discussed in Section 1.4.2.3). However,
the proportional null hypothesis does not correspond to H4 from the Bayesian approach; it
corresponds to colocalization, single-disease association or association with neither disease. A
failure to reject the null hypothesis could also be caused by insufficient power. However, in the
proportional approach, having the power to reject this null hypothesis corresponds to strong
evidence for separate SNP effects (H3 in the notation of the Bayesian approach).
2.6 Details of Datasets
2.6.1 Samples
All samples included in this analysis were gathered in the UK and have reported or self-declared
European ancestry. Informed consent was obtained from all subjects after approval from
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the ethics committee or institutional review board of all participating institutions. Detailed
summaries of the sample cohorts are given in the ImmunoChip reports for celiac disease [Trynka
et al, 2012], rheumatoid arthritis [Eyre et al, 2012], multiple sclerosis [Beecham et al, 2013] and
T1D [Onengut-Gumuscu et al, 2015]. For rheumatoid arthritis and multiple sclerosis, we used
the subset of cases from the UK. Sample exclusions were applied as described in each paper;
in total, 6,691 T1D, 3,870 rheumatoid arthritis, 7,987 celiac disease, 5,112 multiple sclerosis
and 12,370 control samples were analysed. SNPs were filtered to meet the following criteria:
call rate > 0.99; minor allele frequency > 0.01; Hardy–Weinberg |Z| < 5. SNPs that passed
these thresholds in controls and any specific pair of cases were used for that pairwise analysis.
I excluded low frequency variants (MAF< 1%), both to reduce the number of models to be
considered and because genotyping errors are more common amongst this group of SNPs, and
I did not have cluster plots available for all diseases. Although GWAS typically have sufficient
power to detect association only with more common SNPs, some rarer variants (for example,
in TYK2 [Mero et al, 2010]) have been reported with these diseases which will be missed in
my analysis.
Using only UK cases and controls means that I expect any effects of population
stratification to be very limited, as evidenced by the low genomic inflation factors in
published UK ImmunoChip analyses [Cooper et al, 2012], and I did not take any further
specific actions to limit effects from population stratification.
2.6.2 Selection of Regions for Analysis
I considered all regions annotated in ImmunoBase (accessed 11 December 2013) to be associated
with at least one of the four diseases we studied. Where regions overlapped, I formed the union.
Regions containing fewer than 10 SNPs or with a SNP density of < 1 SNP/kb were excluded.
The major histocompatibility complex (MHC) region (chr6:29,797,978–33,606,563, hg18) was
removed from the analysis because this region is known to have complex multi-SNP effects. A
full list of the 126 regions analysed, together with our resulting associations, can be found in
Appendix A.
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2.6.3 Identification of Disease-Specific Regions
To examine evidence for GWAS association with other, non-autoimmune, traits, I took the
index SNP with the smallest p-values in a region and then identified proxy SNPs on the basis
of LD (r2 ≥ 0.9) using 1000 Genomes Project EUR (European) data. I used these SNPs as
a query set to examine associations annotated in the US National Institutes of Health GWAS
catalog (accessed 10 July 2014).
I defined disease-specific regions as those for which (i) the posterior probability of
single-SNP association was >0.5; (ii) the posterior probability of association with any other
disease was <0.2; (iii) the region was not annotated as associated with any other
autoimmune disease in ImmunoBase; and (iv) no proxies for the index SNP were associated
with any other autoimmune disease in the US National Institutes of Health GWAS catalog.
2.6.4 Type 2 Diabetes Data
Summary from a T2D GWAS meta–analysis [Morris et al, 2012] was downloaded from the
DIAGRAM website (accessed 20/10/14).
2.7 Results
2.7.1 Overview of Results
The Bayesian approach assumes a single causal variant per trait in any region. To allow for
multiple causal variants, I used a stepwise method. In the overwhelming majority of cases
(740 out of 756 pairwise comparisons, or 98%) data were consistent with at most one causal
variant per trait in a region. Ninety of the 126 regions (71%) showed association with at
least one disease; in 33 regions, the association was shared between at least two diseases
(Figure 2.3). Complete results can be found in Appendix A, and in Supplementary Table 2
and Supplementary Table 3 of [Fortune et al, 2015] (http://bit.ly/2d7KvUO). For fifty–seven
regions, the greatest support was for association with precisely one of the four diseases; in 21
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Figure 2.3 A Venn diagram a showing summary of disease assignments to 90 regions
which showed association to at least one disease, based upon the results of the
Bayesian analysis. In cases where assignment was uncertain, the assignment most
supported by the posterior probabilities was used. The numbers in brackets correspond
to how many of these regions show evidence of distinct causal variants. Thirty six
regions analysed did not demonstrate association to any disease within my available
data, and so are not included in this figure.
cases, I know of no other immune–mediated diseases that have reported association to these
regions and therefore hypothesize these may be disease specific among autoimmune diseases
(Table 2.2).
In the Bayesian approach, when the posterior probability of a hypothesis is close to 0.5,
assignment cannot be made with confidence to any single hypothesis. However, in the 30
instances in which both diseases showed very strong evidence of association (P(H3 or H4) >
0.9), the Bayesian and proportional approaches produced consistent results. For these 30 cases,
the proportional null was rejected only in cases in which the Bayesian analysis favoured H3, and
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not rejected in cases where H4 was favoured. Focusing on these, the data strongly supported
that the same causal variants underlie all diseases in ten cases, while seven showed strong
evidence for distinct variants, suggesting that just under half, 42%, of overlapping association
signals reflect distinct causal variants. In total, fourteen regions showed evidence of separate
SNP effects (P(H3 > 0.5), see (Table 2.3).
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2.7.2 Disentangling Patterns of Association
For colocalized disease regions, the two diseases generally have consistent directions of effect
(Figure 2.4) with the exception of the 6q25.3 region containing candidate gene TAGAP,
which is associated in my analysis with CEL and MS only: the risk allele for CEL is
protective for MS and vice versa (Figure 2.5). This opposing effect of TAGAP alleles has
been previously described for T1D and CEL [Smyth et al, 2008], although the region did not
provide sufficient evidence for association with T1D in the data available to us. A similar
effect for the 2q12.1 region containing candidate gene IL18RAP has also been
reported [Smyth et al, 2008]. However, later data [Barrett et al, 2009a] have not offered
support for T1D association to 2q12.1, and, in my analysis, the posterior support is
concentrated on CEL association alone.
Patterns of association with multiple diseases can be complex. In the 2q33 region containing
established candidate gene CTLA4, as well as the equally strong functional candidate genes,
CD28 and ICOS, three potential causal variants appear to be partially shared between T1D,
RA and CEL. The strongest association with T1D is at rs3087243 (which has previously been
called CT60), while the strongest association with CEL is with rs231775 (which alters the
amino acid at position 17 of CTLA4, Ala17Thr, and has previously been called CT42). The
two SNPs have r2 = 0.5, and haplotype analysis has previously suggested CT60 and not CT42
is causal for Graves’ disease [Ueda et al, 2003]. For RA, the strongest single SNP signal is
at rs1980422, which is not in LD with either CT42 or CT60 (r2 < 0.1). I fitted the 512
possible standard multinomial models involving these three SNPs for the three diseases, and
computed approximate Bayes factors for each. Assuming each model to be equally likely a
priori, the model with highest posterior probability has rs1980422/rs3087243 (CT60) signals
for CEL and rs231775 (CT42)/rs1980422 for both T1D and RA, although whilst rs231775
(CT42) is the strongest effect for T1D, rs1980422 is strongest for RA (Fig. 2.6). I note that my
analysis is based on SNPs selected through a stepwise process and that without fine mapping
analysis I cannot claim that any one of these models correctly reflects the causal variants for
any disease. These results do, however, clearly illustrate the different patterns of association
58 Colocalization for Common Controls
with the three disorders and emphasize the potential complexity that can arise in regions of
multiple association signals. They motivate the future extension of the colocalization approach
developed here to allow model search strategies that do not require stepwise assumptions.
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Figure 2.4 The distribution of ηˆ, the estimated proportionality coefficient together
with its 95% confidence interval. In the case of colocalization, η is the ratio of the
effects the region exerts upon the two traits. |η| > 1 corresponds to a stronger effect in
Trait 2 than Trait 1. I estimate η by ηˆ. Labels on the x-axis give the traits and regions
analysed; D for T1D, R for RA, C for CEL and M for MS. Note that in some regions,
the conditional analysis supports the existence of multiple associated variants: if none
of these overlap, then I consider the region to have separate SNP effects. (a) Regions
with strong evidence of colocalization (P(H4) > 0.9). As expected, ηˆ is distributed
about 1, which corresponds to the regions having equal effects on each trait. Note that
6q25.3, containing the candidate causal gene TAGAP, has ηˆ < 0, indicating opposite
effects on the two diseases. Trait 1 is listed first, and trait 2 second. (b) Regions with
novel evidence of disease association, in which I believe there to be colocalization
present between the novel association and at least one of the existing associations.
Regions have been ordered such that ηˆ estimates the effect size for the novel trait
divided by the effect size for the known association. The disease at which the novel
association is found is given first in the labels. It can be seen that the effect size tends
to be smaller in the new disease.
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Figure 2.5 The 6q25.3 region containing candidate causal gene TAGAP. There is
strong evidence of colocalization between CEL and MS (P(H4) ∼ 0.94). However, the
proportional approach reveals that the risk allele for CEL is protective for MS and vice
versa.
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Figure 2.6 (a) A Manhattan plot of the 2q33.1 region containing the candidate gene
CTLA4. Three potential causal variants are partially shared between T1D, RA and
CEL; the blue signal corresponds to the tag rs231775, the green to rs1980422 and the
red to rs3087243. All other SNPs are coloured according to their linkage disequilibrium
with these three SNPs. SNPs rs231775 and rs3087243 have r2 = 0.50; all other
pairwise r2 < 1. (b) Each possible model involving these three SNPs was tested; the
four models with highest posterior probabilities, which together encompass over 90% of
the total posterior probability, are shown. (c) Effect size estimates (including 95%
confidence intervals) of each SNP for each disease for the most likely model. (d) Effect
size estimates (including 95% confidence intervals) of each SNP for each disease for the
second most likely model.
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2.7.3 Discovery of Novel Associations
Two regions were associated with all four diseases (Figure 2.3). One was the 6q23.3 region
containing candidate gene TNFAIP3, known to be associated with RA and CEL. There has
been some published evidence that T1D is associated with this region [Fung et al, 2009],
although not at genome–wide significant levels. My results identify a T1D signal, colocalized
with that for RA and CEL, suggesting a single shared causal variant affecting the three diseases.
There is also evidence of MS association, driven by a distinct causal variant (in the CEL-MS
analysis, P(H3) = 0.83, Figure 2.7).
The second region was 19p13.2, known to be associated with T1D, RA and MS,
containing the strong functional candidate gene TYK2, although immune adhesion genes
ICAM1 and ICAM3 are also good candidate genes. My analysis supports these associations,
with a posterior probability of colocalization approaching 1. I also find evidence for a novel
CEL association. In each of the pairwise analyses involving CEL, the probability of both
diseases being associated ≃ 0.88, although this could be a distinct signal: we have
P(H4|H3 ∩ H4) ≃ 0.5 (Figure 2.8). In total, eleven regions showed strong evidence of novel
association with P(H3 ∩H4) > 0.5 (Table 2.4).
In regions with colocalizing novel associations, effect sizes tended to be smaller in the new
disease (Figure 2.4). This could indicate that the stronger effect is in the previously known
association, or it could be due to the Winner’s Curse effect [Ioannidis, 2008], with the previously
known associations displaying inflated effect size estimates. In general for colocalized signals,
the coefficient of proportionality is centred about 1.
One novel association found was in the chromosome 1q24.3 region, known to be associated
with CEL and containing candidate gene FASLG. Pathway analysis also produced evidence
for a T1D-associated variant here [Evangelou et al, 2014], although no SNP has reached the
genome-wide significance threshold. My results support a shared causal variant for T1D and
CEL (posterior probability 0.71). The Bayesian approach also enables fine-mapping when dense
genotyping data are available, as is the case here. I identified a single likely causal variant lying
in a region with strong evidence of predicted regulatory activity, rs78037977 (Figure 2.9), with
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Figure 2.7 The 6q23.3 region containing candidate causal gene TNFAIP3. My results
show that T1D, RA and CEL all colocalize, suggesting a single shared causal variant
affecting the three diseases; rs6933404 being the most likely SNP. There is also
evidence of MS association, driven by a distinct causal variant. Note that this region
was associated with MS at genome-wide significant levels in the analysis of the
international MS dataset [Beecham et al, 2013]. SNPs are highlighted according to
their LD with the SNPs considered most likely to be causal by my analysis.
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Figure 2.8 A Manhattan plot of the 19p13.2 region containing the candidate causal
genes ICAM1, ICAM3 and TYK2. SNPs are highlighted according to their LD with
the SNPs considered most likely to be causal by my analysis. The green signal is
shared across all diseases, whereas the red signal is unique to CEL.
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a posterior probability of being causal amongst all genotyped variants, given the colocalization
hypothesis, of 0.99. Note that rs78037977 was removed from the CEL data in the original
analysis [Trynka et al, 2012] owing to failing a missingness check (the call rate of 99.942% was
just below the 99.95% cut-off). Plots of the signal clouds for the samples at this SNP are given
in Figure 2.10. The clustering shown here is of good quality, implying that the rs78037977
genotype can be considered reliable.
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Figure 2.10 Signal clouds for rs78037977, a SNP within the 1q24.3 region containing
candidate causal gene FASLG. This SNP was removed from the celiac disease data in
the original analysis owing to failing a missingness check. However, the clustering
shown here is of good quality, implying that the rs78037977 genotype can be
considered reliable.
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2.7.4 Prior Sensitivity
We tested prior sensitivity by varying p12 (the probability that an arbitrary SNP is associated
with both diseases) from p12 = 10−5 to 10−7, while keeping p1 and p2 (the probability that this
SNP is associated with only trait 1, or only trait 2) constant at 10−4 (Table 2.5). Whether a
region is disease specific is largely unaffected by choice of p12 and, for the five regions discussed
in detail in this paper (1q24.3/FASLG; 2q33.1/CTLA4 ; 6q23.3/TNFAIP3 ; 6q25.3/TAGAP
and 19p13.2/TYK2 ), the prior does not change which diseases are associated. However, the
posterior odds for H4 : H3 does vary with p12. Under p12 = 10−7, neither 1q24.3/FASLG nor
6q23.3/TNFAIP3 had strong posterior support as a novel T1D region since the evidence for
novel association in these regions comes about due to colocalization with the stronger previously
known association. This dependence on prior belief is a strength of Bayesian methods, but they
require that priors be carefully calibrated. Whilst my prior belief is that about 50% of regions
associated with two immune–mediated diseases are likely to correspond to a shared causal
variant, others may disagree. The results given in Supplementary Table 2 of [Fortune et al,
2015] (http://bit.ly/2d7KvUO) can be used to calculate the posterior under any alternative
p12 using the formula given in Section 2.5.1.3.
Details of the results from the Bayesian and proportional analyses, for regions discussed in
detail in this Chapter, included in Table 2.3 or in Table 2.4, are given in Appendix B.
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2.8 Discussion
Colocalization methods so far have allowed for the simultaneous analysis of only two traits: a
potential weakness when considering more than two diseases, as investigated here. The
Bayesian approach could be extended to arbitrarily many traits, at the cost of increased
computational complexity and spreading the posterior over an exponentially increasing
hypothesis space, potentially making it difficult to draw firm conclusions. [Flutre et al, 2013],
in their description of an alternative method for partitioning the association of a single SNP
amongst multiple related quantitative traits, suggest dealing with this complexity by
considering only the extremes - a SNP is associated with all traits, exactly one, or none. Such
reduction is impractical when analysing regions, since it does not allow for overlapping but
distinct signals. Although I have extended my software to consider three diseases
simultaneously, I have chosen for practical reasons to focus on pairwise analyses with manual
curation of the 11 cases (9%) for which more than two diseases showed association.
[Giambartolomei et al, 2014] showed that inference is consistent when the causal variant
is directly genotyped or well imputed. The decision was taken when the ImmunoChip was
designed not to thin by LD, but instead target all SNPs and small insertions/deletions known
at that time in 1000 Genomes European samples and it has since been shown that common
variants may be very accurately imputed using ImmunoChip [Deelen et al, 2014]. Therefore I
am likely to be very close to the situation where causal variants are directly genotyped. The
application of my method to the less complete coverage provided by genome–wide SNP arrays
would require an imputation step to allow consistent inference to be made. The Bayesian
colocalization analysis assumes a single causal variant per region, which could be restrictive,
and I addressed this using a stepwise approach, attempting to colocalize the individual signals
for each disease where there was evidence for more than one. The agreement between my
results with this approach and using the proportional colocalization approach which does not
make this assumption confirms the appropriateness of the stepwise approach in the cases I
consider.
I identified 21 regions that appeared to be associated to only one autoimmune disease.
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One challenge in interpretation when defining disease unique signals is exemplified by a region
on chromosome 7p12.2 which contains the candidate causal gene IKZF1. This gene overlaps
two ImmunoChip regions separated by a recombination hotspot, one 5’ of IKZF1 and one 3’
of IKZF1. The 5’ region contains a colocalized signal for MS and T1D, whilst the 3’ region
contains only a T1D signal (Figure 2.11). My analysis has been based on regions, as defined in
the design of the ImmunoChip and based on recombination hot spots. However, whilst the T1D
signals in these regions are independent and the 3’ region of IKZF1 appears unique to T1D, it is
plausible that the causal variants in both regions act through the same gene, IKZF1. Another
challenge is to deal with the effects of power, given the established influence of sample size on
power to detect associations [Visscher et al, 2012]. Many of the regions in Table 2.2 contain
genes linked to immune function, and I expect a number of apparent disease–specific results
to associate with other diseases as sample sizes for each disease continue to increase. Indeed,
the chromosome 19p13.11 region, associated only with MS in my analysis, has previously been
associated with lymphocyte count [Nalls et al, 2011], with high LD between the peak MS SNP
(rs1870071) and the lymphocyte count SNP (rs11878602, r2 = 0.99), suggesting an immune
mechanism for the association.
However, in the case of T1D, three disease–unique regions overlap known type 2 diabetes
(T2D) regions. Chromosome 9p24.2, containing the candidate gene GLIS3, has been associated
with T2D [Morris et al, 2012] and fasting glucose [Dupuis et al, 2010] with high LD between the
peak SNP for T1D (rs10814914) and these other traits (rs7041847, r2 > 0.9). GLIS3 and its
causal allele alter disease risk by altering pancreatic beta–cell function, probably by increasing
beta–cell apoptosis [Nogueira et al, 2013]. Chromosome 16q23.1, containing the candidate
gene BCAR1, is associated with T1D in my analysis and T2D [Morris et al, 2012], and the
T2D alleles in this region have been associated with reduced beta cell function [Harder et al,
2013], again with high LD between the peak SNPs for T1D (rs8056814) and T2D (rs7202877,
r2 = 0.81). Inspecting the distribution of T2D GWAS p-values at the peak SNPs in my T1D
associated regions (Figure 2.12), I note that the peak SNP in the T1D associated region 6q22.32,
rs17754780, also shows association to T2D (p = 7.9× 10−5) and is in tight LD with peak T2D
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Figure 2.11 The 7p12.2 region containing candidate causal gene IKZF1. This gene
overlaps two ImmunoChip regions separated by a recombination hotspot, one at the 5’
end, one at the 3’ end. The 5’ region contains a colocalized signal for multiple sclerosis
(MS) and type 1 diabetes (T1D), while the 3’ end contains only a T1D signal.
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SNP in the region (rs9385400, r2 = 0.97). This region has been reported as associated with
T2D at genome–wide significance in a larger study [Scott et al, 2014]. Chromosome 6q22.3
is not uniquely associated to T1D in my analysis because it overlaps an established Crohn’s
disease region [Jostins et al, 2012], but the lead Crohn’s SNP (rs9491697) is not in LD with
the T1D SNP (r2 = 0.03). This is then likely to be a third shared signal between T1D and
T2D. The nearest genes are MIR588, about which little appears to be known, and CENPW
(centromere protein W) which has no obvious functional candidacy. This genetic overlap
between T1D and T2D (Table 2.6) emphasizes that T1D results from an interaction between
the immune system and beta cells, and it is probable that some of my other apparent disease
unique regions will also prove to be specific to the target of autoimmune destruction in MS
and RA.
By analyzing regions known to associate with one disease, I was able to link 11 of them to
additional disorders: in most cases (8/11) the novel disease association was clearly colocalized
with a previously known signal, whilst in one case, GPR183, the evidence supported a distinct
causal variant for the novel association. In others (3/11) the evidence for colocalization was
more equivocal, even with evidence for pairwise association. My results have been incorporated
into the online resource ImmunoBase (www.immunobase.org).
In a standard GWAS analysis, a p–value significance threshold of 5 × 10−8 is used in the
absence of replication data, due to a desire to minimise reporting of false positive results,
although a relaxation of this threshold has been suggested [Panagiotou and Ioannidis, 2012].
However, since autoimmune diseases are known to share aetiology, conditioning upon
association for one autoimmune disease, I should require a less stringent threshold to believe
it significant for another. Indeed, whilst the question of whether the ImmunoChip
significance threshold should be somewhat relaxed remains [Parkes et al, 2013], examination
of p–values in the regions in which I observe novel associations (Figure 2.13) suggests that a
threshold between 10−5 and 10−6 for SNPs that are confirmed index SNPs for another
disease might be more appropriate. This logic was extended to call novel T1D associations
conditional on other genome wide significance associations [Onengut-Gumuscu et al, 2015]. I
2.8 Discussion 75
−
lo
g1
0 
p−
va
lu
e
l l
l
l
ll
l
l
l
l
l ll l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
0
1
2
3
4
Not T1D Unique T1D Unique
6q22.32
16q23.1 BCAR1
9p24.2 GLIS3
Figure 2.12 P-values for Type 2 Diabetes at the peak SNP for all T1D-associated
regions. These regions are divided into those associated with T1D only and those
associated with other autoimmune diseases. Those associated with no other
autoimmune disease tend to have lower T2D p-values. T2D data was taken from the
Stage 1 GWAS and Stage 2 Metabochip: Summary Statistics downloaded from
http://diagram-consortium.org.
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estimate that 42% of overlapping and genome–wide significant immune–mediated disease
signals relate to distinct causal variants. In these regions, therefore, there appear to be
distinct causal variants for two or more autoimmune diseases which are physically proximal
but in low LD. I suggest that physical proximity to a known associated variant in a related
disease, and not only LD with it, may prove to be an appropriate criterion with which to
alter interpretation of a small but not genome–wide significance threshold. Variants meeting
such thresholds might be prioritised for genotyping in replication samples. I note, also, that
the four diseases I studied are all characterized by the presence of autoantibodies. Had I
included autoantibody negative diseases I might have found a higher proportion of discordant
associations as reported in a previous manual curation of ImmunoChip studies [Parkes et al,
2013], given that there remains considerable overlap in location of association signals.
Although a careful and detailed manual curation of several studies has been
conducted [Parkes et al, 2013], the ability of colocalization methods to distinguish shared
from distinct causal variants allows clearer interpretation of genetic results.
In summary, I have developed a methodology for examining shared genetic aetiology
between diseases in the case of common control datasets, extending previous work [Plagnol
et al, 2009; Wallace et al, 2012; Giambartolomei et al, 2014]. This enables the discovery of
new disease associations and the exploration of complex association patterns. Although these
methods have been presented in this paper to analyse autoimmune diseases, the prior is
user-defined, and could be used to analyse any pair of related diseases.
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Figure 2.13 P-value and colocalization data from the regions with newly identified
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Chapter 3
Simulating GWAS Summary
Statistics
3.1 Motivation
In a typical statistical hypothesis test, we have a null hypothesis of no association and quantify
the significance of the result with the p-value: the probability of seeing data at least as extreme
as that observed under the null hypothesis. Often, this is relatively simple to compute. For
instance, in a GWAS, we perform single-SNP based tests, and under the null hypothesis that
the SNP in question has no association with the trait, the test generates a Z Score which has
distribution N(0, 1) from which a p-value can be computed. However, when the null hypothesis
is more complex, the distribution of the test statistic under the null hypothesis may become
difficult to compute.
Consider for instance SNP set enrichment analysis. Here, an entire set of GWAS statistics
is analysed to see whether the GWAS signals or causal SNPs appear to be enriched in areas of
interest; see for instance [Trynka et al, 2015]. In a network analysis, we might be interested in
whether the causal SNPs occur disproportionately nearer genes within the network, implicating
the network in the process of the disease [Carbonetto and Stephens, 2012]. Alternatively, we
might wish to integrate functional annotations with GWAS data, and see whether, for instance,
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the causal variants occur within binding sites of the transcription factors which regulate some
process of interest. In this sort of analysis, the null hypothesis is not that of no association:
instead, it is that there is association, but that association is not enriched within the features
of interest. It is not trivial to compute the null distribution for any enrichment test statistic
without assumptions of independence between SNPs and feature locations which do not hold.
A common technique in such studies, both to enable the generation of an appropriate null
and to ensure that multiple testing is properly corrected for, is permutation testing. Here,
the underlying dataset is used, but the labels are permuted to create a new dataset with
equivalent trait-association but no correlation to the feature of interest. If full genotype data
is known, case/control can be permuted between samples, but this removes any genotype-trait
association. If only summary statistics are given, the Z Scores can be permuted between SNPs,
or the location of the functional annotations can also be moved. By computing the output
statistic from this new dataset and repeating such permutations, one hopes to converge upon
the null distribution of outputs.
However, by permuting, we often destroy the genomic structure within the region, leading
to an estimate of the null distribution which does not accurately reflect the true behaviour.
For instance, SNPs which are in high LD will have similar p-values, but permutation testing
does not preserve this behaviour. Such permutation also relies on an underlying assumption
that causal variation is evenly distributed throughout the region. However, this is not the case.
In a GWAS, we would typically expect to see lower p-values in areas around genes, compared
to those p-values observed in intergenic regions. When we are interested in features that also
locate near genes, proximity to genes becomes a confounding factor.
One approach, which is similar conceptually to permutation testing, but which controls for
genomic structure, is GoShifter [Trynka et al, 2015], which tests for enrichment of functional
annotations at causal SNPs. Rather than applying a random permutation, the method shifts
annotations by a random distance (with annotations shifted beyond the region re-emerging
on the opposite side), thereby preserving the majority of the local structure. It also enables
controlling for a second, potentially causal, annotation which colocalizes with the annotation
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under analysis, by partitioning the region into those sections with the second annotation and
those without, and shifting within these two sections independently. However, this method is
computationally complex. It also only preserves structure within individual genetic loci, not
ideal for pathway analysis, which is frequently conducted over larger regions.
All these methods rely upon somehow simulating an approximation of the null distribution.
This need not be necessary if it is possible instead to use a competitive null. This approach
is taken in the VSEAMS package [Burren et al, 2014]. In this method, a control set of genes,
not believed to have any association with the trait but selected to match the structure around
the test set of genes, are chosen, and p-values near each set are compared. If the control is
well chosen, this category of methods works well. However, they rely upon the existence of a
large body of prior knowledge about the regions being analysed; it is also necessary to very
carefully specify the biological hypothesis being tested.
In this chapter, I present a method which takes as input a list of causal SNPs, W, and a
list of odds ratios of effect, γ, and returns the expected output from a GWAS of the region
in question with N0 control samples and N1 case samples, assuming the causal model holds.
The only additional input required is the LD structure of the region(s) under analysis, which
can be inferred from an appropriate reference dataset; hence, it can be used in cases where
raw genotype data is not available. By selecting appropriate causal SNPs, multivariate normal
sampling given this expected Z Score can then be used to form outputs which could have
arisen under a competitive null. By repeatedly computing such expected Z Scores for random
causal models rather than perturbing the observed GWAS output in some way, the true null
distribution may be estimated while preserving genomic structure. The code used can be found
at https://github.com/mdfortune/simGWAS.
3.2 Estimation of Expected Z Scores from a GWAS
In this section, I show how expected GWAS Z Scores may be computed given only data on
allele frequencies in controls, reference haplotype frequencies, and a model of which SNPs are
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causal and their effects on disease odds.
3.2.1 Value of the Z Score
For a GWAS dataset, let Yi ∈ {0, 1} denote the indicator of disease status at the ith sample.
Let there be a total of N samples selected, with N1 having been chosen from disease cases
(Yi = 1) and N0 having been chosen from disease controls (Yi = 0). Since this sampling is
conditional upon case/control status, genotype frequencies may differ between our N samples
and the whole population at disease associated SNPs. I therefore need to distinguish between
which datasets my genotype probabilities are from; write Psam for probabilities computed for
the samples (i.e. Psam(Yi = 1) = N1N )
Let n be the total number of SNPs. For any SNP X, write GXi for its genotype coding
∈ {0, 1, 2} at sample i .
For the commonly used Cochran-Armitage test, the Z-Score at SNP X is computed as:
ZX =
UX√
V
Where:
UX =
N∑
i=1
((GXi −GX)(Yi − Y¯ ))
V = (N − 1)VXVY
and VX , VY are the variance of GX and Y respectively:
VX =
N
N − 1
∑N
i=1(GXi −GX)2
N
VY =
N0N1
N(N − 1)
i.e.:
V = N0N1
N(N − 1)
N∑
i=1
(GXi −GX)2
Under the null hypothesis of no association at SNP X, ZX is distributed as a standard
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normal. Hence the two-sided p-value at X is given by:
pX = 2(1− Φ(|ZX |))
where Φ is the cumulative distribution function of the standard normal distribution.
Conversely, given the unsigned p-value at X, the absolute value of the Z-Score is:
−Φ−1
(
p
2
)
3.2.2 The Causal Model
Write W = W1, ...,Wm for the vector of causal SNPs. Since they are causal, the allele
frequencies at these SNPs will vary between cases and controls. From publicly available
reference datasets such as UK10K [Walter et al, 2015], it is possible to estimate the
haplotype frequencies, P(GW = w|Y = 0) using SNPHAP (Clayton D,
http://www-gene.cimr.cam.ac.uk/clayton/software/), which implements an EM
Algorithm. Note that, since sampling is independent of anything but case/control status, I
can assume:
Psam(GW = w|Y = 0) = P(GW = w|Y = 0)
Write γ1, ..., γm for the log odds ratios of effect for the causal SNPs in the population. I assume
that Y given GW can be modelled as a binomial logistic regression. Then, from [Prentice and
Pyke, 1979], the sample-specific odds ratios are the same as those at the population-level, and
I can write:
Psam(Yi = 1|GWi = w) =
eγ0+γ1w1+...+γmwm
1 + eγ0+γ1w1+...+γmwm
where γ0 is a parameter which corresponds to the overall proportion of cases. Since GWAS
sampling is retrospective, this proportion is fixed at N1N , constraining γ0, which can be computed
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as follows:
Psam(Yi = 1) =
N1
N
=
∑
w∈Zm3
Psam(Yi = 1|GWi = w)Psam(GWi = w)
=
∑
w∈Zm3
Psam(Yi = 1|GWi = w)
Psam(Yi = 0|GWi = w)
Psam(Yi = 0|GWi = w)
Psam(GWi = w)
=
∑
w∈Zm3
Psam(Yi = 1|GWi = w)
Psam(Yi = 0|GWi = w)
Psam(Yi = 0)P(GWi = w|Yi = 0)
= N0
N
∑
w∈Zm3
eγ0+γ1w1+...+γmwmP(GWi = w|Yi = 0)
γ0 = ln
(
N1
N0
∑
w∈Zm3 e
γ1w1+...+γmwmP(GWi = w|Yi = 0)
)
Hence I can compute:
Psam(GWi = w) =
P(GWi = w|Yi = 0)Psam(Yi = 0)
Psam(Yi = 0|GWi = w)
And also:
Psam(GWi = w|Yi = 1) = P(GWi = w|Yi = 1) =
Psam(Yi = 1|GWi = w)Psam(GWi = w)
Psam(Yi = 1)
I assume that LD structures do not differ between cases and controls, and hence the correlation
between W and X is independent of disease status, or of our sampling. Thus:
Psam(GXi = x|GWi = w) = P(GXi = x|GWi = w)
and I can estimate, for both the whole population, and for my sample:
E((GXi )a|GWi = w) = 2a
P(GXi = 2 ∩GWi = w|Yi = 0)
P(GWi = w|Yi = 0)
+ P(G
X
i = 1 ∩GWi = w|Yi = 0)
P(GWi = w|Yi = 0)
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from my reference dataset, for any constant a. From this, I compute:
E((GXi )a|Yi = 1) =
∑
w∈Zm3
E((GXi )a|GWi = w)P(GWi = w|Yi = 1)
=
∑
w∈Zm3
P(GWi = w|Yi = 1)
P(GWi = w|Yi = 0)
[
2aP(GXi = 2 ∩GWi = w) + P(GXi = 1 ∩GWi = w)
]
E((GXi )a|Yi = 0) =
∑
w∈Zm3
E((GXi )a|GWi = w)P(GWi = w|Yi = 0)
=
∑
w∈Zm3
2aP(GXi = 2 ∩GWi = w) + P(GXi = 1 ∩GWi = w)
By expanding out the numerator in terms of probabilities within the sample dataset, I see that:
P(GWi = w|Yi = 1)
P(GWi = w|Yi = 0)
= Psam(Yi = 1|G
W
i = w)Psam(GWi = w)
P(GWi = w|Yi = 0)Psam(Yi = 1)
= Psam(Yi = 1|G
W
i = w)Psam(GWi = w|Yi = 0)Psam(Yi = 0)
P(GWi = w|Yi = 0)Psam(Yi = 1)Psam(Yi = 0|GWi = w)
= N0
N1
eγ0+γ1w1+...+γmwm
And hence:
Esam((GXi )a) =
N1
N
E((GXi )a|Yi = 1) +
N0
N
E((GXi )a|Yi = 0)
= N0
N
∑
w∈Zm3
eγ0+γ1w1+...+γmwm
[
2aP(GXi = 2 ∩GWi = w) + P(GXi = 1 ∩GWi = w)
]
+N0
N
∑
w∈Zm3
[
2aP(GXi = 2 ∩GWi = w) + P(GXi = 1 ∩GWi = w)
]
= N0
N
∑
w∈Zm3
(
eγ0+γ1w1+...+γmwm + 1
)
[
2aP(GXi = 2 ∩GWi = w) + P(GXi = 1 ∩GWi = w)
]
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3.2.3 Estimation of Z Score for the causal model given by W
and γ
Finding the true expectation of UX√
V
is intractable, so instead I compute a first order
approximation by assuming independence:
E(ZX) = E
(
UX√
V
)
≈ E(UX)× E( 1√
V
)
These terms can be computed as shown in the following sections.
3.2.3.1 Estimation of UX, the covariance between GX and Y , for the causal
model given by W and γ
I compute the expectation of UX in my sample as follows:
Esam(UX) = Esam
[
N∑
i=1
(GXi −GX)(Yi − Y¯ )
]
= Esam
[
N
(
N∑
i=1
GXi Yi
)
− 1
N
(
N∑
i=1
GXi
)(
N∑
i=1
Yi
)]
= NEsam(GXi Yi)−
1
N
[
NEsam(GXi Yi) +N(N − 1)Esam(GXi Yj)
]
i ̸= j
= (N − 1)
[
Esam(GXi Yi)− Esam(GXi Yj)
]
= (N − 1)
[
Esam(GXi |Yi = 1)Psam(Yi = 1)
]
−
−(N − 1)Esam(Yj)
[
Esam(GXi |Yi = 1)Psam(Yi = 1) + Esam(GXi |Yi = 0)Psam(Yi = 0)
]
= (N − 1)N0N1
N2
[
Esam(GXi |Yi = 1)− Esam(GXi |Yi = 0)
]
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Using the expressions for Esam(GXi |Yi) given in Section 3.2.2, this becomes:
Esam(UX) =
(N − 1)N0N1
N2
∑
w∈Zm3
[(
N0
N1
eγ0+γ1w1+...+γmwm − 1
)
[
2P(GXi = 2 ∩GWi = w) + P(GXi = 1 ∩GWi = w)
]]
3.2.3.2 Estimation of VX, the variance of GX, for the causal model given by
W and γ
Recall:
VX =
1
(N − 1)
N∑
i=1
(GXi −GX)2
= 1(N − 1)
( N∑
i=1
(GXi )2
)
− 1
N
(
N∑
i=1
GXi
)2
However, I need to find E
(
1√
VX
)
.
VX is the variance of a normal, and so I model it as an Inverse Gamma (α, β) distribution.
Then V −1X has a Γ(α, β−1) distribution, and
√
V −1X has a generalised gamma distribution with
parameters p = 2, d = 2α, a =
√
β−1. If VX ∼ Inverse Gamma (α, β), then
E(VX) =
β
α− 1 V ar(VX) =
β2
(α− 1)2(α− 2)
Assuming I can compute computed Esam(VX) and Esam(V 2X), α and β are completely specified
as:
α = 2E(V
2
X)− (E(VX))2
E(V 2X)− (E(VX))2
β = E(VX)E(V
2
X)
E(V 2X)− (E(VX))2
and E
(
1√
VX
)
may be simply computed using:
E
( 1√
VX
)
= a
Γ(d+1p )
Γ(dp)
= 1√
β
Γ(2α+12 )
Γ(α)
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Expectation of VX
Esam(VX) =
1
(N − 1)
[
NEsam((GXi )2)−
1
N
(
NEsam((GXi )2) +N(N − 1)Esam(GXi GXj )
)]
= 1(N − 1)
[
(N − 1)Esam((GXi )2)− (N − 1)Esam(GXi GXj )
]
= Esam((GXi )2)− (Esam(GXi ))2
Expectation of V 2X
Esam(V 2X) =
( 1
(N − 1)
)2
Esam
( N∑
i=1
(GXi )2
)2
− 2
N
(
N∑
i=1
(GXi )2
)(
N∑
i=1
GXi
)2
+ 1
N2
(
N∑
i=1
GXi
)4
Let En = Esam((GXi )n). Breaking this down into terms, for (i, j, k, l) representing different
indices, I have:
Esam
( N∑
i=1
(GXi )2
)2
= NEsam((GXi )4) +N(N − 1)Esam((GXi )2(GXj )2)
= NE4 +N(N − 1)
Esam
( N∑
i=1
(GXi )2
)(
N∑
i=1
GXi
)2
= NEsam((GXi )4) + 2N(N − 1)Esam((GXi )3(GXj )) +N(N − 1)Esam((GXi )2(GXj )2) +
+ N(N − 1)(N − 2)Esam((GXi )2(GXj )(GXk ))
= NE4 + 2N(N − 2)E3E1 +N(N − 1)E22 +N(N − 1)(N − 2)E2E21
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Esam
( N∑
i=1
GXi
)4
= NEsam((GXi )4) + 4N(N − 1)Esam((GXi )3(GXj )) + 6N(N − 1)Esam((GXi )2(GXj )2) +
+ 6N(N − 1)(N − 2)Esam((GXi )2(GXj )(GXk )) +
+ N(N − 1)(N − 2)(N − 3)Esam((GXi )(GXj )(GXk )(GXl ))
= NE4 + 4N(N − 1)E3E1 + 6N(N − 1)E22 + 6N(N − 1)(N − 2)E2E21 +
+ N(N − 1)(N − 2)(N − 3)E41
Giving:
Esam(V 2X) =
1
N
E4 − 4
N
E3E1 + 2
N2 − 2N + 6
N(N − 1) E
2
2 − 2
(N − 2)(N − 3)
N(N − 1) E2E
2
1 +
(N − 2)(N − 3)
N(N − 1) E
4
1
3.2.4 Summary
Thus, given only a choice of which SNPs are causal (W), their effect sizes (γ), sample sizes
(N0, N1) and a reference dataset from which I can derive allele frequencies (E(GXi |Yi = 0)) and
the relationships between SNPs (E(GXi |GWi = w)), I can derive an expected Z Score, ZEXP
at any SNP, causal or not. This can then either be used directly, or in order to compute the
simulated output from such a GWAS, ZSIM , which will be distributed:
ZSIM ∼ N(ZEXP ,LD)
where LD is the LD matrix of SNPs within the region.
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3.3 Choice of Parameters for Simulation
In order to compute a null distribution, we may wish to simulate the Z Scores from many
causal models {W,γ}, requiring a choice of sampling distribution over m, W and γ. It may
be that the context of the analysis constrains the choice of causal models. However, in the
absence of such context, I suggest the following null distributions:
3.3.1 Choice of m: number of causal SNPs
m is the number of causal SNPs in an LD-defined region in our model. It is difficult to
obtain an appropriate prior for m. Although a great many GWAS have been done (see,
for instance, the GWAS catalogue, www.ebi.ac.uk/gwas/), these typically report only the
top hit per region. When additional associations are sought, a typical approach is to work
conditionally, at each iteration finding the strongest signal which explains the remaining trait
variance; this is the strategy I took in my colocalization analysis (see Section 2.5.1.6). By
doing this, we potentially miss a set of multiple causal variants, none of which is individually
the top performing SNP [Wallace et al, 2015]. In addition, conditional approaches tend to be
conservative about the number of causal variants, with strong, often genome-wide significant,
evidence of an additional signal required, although this is not universal and more relaxed
thresholds are used too [Trynka et al, 2012]. This means that our estimates of m are likely
under-estimates.
It is also likely that the number of causal SNPs within a genetic locus varies with the disease
being studied. However, the biological focus of my analysis is upon autoimmune diseases.
Hence I present here my suggestion for the prior of m when testing autoimmune association.
GUESSFM [Wallace et al, 2015] is a fine mapping algorithm which uses a Bayesian
Stochastic Search to find the most likely set of causal variants in a region. As part of its
output, it gives its posterior belief about the number of causal SNPs in that region. I
obtained my prior on m by taking the GUESSFM results from 918 analyses (of 95 genetic
regions and for 10 autoimmune diseases) and averaging over these posterior probabilities
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m Probability
1 0.892
2 0.0856
3 0.0105
4 0.00754
5 3.59× 10−3
6 3.49× 10−4
7 1.20× 10−5
8 4.08× 10−8
9 2.98× 10−11
Table 3.1 Prior on m, the number of causal SNPs in a model.
(Chris Wallace, unpublished data). The numeric values of my prior are given in Table 3.1.
Although these results are highly dependent on the priors input into GUESSFM, the
stochastic search algorithm performs better than a conventional stepwise approach, and more
accurately incorporates knowledge about m in regions where the causal model does not
include the top hit.
3.3.2 Choice of W: causal SNPs
W1, ...,Wm are the causal SNPs. In the absence of any information about the region, the
most appropriate prior to use is a flat prior. Since causal variants are not distributed evenly
throughout the genome, if additional functional data about a region are available, it may be
appropriate to incorporate this to create a more informative prior.
Typically in GWAS, causal variants are found in non-coding but functionally active regions.
We also expect to see disease-specific effects; in a study of causal autoimmune disease variants,
∼ 60% were found to map to immune-cell enhancers [Farh et al, 2015]. There is evidence that
causal variants are disproportionally found in DNase 1 Hypersensitivity sites, regions where
the structure of chromatin exposes DNA to cleavage by the DNase enzyme [Maurano et al,
2012]. A variable prior for W could be found by application of a fine mapping tool which
incorporates this information, such as fgwas [Pickrell, 2014].
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3.3.3 Choice of γ: SNP effect sizes
The values of γi give the log odds ratio of the effect of each causal SNP i upon disease risk.
These can be user specified, and if a null is being generated, previous knowledge about the
specific circumstance may suggest values of γi. However, for those who do not have such
constraints, I suggest the following prior:
In order to estimate an appropriate prior distribution, I generated an empirical
distribution for γi by sampling ∼ 6000 studies of a similar design from the genome catalogue
(http://www.ebi.ac.uk/gwas/ ) and took the odds ratios for the potential causal SNPs found.
I then took the absolute values of the log odds, since sign corresponds to whether the allele
under study is the protective or deleterious allele, and this should be independent of the
absolute value of the effect. A plot of their distribution is given in Figure 3.1. This
distribution appears to be shaped like a gamma distribution, with the best fit being
Γ(0.81, 1.15).
Hence, I will use a Γ(0.8, 1.2) distribution as the prior for the absolute value of γi, with the
sign being positive or negative with equal probability (that is, I assume each direction of effect
is equally likely). Note that, this distribution is slightly flatter than the empirical distribution
of γi. However, this may be beneficial in cases where I am simulating multiple values of γ for
the same causal variants (see Chapter 4), as it enables me to search the space of odds ratios
more quickly.
As discussed in Section 3.2.2, once γ1, ..., γm have been chosen, γ0 is constrained to be:
γ0 = ln
(
N1
N0
∑
w∈Zm3 e
γ1w1+...+γmwmP(GWi = w|Yi = 0)
)
Note, however, that selecting γ from this distribution does not guarantee that the resulting
simulated output will be GWAS significant, even if the same odds ratios gave a significant result
on a different study. ZX is a function of both UX and VX ; when the MAF of X is low, VX is
large and hence the resulting Z Score is lower than it would be for a more common SNP.
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Figure 3.1 In black is given an estimated density of the empirical distribution of the
absolute value of the log odds ratio of effect for potential causal SNPs in GWAS, as
taken from the genome catalogue. In red is given the distribution of a Γ(0.8, 1.2)
random variable, which is an acceptable approximation.
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3.4 Validation of Method
3.4.1 Output from Method
Manhattan plots giving the p-values obtained from simulated GWAS (for one, two, three
and four causal variants) are shown in Figure 3.2. All SNPs are coloured according to their
correlation with the causal SNPs (which are shown by diamonds rather than circles). From
this, I see that the output appears to take the correct form, with causal SNPs having high
association and the p-value of other SNPs corresponding to their LD with the causal SNPs.
However, in order to validate my method, I must compare the outputs it gives to the true
Z Scores computed directly from a dataset where the causal model is known.
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Figure 3.2 Example outputs from simulated GWAS, for one, two, three and four
causal SNP models. Causal SNPs are designated by a coloured diamond. Non-causal
SNPs are designated by a circle, coloured according to their LD with their most
correlated causal SNP.
(a) A single causal variant, with γ0 = −0.19,γ = 0.25
(b) Two causal variants, with γ0 = −0.84,γ = (0.4, 0.2)
(c) Three causal variants, with γ0 = −0.37,γ = (0.2, 0.2, 0.2)
(d) Four causal variants, with γ0 = −2.30,γ = (0.4, 0.4, 0.4, 0.4)
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3.4.2 Construction of Datasets for Testing
I wish to generate a dataset of case/control genotypes with known causal SNPs and odds ratios
of effect. Control data can be sampled from a reference dataset used to estimate genotype
frequency, since by definition it has the desired P(GW = w|Y = 0). Sampling case data,
however, is harder; reference datasets for the disease under study may not be available, and,
in any case, unless the model {W,γ} is correct, true case data will not have the desired
Psam(GW = w|Y = 1). Hence, I also sample case data from the reference dataset, with
subject i, where GWi = w, being sampled with weight ζw. Since under this sampling scheme:
Pcase data(GW = w) = ζwP(GW = w in reference dataset)
= ζwP(GW = w|Y = 0)
by sampling with (non-normalised) weights ζw = P(G
W=w|Y=1)
P(GW=w|Y=0) I obtain a dataset with the
desired features.
3.4.3 Comparision between Observed and Expected Z Scores
Using the control datasets from my colocalization analysis (see Section 2.6 for details of samples
and QC) as reference datasets, I computed expected Z Scores for 600 GWAS with N0 = N1 =
5000, using the methods outlined in Section 3.2; causal models {m,W,γ} were generated using
the priors discussed in Section 3.3 and selected so that at least one GWAS-significant p-value
was expected.
For each of these causal models, I generated 100 case/control testing datasets using the
strategy detailed above. I then estimated an empirical expected observed Z Score by averaging
over the Z Scores computed directly from the datasets; by computing the mean, I reduce the
effect of randomness in dataset generation and hence have a better basis of comparison with
my theoretical expected Z Scores.
Ideally, my observed and expected Z Scores would be identical. In order to compare them,
I regressed the expected Z Score onto the observed Z Score for each of the 600 GWAS scenarios,
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with the intercept set to one. Figure 3.3 shows the results of this regression. On the left is the
distribution of R2, a measure of how collinear the two vectors are. The values from my analyses
are very close to one, indicating that expected and observed Z Scores are very proportional.
The coefficient of the regression indicates whether there is a difference of a constant factor
between the vectors; I have plotted the log transform of this for ease of interpretation. This
log coefficient is distributed tightly around zero, indicating that the expected and observed Z
Scores have almost identical values.
Taken together, these outputs demonstrate that my method produces an expected Z Score
which very closely matches the empirical expected Z Score from full data simulations. Outlying
points on Figure 3.3 typically correspond to datasets where even the top hit barely reaches
genome-wide significance. In these cases, the variance in the distribution of Z Scores around
zero, from those SNPs which are not associated with the disease, causes the linear fit to be
less good.
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R2 between Expected and Observed Z Scores
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Figure 3.3 Results when the expected Z Score, as generated by my algorithm, is
regressed upon the observed Z Score, with no intercept included.
(a) The R2, or coefficient of determination. Values close to 1 indicate that almost all
the variance in the observed Z Score can be predicted by the expected Z Score.
(b) The log of the regression coefficient. This is close to 0, corresponding to the
observed and expected Z Scores having almost identical values.
3.5 Discussion
I present in this chapter an algorithm for computing the expected output of a GWAS analysis
under a specified causal model. The only input required is a reference dataset of control
samples; genotyping of case samples is not needed. My results very closely match the summary
statistics generated from direct analysis of fully genotyped case/control datasets.
By generating many such GWAS and applying whichever enrichment analysis is of interest,
I can now estimate the null distribution for any test of whether the set of causal SNPs appears
to be significantly enriched within a particular annotation of interest. Unlike existing methods
such as GoShifter [Trynka et al, 2015], this fully preserves the genomic structure, even when
analysis is scaled over multiple regions.
In principle, this algorithm could be used to simulate output for any disease and in any
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region. However, it assumes that we can accurately estimate E(GXi |Yi = 0) from the reference
dataset used; this is, it assumes that the reference data, which may come from a cohort collected
for other purposes, and for which phenotype information is not available, contains no cases.
For rare diseases, such as autoimmune diseases, this may be an accurate assumption. While
there may be occasional disease cases within the reference dataset, the effect should be small
enough to not significantly change our results. However, this assumption is not justifiable for
a more common trait, such as obesity, and this algorithm is not appropriate for the case of a
common disease unless care is taken to ensure that the reference dataset used does accurately
reflect the genotypes of control samples.
With the benefit of more time, I would apply this method to integrate GWAS outputs
with epigenetic information. By using ChIP-seq data, I could determine whether disease-
associated variants occur within protein-binding sites, thereby implicating the protein in the
disease process. Integrating promoter capture Hi-C analysis would enable me to discover
whether causal variants are significantly enriched within promoter interacting regions for genes
of interest; this may also enable me to find tissue-specific effects.
However, this algorithm also has the potential to be used in fine mapping for datasets
in which only GWAS summary data are available. I can evaluate how well a causal model
fits the data given by computing the expected Z Scores, assuming that the model is true,
and comparing them to the Z Scores observed in the real data. Given the limitations in the
availability of full genotyping data I have encountered, this seemed a more pressing need. This
extension is the subject of my next chapter.
Chapter 4
Fine Mapping using GWAS
Summary Statistics
4.1 Motivation
Although GWAS have enabled the identification of many regions of association with complex
traits such as autoimmune disease, the top signals reported do not necessarily correspond to
the underlying causal variants (CVs); instead a low p-value may be caused by the apparent lead
SNP being in high LD with the true CV, and therefore “tagging”, it. Similarly, a gene located
in, or close to, a region showing disease association need not have any role in disease aetiology;
the CVs may instead act upon a different gene, some distance away from themselves. In order
to understand disease aetiology then, once a GWAS has reported association to a region, fine
mapping algorithms must be used in order to infer which variants are causal. These can
then be integrated with functional annotation data (for instance by performing a SNP set
enrichment analysis such as those discussed in Chapter 3 upon the set of causal SNPs) to find
disease-associated genes.
An obstacle often encountered in fine mapping is a lack of genotype data for the original
samples analysed in GWAS. GWAS datasets are very large, possibly consisting of a meta-
analysis of datasets from different sources; together with privacy concerns, this makes accessing
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raw data from studies difficult. Results from GWAS are typically reported as the summary
statistics from single-SNP regressions upon the trait of interest. For eQTL studies, even these
are often trimmed, only reporting nominally significant results. It is rarely reported whether
missing SNPs have p-values above the significance threshold, or whether they failed quality
control. While odds ratios are reported, or inferable, without specification of reference and
alternative alleles, and strand information in the case of A/T and C/G SNPs, it is not possible
to know the direction of effects of SNPs, and this information is not always given. There is
therefore need for fine mapping methods based solely upon p-values, with the use of a publicly
available reference dataset when required to estimate correlation between SNPs.
There are many approaches to fine mapping. One can directly use the p-values, and
consider all SNPs which reach a certain threshold, or which are in high LD with the top
GWAS signals, as potentially causal. Alternatively, a Bayesian approach can be taken, and
posterior probabilities for each SNP being the CV computed; these can then be combined
to obtain a credible set of SNPs which contain the true CV with some desired probability.
However, these methods assume that there is a single causal variant: a common simplifying
assumption, but not one which is biologically plausible in many regions. An iterative approach
can be used, repeatedly running such techniques until no additional CVs are found. However,
this risks making incorrect inferences in the case where no SNP in the true (multi-SNP) CV
set is individually the top performing SNP. These methods also require that all SNPs to be
considered are analysed (or the results imputed) in the GWAS.
In Section 1.5 I summarised two existing techniques, PAINTOR [Kichaev et al, 2014] and
CAVIAR [Hormozdiari et al, 2014] which perform fine mapping, using only marginal test
statistics from GWAS and the correlation between SNPs. They both allow for multiple-CV
models; PAINTOR also integrates functional genomic annotation data. However these methods
are likelihood based, requiring directions of effects for each SNP.
In this Chapter, I present a fine mapping technique I have developed which allows for
multiple causal variants while requiring only summary GWAS p-values and publicly available
reference datasets. It does not depend upon availability of effect size estimates or the allelic
102 Fine Mapping using GWAS Summary Statistics
direction of effect, and it can infer whether the pattern of association is likely to be caused
by a non-genotyped SNP without requiring imputation of summary statistics at this position.
Using the method outlined in Chapter 3, I am able to compute the expected Z Score from a
GWAS assuming the true causal model to be parameterized by {W, the causal SNPs, and γ
, their odds ratios of effect}. I can then compare this to the absolute Z Score I have from my
GWAS derived from the observed p-value; if the model is true, I would expect these two to be
similar. By considering many such models {W,γ}, and finding those which best fit with the
observed data, I am able to propose a set which likely contains the true causal model.
4.2 Development of my Approach
4.2.1 Likelihood Based Approaches
Using the same framework as in Section 3.2.1, the Z-Score at SNP X is given by:
ZX =
∑N
i=1((GXi −GX)(Yi − Y¯ ))√
N0N1
N(N−1)
∑N
i=1(GXi −GX)2
Let ZOBS denote the Z Score derived from a GWAS p-value. WritingW =W1, ...,Wm for the
causal SNPs, and γ = (γ0, γ1, ..., γm) for their odds ratios of effect, as before, I can decompose:
P(GXi = x|Yi = 0) =
∑
w∈Zm3
P(GXi = x|GWi = w)P(GWi = w|Yi = 0)
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P(GXi = x|Yi = 1) =
∑
w∈Zm3
P(GXi = x|GWi = w)P(GWi = w|Yi = 1)
=
∑
w∈Zm3
P(GXi = x|GWi = w)Psam(Yi = 1|G
W
i = w)Psam(GWi = w)
Psam(Yi = 1)
=
∑
w∈Zm3
P(GXi = x|GWi = w)P(GWi = w|Yi = 0)
(
Psam(Yi = 1|GWi = w)
Psam(Yi = 0|GWi = w)
Psam(Yi = 0)
Psam(Yi = 1)
)
=
∑
w∈Zm3
N0
N1
eγ0+γ1w1+...+γmwmP(GXi = x|GWi = w)P(GW = w|Yi = 0)
Using this, I could compute the likelihood of seeing the data observed, L(W,γ|ZOBS) =
P(ZOBS = zOBS |W,γ), using a simular approach to that used in Chapter 3 to compute
E(ZOBS |W,γ), and hence proceed with a likelihood based inference for W and γ.
A disease associated SNP can either be protective (that is, with a negative Z Score) or
deleterious (that is, with a positive Z Score) for the disease in question. However, in practice,
it is disease association which studies report, rather than direction of effect, and so summary
data is typically given as unsigned p-values; see, for instance, [International Consortium for
Blood Pressure Genome-Wide Association Studies, 2012]. From these, it is only possible to
compute the absolute value of the Z Scores, |ZOBS |.
Hence, the likelihood function of W and γ is actually the sum of 2n terms:
L
(
W,γ
∣∣∣∣ |ZOBS |) = P(|ZOBS | = ζ ∣∣∣∣W,γ)
=
∑
s∈{−1,1}n
P
(
ZOBS = s ◦ ζ
∣∣∣∣W,γ)
where s ◦ ζ gives the elemental pairwise multiplication between the sign vector s and the
observed absolute Z Scores ζ.
As n is typically in the 100s, a direct calculation of this likelihood is computationally
intractable. I considered a number of strategies to manage this:
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SNPs which are in very high LD with each other are very unlikely to have different directions
of effect. Hence, the SNPs could be grouped into blocks of high LD, and contributions to the
likelihood which have different signs within these blocks could be discarded.
If a SNP has a Z Score very close to 0, its contribution to the likelihood sum is unlikely
to differ much by sign; for any combinations of signs over the other SNPs, the likelihood
contribution when our SNP is assumed to be protective can be assumed to be identical to the
contribution when our SNP is assumed to be deleterious, and hence only one of these terms
needs to be computed.
However, these techniques are unlikely to reduce n down to a value n∗ such that 2(n∗) is
tractable; they also risk losing a significant fraction of our information. Instead, then, I used
an approach which does not require the evaluation of the likelihood function.
4.2.2 The theory of ABC
Approximate Bayesian Computation (ABC) [Tavaré et al, 1997] is a technique which enables
parameter inference without the need for evaluating the likelihood function. Instead, the
likelihood is approximated by simulating data from the prior distribution of the parameters
and comparing simulated data to observed.
Consider the case where we have data D from some model with parameter θ, and we
wish to make an inference about the value of θ. We have some belief, π(θ), about the prior
distribution of θ. We sample θ˜1, ..., θ˜p from π(θ) and for each i = 1, . . . , p, we simulate D˜i from
the model parameterized by θ˜i. We compare D˜i with the true dataset D, using some distance
metric ρ which we must specify (possibly a function of summary statistics rather than the
complete data). If ρ(D, D˜i) ≤ ϵ, for some appropriate value of ϵ, we accept the simulation;
otherwise reject it. The posterior distribution of θ|D can then be approximated from those θ˜i
corresponding to accepted simulations. See Figure 4.1 for an illustration of the algorithm.
As the number of parameters, θ˜i sampled from π(θ), the posterior distribution of θ will
converge towards the value which would be obtained by directly evaluating the likelihood,
However, there are several limitations when it is applied in practice. The tolerance parameter,
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Figure 4.1 The ABC Algorithm, showing the stages of sampling from the prior
distribution, computing a summary statistic for each simulation and comparing this to
the observed data using some threshold ϵ. This figure is taken from [Sunnåker et al,
2013].
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ϵ, must be specified, and the use of a non-zero ϵ introduces a source of bias. As in any Bayesian
technique, the results are dependent upon the choice of π(θ). Additionally, in ABC, we must
simulate from this prior; in the case of high dimensional θ, it may not be computationally
feasible to sample enough datapoints to properly cover the parameter space.
4.3 Testing Goodness of Fit For a Causal Model
Given a causal model parametrised by {W,γ}, I need to compute how well it compares to the
vector of GWAS Z Scores, ZOBS .
Section 3.2 explains how to compute ZEXPX , the expected Z Score at SNP X if the model
parametrized by {W,γ} is true. Then the observed Z Score at X is distributed N(ZEXPX , 1).
However, due to the LD between SNPs within a region, these distributions are not independent.
To simulate a Z Score, given ZEXP , I take LD to be the matrix of correlations between SNPs,
where LDii = 1 and LDij , i ̸= j, is the signed R statistic between the genotypes of SNP i and
SNP j. Then I compute ZSIM , the simulated output if {W,γ} were true, from:
ZSIM ∼ N(ZEXP ,LD)
Note that ZOBS is itself sampled from some N(ZTRUE ,LD).
For my purposes, γ is essentially a nuisance parameter. I aim to fine map a region and
discover the likely causal SNPs; the exact values of their odds ratios of effect are not of
particular interest. However, especially when the model contains many CVs, changing the
relative values of γ greatly changes the pattern of ZEXP ; hence, γ must be included. However,
if a distance metric can be found which reduces the degree to which γ-space must be sampled
to verify a W, it would be a valuable speed-up.
4.3.1 Choice of Distance Metric for Comparison
I considered two approaches to compute a measure of the goodness of fit.
4.3 Testing Goodness of Fit For a Causal Model 107
4.3.1.1 First Approach: pmcc
When the causal SNPs W are correct, and γ exhibits the right behaviour, we would expect
to see peaks of association at the same SNPs in both the observed and simulated Z Scores. If
there are several such peaks, we would also expect the ratios of their heights to be similar. This
corresponds to a requirement of collinearity between the observed Z Scores and the simulated
Z Scores under the model, and hence to a requirement of collinearity between the absolute
values of these Scores. This suggests that searching for collinearity rather than equality may
suffice to find the best W.
Hence, I tried the Pearson product moment correlation coefficient (pmcc) as my distance
metric between the observed and expected data. This measures the linear correlation between
two variables and takes values in [−1, 1], with 1 corresponding to perfect collinearity, and hence
perfect model fit. It is computed as:
pmcc(|ZOBS |, |ZSIM |) =
∑
X∈SNPs(|ZOBSX | − |ZOBS |)(|ZSIMX | − |ZSIM |)√∑
X∈SNPs(|ZOBSX | − |ZOBS |)2
√∑
X∈SNPs(|ZSIMX | − |ZSIM |)2
The pmcc provides a good measure of the linear dependence between two vectors when
the individual values within these vectors are independent. However, this is not the case for
a vector of Z Scores. The correlation structure within a region results in LD blocks of SNPs
with similar Z Scores.
If the observed and simulated Z Scores were strongly collinear, save for at a single SNP, we
would still conclude that the model fitted well, and correspondingly, the effect of the outlying
SNP would not distort the pmcc by much. However, if that SNP happened to be in high LD
with many other SNPs, the weight of that LD block would cause the pmcc to be low, leading
us to conclude that the Z Scores were not collinear despite this behaviour truly only occurring
at a single signal. Similarly, not adjusting for LD could cause false positive results; if there
are very few associations significantly greater than 0, then a single significant LD block could
lead to a high pmcc.
I used LDAK [Speed et al, 2012] to compute weightings reflecting the correlation patterns
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of SNPs in my region. I then used these to compute the weighted pmcc between the observed
and simulated Z Scores, which gives a more accurate measure of whether the Z Scores at signals
are collinear. If SNP X has weight WX then it is computed as:
pmcc(|ZOBS |, |ZSIM |) =
∑
X∈SNPsWX(|ZOBSX | − |ZOBS |)(|ZSIMX | − |ZSIM |)√∑
X∈SNPsWX(|ZOBSX | − |ZOBS |)2
√∑
X∈SNPsWX(|ZSIMX | − |ZSIM |)2
As in a standard ABC algorithm, I simulate ZSIM from the model parameterized by
the values I have sampled from their prior, and compare this to the observed data ZOBS .
However, as an intermediate step, I compute ZEXP . If the causal model were true, then
ZOBS ∼ N(ZEXP ,LD). By working directly with ZEXP , it might be possible to avoid having
to account for the extra error in simulating ZSIM .
However, unlike the ZSIM case, we would not expect |ZEXP | and |ZOBS | to be collinear
in the case of a correct causal model. The majority of SNPs in most regions are not disease-
associated; these will have |ZEXP | ∼ 0. However, if Z ∼ N(0, 1), then E(Z) = 0 but E(|Z|) =√
2
π ≈ 0.8, and so these SNPs will have |ZOBS | >> 0, resulting in the collinear behaviour
being disrupted around 0. Any comparison used would have to take account of this behaviour;
the simplest solution would be to discount points around 0, but this risks losing important
information.
4.3.1.2 Flaw in the pmcc Approach
The pmcc initially appears to be a good metric. When tested upon datasets with known causal
models, it performs well, and the number of γ tested before the result starts to converge is
computationally manageable.
Recall that there is some true ZTRUE , and the observed Z Score ZOBS ∼ N(ZTRUE ,LD).
Similarly, the simulated Z Score ZSIM ∼ N(ZEXP ,LD).
Consider two cases. In Case (a), the model being tested is the correct one, and ZEXP =
ZTRUE . However, in Case (b), while the model being tested is substantially correct, its odds
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ratio is inflated, causing ZEXP = αZTRUE for some constant α > 1.
In Case (b), ∑X∈SNPsWX(|ZOBSX | − |ZOBS |)2 is unchanged from Case (a). However, since
ZEXP has changed, the distribution of ZSIM has also changed. In Case (b), the expectation
of ∑X∈SNPsWX(|ZOBSX | − |ZOBS |)(|ZSIMX | − |ZSIM |) is equal to α times the value obtained
in Case (a). However, while the mean in Case (b) has changed, the variance of ZSIM about
ZEXP is still 1, and so the expectation of ∑X∈SNPsWX(|ZSIMX | − |ZSIM |)2 is less than α2
times the value obtained in Case (a).
Hence, the pmcc in Case (a) is less than the pmcc in Case (b), despite Case (a) being the
correct model (See Figure 4.2 for an illustration of this effect). For any model, we can improve
the pmcc by sampling a gamma which results in the same ZEXP multiplied by a constant
factor; any deviation away from the line of best fit being y = x will improve our apparent
fit. It follows that a γ which results in an extremely large ZEXP will result in a high pmcc
regardless of true model fit.
Note that this effect is not due to some peculiarity in the pmcc, but will also hold for any
other measure of collinearity (for instance, the Adjusted R Squared from the best fitting linear
model between ZOBS and ZSIM will behave identically).
This means that, although in general a high pmcc will correspond to a good model fit,
pmcc is not a valid proxy for model fit. It is particularly dangerous to use pmcc to compare
two models which both appear to fit well, since the slight improvement in the “better” model
may well only be due to it having an inflated γ.
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Figure 4.2 The red line shows the case when the model is correct, with dotted circles
showing the errors in the points. The blue line shows a case when the causal SNPs are
correct, but the odds ratios sampled cause the ZEXP to be inflated to twice the true
values. Since the variance of ZSIM around ZEXP is the same in each case, sampled
points about the blue line are more collinear than sampled points about red line, and
will perform better under distance metrics such as pmcc.
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4.3.1.3 New Approach: Weighted Sum of Squares
Since any test for collinearity will have the flaw described above, instead I must use a distance
measure which tests for equality. Although this unavoidably requires sampling a larger number
of γ in order to have a good chance of verifying whether a given W fits well, it does mean
that any γ which performs well is likely to be close to the correct one; hence such a distance
metric also enables us to make inference about the odds ratios of the causal SNPs if desired.
Any measure of whether two vectors are identical is fundamentally a function of the distance
of the points from the y = x line. The simplest of these measures the sum of squares of the
difference between the observed Z Score and the Z Score under my model, and it is this I shall
use for my distance metric. As in the pmcc case, I shall weight this by the values computed
by LDAK, in order to control for the effect of large LD blocks.
Although standard ABC uses |ZSIM |, simulating such values produces extra error, requiring
additional runs of the algorithm to converge to an optimal solution, which is not necessary in
this case. Since under the true model ZOBS ∼ N(ZEXP ,LD), I shall directly compare |ZOBS |
and |ZEXP |. (I did not do this in the pmcc case, since when ZEXP is close to zero, we expect
|ZOBS | > |ZEXP | and so collinear behaviour is disrupted even in the case of the true causal
model. However, the sum of squared differences does not take account of in which direction
deviance from the y = x line has occurred, and so it is valid to compare |ZOBS | and |ZEXP |.)
Hence, my measure of model fit is:
sumsq(|ZOBS |, |ZEXP |) =
∑
X∈SNPsWX(|ZOBSX | − |ZEXPX |)2∑
X∈SNPsWX
Note that, while the true causal model will have a low sumsq, we would expect spurious
results in cases where ZOBS is close to zero. The variance in the true model at any SNP X
between ZOBSX and ZTRUEX is 1; if all Z Scores are small, there will be many other non-significant
and non-associated models which still have their ZEXP within the bounds of variance 1 from
ZOBS . However, this is a feature of the variance in the observed Z Score, and we would see
this effect regardless of distance measure used. It is not appropriate to perform a fine mapping
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analysis upon a region which has no evidence of disease association.
4.3.2 Choice of Tolerance Parameter
Given a value of sumsq, we wish to know whether it is consistent with the model being analysed
being the true causal model. In the standard ABC approach, this would be done by accepting
a model if sumsq < ϵ for some tolerance parameter.
4.3.2.1 True Distribution of sumsq(|ZOBS|, |ZEXP |)
If the model is true, then ZOBS ∼ N(ZEXP ,LD); equally ZEXP ∼ N(ZOBS ,LD). (It is
this second formulation I shall use, since it more accurately reflects the nature of my task;
ZOBS is a fixed input, and I wish to find a model whose resulting ZEXP is consistent with
ZEXP ∼ N(ZOBS ,LD).) Hence, at any SNP X, |ZOBSX | has a folded normal (ZEXPX , 1) .
The folded normal (µ, 1) distribution has moments:
EZ =
√
2
π
e
−µ2
2 + µ [1− 2Φ(−µ)]
EZ2 = µ2 + 1
EZ3 = (µ2 + 2)Ez − µ [1− 2Φ(−µ)]
EZ4 = µ4 + 6µ2 + 3
Hence I can compute:
E
[(
|ZOBSX | − |ZEXPX |
)2]
= E
(
|ZEXPX |2
)
− 2|ZOBSX |E
(
|ZEXPX |
)
+ |ZOBSX |2
= 1 + 2|ZOBSX |2 − 2|ZOBSX |
(√
2
π
e
−(ZOBS
X
)2
2 + ZOBSX
[
1− 2Φ(−ZOBSX )
])
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And thence:
E
(
sumsq(|ZOBS |, |ZEXP |)
)
=
∑
X∈SNPsWXE
(
|ZOBSX | − |ZEXPX |
)2
∑
X∈SNPsWX
Similarly, I can compute
V ar
(
|ZOBSX | − |ZEXPX |
)2
= E
(
|ZOBSX | − |ZEXPX |
)4 − (E (|ZOBSX | − |ZEXPX |)2)2
With these values, I could in theory compute some appropriate tolerance parameter ϵ, which
would enable me to select or reject causal models, with the selected models being used to
approximate the true distribution of {W,γ}. However, this distribution is complex, and not
easily tractable. Is it possible instead to approximate its behaviour and thereby obtain a
practical form for ϵ?
4.3.2.2 Approximating the Distribution of sumsq(|ZOBS|, |ZEXP |)
Under the true model,
(
ZOBSX − ZEXPX
)2 ∼ χ21, which has mean 1 and variance 2. When ZOBSX
and ZEXPX have the same sign,
(
|ZOBSX | − |ZEXPX |
)2
=
(
ZOBSX − ZEXPX
)2
Hence, if the majority of observed Z Scores are sufficiently greater than 0, we have:
Esumsq =
∑
X∈SNPsWX∑
X∈SNPsWX
= 1
However, when the Z Scores are ∼ 0,
(
|ZOBSX | − |ZEXPX |
)2
<
(
ZOBSX − ZEXPX
)2
Since, in practice, the majority of SNPs in a region are not disease associated, we can expect the
true mean of sumsq to be below 1; any more precision will require considering the behaviour
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of the folded normal distribution around the origin.
Assuming all SNPs to be independent, then:
Var
(∑
X∈SNPsWX(ZOBSX − ZEXPX )2∑
X∈SNPsWX
)
=
∑
X∈SNPsW2X
(∑X∈SNPsWX)2
Although the SNPs are not independent, the SNP weightings computed by LDAK ensure that
no two SNPs in high LD are included in the sum, and hence this is a valid assumption to a
first approximation. As in the E case, the effect of non-associated SNPs means that this is
likely to be an overestimate for the variance of sumsq.
4.3.2.3 Use of sumsq(|ZOBS|, |ZEXP |) for Comparison
Hence, while I expect well fitting models to have sumsq(|ZOBS |, |ZEXP |) < 1, there is no
obvious way to compute an appropriate tolerance parameter ϵ. Any such ϵ would need to be
region specific; certainly depending upon the weights WX , but possibly also upon the values
of ZOBS . However, it might be possible to use simulations to choose and appripiate ϵ for a
specific instance.
If the model being testesd is truely causal, then ZOBS ∼ N(ZEXP ,LD), and so ZEXP ∼
N(ZOBS ,LD). Hence, by simulating from a N(|ZOBS |,LD) distribution and taking absolute
values we can estimate the space where we will see |ZEXP | for the true causal model and hence
the empirical distribution of sumsq(|ZOBS |, |ZEXP |) for the true causal model. ϵ can then be
taken to be some appropiate quantile of this distribution.
Future work will explore choices of ϵ. However, within a region, sumsq provides a very
good proxy for how close each proposed causal model comes to the observed data relative to
other proposed models. For the rest of this chapter, I shall use sumsq to provide a ranking of
models within a region, but shall not attempt to compare sumsq values between regions.
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4.4 Implementation of Algorithm
4.4.1 Efficient Search of Model Space
Implementing this method using a standard ABC framework would proceed as in Algorithm
1. The priors discussed in Section 3.3 are used as the priors for the causal model, ΠW and Πγ .
Algorithm 1 Inferring Causal Models using ABC
1: procedure Implementation1
2: load |ZOBS|
3: load RefData
4: load N0, N1
5: load LDAK weights
6: compute LD from RefData
7: for iterations in NumIterations do
8: sample m from Πm, W from ΠW, γ from Πγ
9: compute γ0
10: extract relationships between W and other SNPs from RefData
11: compute ZEXP
12: compute ZSIM ∼ N(ZEXP ,LD)
13: compute sumsqW,γ , the weighted sumsq between |ZSIM | and |ZOBS|
14: if sumsqW,γ < ϵ then
15: accept the model {W,γ}
16: return Distribution inferred from all models {W,γ} with sumsqW,γ < ϵ
However, as discussed in Section 4.3, I am not using a standard ABC framework. Rather
than sampling ZSIM , I am directly using ZEXP in my comparison. Also, rather than having a
single tolerance parameter ϵ, I am using my distance metric, sumsq to rank all models sampled;
I can then return either the ranking of all models, or the identities of the top Nmod models.
Hence, my method proceeds as in Algorithm 2.
Note that in these algorithms, the step on Row 9 of Algorithm 2, “extract relationships
between W and other SNPs from RefData” must be repeated for each iteration. This
computation is complex, requiring the inference of genotype probabilities from haplotype
data, and the requirement to perform it NumIterations times results in a procedure which is
prohibitively slow to run on typical genomic regions. Many times this is repeated
computation, since in order to reasonably sample the causal model space, many γ must be
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Algorithm 2 My Method: Inferring Causal Models using the Weighted Sums of Squares
as Distance Metric
1: procedure Implementation2
2: load |ZOBS|
3: load RefData
4: load N0, N1
5: load LDAK weights
6: for iterations in NumIterations do
7: sample m from Πm, W from ΠW, γ from Πγ
8: compute γ0
9: extract relationships between W and other SNPs from RefData
10: compute ZEXP
11: compute sumsqW,γ , the weighted sum of squared differences between |ZOBS|
and |ZEXP |
12: save {W,γ, sumsqW,γ}
13: return Models {W,γ} with top Nmod sumsqW,γ
sampled for each W, and this step is dependent only upon W.
One option might be to compute this data once for each W at the start of the procedure.
This could then be saved and retrieved when needed. However, although this is computationally
more efficient, it is unrealistic in terms of memory usage. Consider the regions analysed in
Chapter 2 as an example of typical region size. After QC, these have in expectation 261 SNPs;
some have many more. This corresponds to 33930 2 SNP models, and over 9 billion 5 SNP
models (although with the prior on m = 5 being 2.98× 10−11, not many 5 SNP models will be
sampled); it is infeasible to store results for all of these.
Instead, rather than only considering a single γ at each iteration, I propose to sample from
W, and then test many values of γ before moving onto the next W, as in Algorithm 3. For
each W, I can save the top sumsq, and compare these.
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Algorithm 3 My Method: Inferring Causal Models using the Weighted Sums of Squares
as Distance Metric
1: procedure Implementation2
2: load |ZOBS|
3: load RefData
4: load N0, N1
5: load LDAK weights
6: for iterations in NW do
7: sample m from Πm, W from ΠW
8: extract relationships between W and other SNPs from RefData
9: for iterations in Nγ do
10: sample γ from Πγ
11: compute γ0
12: compute ZEXP
13: compute sumsqW,γ
14: save {W,γ, sumsqW,γ}
15: find sumsqW, the top sumsqW,γ for this W, which occurs at γ∗W
16: save {W,γ∗W, sumsqW}
17: return Models {W,γ∗W} with top Nmod sumsqW
4.4.2 Number of Samples of Gamma
Recall from above that Nγ is the number of times we sample γ for a particular value of W. It
is not obvious what the value of Nγ should be; it may well be that a more efficient approach is
instead to use some probabilistic technique such as simulated annealing to optimise the sumsq
over γ. However, in this section, I concern myself merely with the question: ifW is indeed the
true set of causal variants, how many γ must I sample from ΠW to demonstrate this? Since
the size of the search space is a subset of Rm, the appropriate Nγ will increase as m does.
Figure 4.3 shows a typical distribution of sumsq when plotted against γ, in both the 1-CV
and 2-CV cases, for simulated data (generated using the method discussed in Section 3.4.2)
with a knownW also used to calculate sumsq. We see that the plots are smooth, dipping to a
minimum around 1 at both γTRUE and −γTRUE (since we have only the absolute value of the
Z Score, it is not likely to be possible to distinguish between these two cases). The gradients
of these dips are such that, especially around γTRUE , if two values of γ are close to each other,
the resulting sumsq statistics will also be close to each other. Hence, sampling a γ which is
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“too close” to an already-analysed value of γ adds very little useful information, and is wasted
computation time. Rather than sample independently from Πγ , I propose instead to reject new
samples if they are within some distance δγ of an already existing γ (with distance defined as
the Euclidean distance in the multi-dimensional cases). Since the width of the “dip” in sumsq
appears similar for different values of γ and for different value of m, I shall determine δγ from
the 1-CV case and then use it for all analyses.
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Figure 4.3 Isolated examples to show the shape of the distribution of the sumsq
statistic when γ varies, for the true value ofW. These are results from simulated data,
generated using the method discussed in Section 3.4.2.
(a) A single causal variant. This region had N0 = 11750, N1 = 6500 and γ = 0.4. The
observed p-value at the causal SNP was 8.04× 10−19, corresponding to an observed Z
Score of 8.86.
(b) Two causal variants. This region had N0 =, N1 = and γ = (0.25, 0.2). The
observed p-values at the causal SNPs were (2.50× 10−20, 1.57× 10−5), corresponding to
an observed Z Score of (9.24, 4.32).
I am satisfied if I sample a γ with a sumsq within 0.1 of that generated at the γTRUE .
0.1 is a small enough difference that I shall still categorise the model as well fitting; it is large
enough that I will not have to set my δγ to an impractically low value. If at the end of my
algorithms I have found a small number of models which all perform very well, and have sumsq
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within ∼ 0.1 of each other, making it impossible to rank them, then I could run a second-pass
analysis of these models alone, trying more γ in order to hone in upon the true relative fits.
I calculated the size of this “dip” in 500 simulated regions with true causal model containing
a single CV. The median width of the area within 0.1 of the sumsq corresponding to γTRUE is
0.1. Hence, I shall take δγ = 0.025, a quarter of this distance, to ensure that with a reasonable
sample size Nγ , I sample within this area. Note also that the median width of the area within
0.01 of the sumsq corresponding to γTRUE is 0.06, so it is likely that at least one of my models
tested will be in this area also.
Given a set of true causal variants W, I wish to know how many γ, Nγ , I must sample
(pruning all within distance δγ = 0.025 of a value of γ already analysed) in order to achieve
convergence to within 0.1 of the sumsq obtained at the true model. I therefore simulated
600 datasets with known 1-CV models, and 600 datasets with known 2-CV models, using the
method given in Section 3.4.2, and tested different values of γ within models containing the
true W. I counted the number of γ tested until the resulting minimum sumsq came to within
0.1 of the sumsq obtained at the true causal model, for 1-CV and 2-CV cases. Figure 4.4
shows the empirical cumulative distribution of this value. From this, I shall take Nγ = 100 in
the 1-CV case, and Nγ = 2000 in the 2-CV case. In order to obtain ∼ Nγ values 0.025 apart,
I shall sample N∗γ > Nγ , and filter by distance.
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Figure 4.4 The value of Nγ required to converge within 0.1 of the true value, when
analysing with the true W for 1 CV and 2 CV models, taking only values of γ which
are distance greater than 0.025 away from any which have already been sampled.
Distribution is estimated using the results from 600 simulations for each of the 1-CV
and 2-CV models.
4.4 Implementation of Algorithm 121
4.4.3 Sampling from ΠW: Random Sampling or Exhaustive
Search?
In a typical application of ABC, causal models are randomly sampled from their priors; in the
limit, resulting posterior distribution will converge towards the value which would be obtained
by directly evaluating the likelihood. However, I am not preforming a true random choice of
causal models independent of those previously sampled. Instead, each time I sample a W,
I test enough γ to hopefully confirm whether it is a plausible candidate for the true causal
SNPs. Following this, there is little further value in testing W again; hence, for efficiency, I
should sample from ΠW without replacement.
That being the case, it often makes sense to perform an exhaustive search of all models
of interest, rather than sample from ΠW (indeed, using the priors given in Section 3.3, it is
likely that sampling without replacement will result in an exhaustive search of all 1-CV models
regardless). Rather than doing a slow sampling of the entire model space, I could perform a
relatively fast test of all 1CV models, to determine whether data in a given region is compatible
with having a single causal SNP, as a first-pass analysis of a large number of regions. By
testing all 1-CV and 2-CV models, I gain a good understanding of the causal structure within
the region, and with a better appreciation of the limitations of my conclusions than had I
performed a random search. The results of my analysis may also suggest avenues to explore
even if none of the models considered appear to adequately fit the observed Z Score.
One case in which exhaustive testing is certainly appropriate is when potential causal SNPs
have been narrowed down by prior research to a small number, and the question of interest
is which specific SNPs are truly causal. Indeed, in this case, the number of possible W being
tested is so few that I would recommend using a higher value of Nγ than that suggested in
Section 4.4.2, in order to more accurately rank the goodness of fit of the models. If the region
has complex association, several of the models may perform well.
122 Fine Mapping using GWAS Summary Statistics
4.5 This Approach Allows Direct Evaluation of Non-
Genotyped SNPs without any Imputation
GWAS typically provide sparse coverage of the genome. It may often be the case that there
are SNPs we are interested in considering as potential causal variants, and for which we have
reference data, but for which we do not have p-values to analyse. Possibly the GWAS contains
only common SNPs, and we wish to consider a denser set of causal models in a region. Possibly
a SNP which has elsewhere been implicated in the disease process failed QC in the GWAS,
but we nevertheless wish to include it in my fine mapping analysis. If I had access to full
genotype data from the GWAS, I could use imputation to infer the genotypes of the missing
SNPs from reference data, and hence approximate their true p-values. However, if this data is
not available, then imputation is impossible.
However, my method computes the expected Z Score at any SNP as a function of the
correlation between it and the causal variants within the model being analysed, and compares
this to the vector of observed Z Scores. If the true causal variants are not genotyped, a
comparison of observed and expected Z Scores at a subset of SNPs containing some in LD
with the causal SNPs will suffice as a measure of model fit. (If no SNPs in LD with the true
causal variants are genotyped, the region will appear to have no disease association, and hence
any fine mapping approach must necessarily fail). In this section, I explore the application of
my method when the most likely causal variants are “hidden” in two exemplar regions.
4.5.1 1p13.2 Region Containing PTPN22
As an example of this, consider the 1p13.2 region containing candidate causal gene PTPN22.
This region shows very strong evidence of T1D-association (minimum p-value < 10−80). In
addition, the association appears to be caused by a single causal SNP. Figure 4.5 shows the
Manhattan plot of T1D-associated p-values in this region; from this we see that there are
clearly two top SNPs, rs6679677 and rs2476601. They have an R2 of 0.995, and so it would
take a much larger sample size than is realistically feasible to disentangle their effect in a fine
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Figure 4.5 Manhattan plot of T1D Association in the 1p13.2 region containing
candidate causal gene PTPN22. SNPs are coloured according to their LD with
rs2476601, the probable causal SNP.
mapping analysis. However, rs2476601 is a non-synonymous protein coding SNP, and hence is
generally accepted to be the causal variant.
Using p-values obtained from the ImmunoChip T1D study discussed in Section 2.6 I
conducted a fine mapping analysis of the region. I computed Approximate Bayes Factors for
each SNP using Wakefield’s approximation [Wakefield, 2009] and used these to compute
posterior probabilities that the SNP is the single causal SNP in the region, following [Bowes
et al, 2015]. This is now a standard fine mapping technique, but it assumes that there is a
single causal variant, and requires that all SNPs have been assigned a p-value. The results
are shown in Figure 4.6.
In the complete analysis, rs2476601 is assigned posterior probability of being causal 0.993,
while the posterior probability of rs6679677 being causal is 0.007. Although rs2476601 does
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Figure 4.6 Posterior probabilities of being causal, from a standard single CV
summary statistic fine mapping of the PTPN22 region for T1D, using Wakefield’s
approximation to computhe Bayes Factors. The two SNPs highlighted in red in the
left-hand plot are rs6679677 and rs2476601. These have been trimmed from the
p-values analysed in the right-hand plot.
have a slightly lower p-value, since both SNPs have p-value < 10−80, and are in high LD, this
assignment of probability of causality seems overconfident given the data it is based on. When
rs6679677 and rs2476601 are trimmed, the fine mapping confidently assigns causality to the
third signal in the region, rs1230666. Hence, by removing the top SNPs, my inference changes
completely.
I ran my method upon single SNP models on this region, using Z Scores taken from the
following sources:
1. An ImmunoChip analysis of T1D for UK samples, data as discussed in Section 2.6
(containing 687 SNPs)
2. The same ImmunoChip analysis, but with the p-values for the top pair of SNPs removed
(containing 685 SNPs)
3. A GWAS analysis of T1D for UK samples [Barrett et al, 2009a], containing a subset of
those SNPs present in the ImmunoChip analysis (containing 127 SNPs)
4. The same GWAS analysis, but with the p-values for the top pair of SNPs removed
(containing 125 SNPs)
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Figure 4.7 Results from testing single CV models for T1D association in the 1p13.2
region containing candidate causal gene PTPN22, using four different sources of
observed Z Scores but the same reference dataset. The results for SNPs rs6679677 and
rs2476601 are highlighted in red. The blue line denotes log10(sumsq) = 0, which
corresponds to sumsq = 1. Notice that my conclusions are the same in all four
analyses: even if I analyse a thinned dataset, with the Z Scores for rs6679677 and
rs24766 removed, I still conclude that one of these two SNPs is causal.
Since I have the full genotype data from the ImmunoChip analysis, I used the control samples
from this for my reference dataset. I analysed all SNPs contained in this dataset as potential
causal SNPs, regardless of whether or not they had a corresponding observed Z Score. The
resulting minimum sumsq obtained for each SNP are shown in Figure 4.7.
For each set of Z Scores, my conclusions are the same; even with rs6679677 and rs2476601
removed, the best models, with sumsq ≈ 0.7 in the ImmunoChip analyses and ≈ 1.4 in the
GWAS analyses, are those corresponding to these SNPs. These sumsq are well within the
tolerance for belief that a model is causal; no other SNPs are plausible by comparison. Hence,
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even with a much trimmed dataset, and the top SNPs themselves not genotyped, my algorithm
comes to the same conclusion about the likely causal variants.
Note that removing rs6679677 and rs2476601 does not appear to greatly affect my sumsq
for any model. However, moving from the ImmunoChip Z Scores to the GWAS Z Scores can
have a dramatic effect.
This may be due to the trimming of SNPs; for instance, the third signal in the region,
rs1230666, which is in high LD with rs6679677 and rs2476601 (R2 = 0.61), is not present in
the GWAS data. Another plausible explanation is that the GWAS data is partially imputed,
which will result in the expected Z Score not matching the observed Z Score as well, even for the
true model. However, it may also be caused by subtle changes between the control populations
used in the analyses, resulting in my reference dataset not being quite the appropriate one for
the GWAS; for more discussion of this effect, see Section 4.7.
4.5.2 1q24.3 Region Containing FASLG
Although PTPN22 demonstrates that finding non-genotyped CVs is possible with my method,
the strength of the T1D-association means it is not a typical region. In order to see how well
my method performs upon non-genotyped SNPs in a region with more subtle effects, I will
analyse the 1q24.3 region containing candidate causal gene FASLG.
Recall from Section 2.7.3 that this region has been associated to CEL. There is some
evidence of T1D association, however, none of the T1D SNPs reach genome-wide significance.
My colocalization analysis suggested that there is a shared CV for T1D and CEL, and
furthermore using the colocalization results to perform fine mapping identified SNP
rs78037977 as being this CV, with a posterior probability of 0.99. However, this SNP failed a
QC step, and hence was removed from the CEL analysis. I wish to see whether my fine
mapping method will also recover this SNP using only data from SNPs which have passed
QC (those shown in the CEL plot of Figure 4.8).
Using the p-values obtained from ImmunoChip T1D and CEL studies, I first conducted a
fine mapping analysis of the region for genotyped SNPs only. As in my analysis of the PTPN22
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Figure 4.8 Manhattan plot of T1D and CEL Association in the 1q24.3 region
containing candidate causal gene FASLG, using p-values from ImmunoChip studies.
SNPs are coloured according to their LD with rs78037977 (designated by a red
diamond), which I identified as a potential common causal SNP in section 2.7.3 but
which was dropped from the published CEL ImmunoChip dataset due to QC conerns.
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region above, I followed the method in [Bowes et al, 2015]. Recall that this technique assumes
that there is a single causal variant, and requires that all SNPs have been assigned a p-value.
The results are shown in Figure 4.9.
In the T1D fine mapping (Figure 4.9), although rs78037977 does come within the top set
of 13 models with non-zero posterior probabilities, I cannot choose a single SNP. By contrast,
from the CEL analysis (Figure 4.9), I can clearly see rs2157477 is the top performing causal
model. Since it is not genotyped, it is impossible to come to any conclusions about rs78037977
using this method. However, it and rs2157477 have high LD, with R2 = 0.62.
I therefore ran my method upon the FASLG region, using three sets of Z Scores:
1. An ImmunoChip analysis of T1D for UK samples (containing 291 SNPs)
2. The same T1D ImmunoChip analysis, but with the p-value for rs78037977 removed
(containing 290 SNPs)
3. ImmunoChip analysis of CEL for UK samples; rs78037977 does not have a p-value
(containing 244 SNPs)
using the genotypes from the ImmunoChip controls as my reference dataset. The resulting
minimum sumsq obtained for the T1D analyses are shown in Figure 4.10, and for CEL in
Figure 4.11.
From the CEL analysis, we clearly see that rs78037977 is the top performing SNP; with a
sumsq of 1.72, it is the only model within the range we would expect to contain the true causal
model. The T1D analysis is less clear cut; there are a number of SNPs, including rs78037977,
which cluster with sumsq < 1, and though this set is likely to contain the true CV(s), it is not
obvious how to distinguish between them. Since the T1D association in this region is relatively
small (minimum observed p-value = 8.71 × 10−6, maximum observed Z Score = 4.45), it is
possible that some models with low association will appear to perform well by random chance.
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Figure 4.9 Posterior probabilities of being causal, from a standard single CV
summary statistic fine mapping of the FASLG region for T1D and CEL, using
Wakefield’s approximation to compute Bayes Factors. The SNP highlighted in red is
rs78037977, which I identified as a potential common causal SNP in section 2.7.3 but
which was dropped from the published ImmunoChip CEL dataset due to QC concerns.
The top SNP in the CEL analysis is rs2157477.
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Figure 4.10 Results from testing single CV models for T1D association in the 1q24.3
region containing candidate causal gene FASLG. The results for SNP rs78037977 are
highlighted in red. The blue line denotes log10(sumsq) = 0, which corresponds to
sumsq = 1.
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Figure 4.11 Results from testing single CV models for CEL association in the 1q24.3
region containing candidate causal gene FASLG. The result for SNP rs78037977 (not in
the summary data, but captured through LD) is highlighted in red.
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4.6 Comparison of Top Models for a Complex
Region
The 10p15.1 region containing candidate causal gene IL2RA has been associated with multiple
autoimmune diseases. In ImmunoBase, it is associated with the diseases: Autoimmune Thyroid
Disease (ATD); Crohn’s Disease (CD); Juvenile Idiopathic Arthritis (JIA); MS; RA; T1D and
Ulcerative Colitis (UC). I analysed this region in Chapter 2, and found strong evidence of
association with both T1D and MS; however, I also found evidence that this association is
caused by distinct causal variants. In the Bayesian analysis (which assumes at most one
causal variant per disease), I obtained a posterior probability of 1.00 for H3 (there is a SNP
associated with trait 1, and a different SNP associated with trait 2), while in the proportional
analysis, I obtained a posterior predictive p-value of 5.04 × 10−9 against the null hypothesis
of proportionality. I also found evidence for multiple SNP association with T1D from the
conditional Bayesian analysis. Figure 4.12 shows Manhattan plots of association in this region
with the seven autoimmune diseases listed above; from this, the pattern of association across
the diseases is heterogeneous.
A recent fine mapping analysis of this region [Wallace et al, 2015], using Bayesian model
comparison with a stochastic search applied to full genotyping data, identified a four causal
variant model for T1D and two competing causal models for MS, one containing a single SNP
and one containing two causal SNPs. It divides potential causal SNPs up into six LD blocks
(see Figure 4.13), labelled Group A, ..., Group F. The patterns of potential causal variants
are very different between the two diseases; while MS appears to be associated with SNPs in
Groups A and D, or in group B alone, T1D appears to be associated with SNPs in Groups A,
C, E and F.
The two causal variant model for MS (A and D) is notable since neither of the SNPs
it contains comes top on an analysis assuming a single causal variant (in which B alone is
selected); hence, a conventional stepwise approach to fine mapping allowing for multiple causal
variants would neglect this model. Nonetheless, a haplotype analysis of the regional association
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Figure 4.12 Manhattan plots of association with seven autoimmune diseases in the
10p15.1 region containing candidate causal gene IL2RA.
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Figure 4.13 The locations of MS and T1D associated variants within the 10p15.1
region containing candidate causal gene IL2RA. Variants seem to fall into six groups,
labelled Group A, ..., Group F; R2 between these SNPs is shown in the lowest of the
figures. Figure is taken from [Wallace et al, 2015].
(see Figure 4.14) demonstrates that, while the two SNP model is preferred, rs2104286 (group
B) is selected by a univariate model, since it tags the common disease susceptible haplotypes
formed by A and D.
Given that this fine mapping analysis suggests an overlap between causal variants for
MS and T1D not evident from univariate, or stepwise, analyses, it suggests multi-SNP causal
models might perform well when fitted to the other associated diseases, for which full genotype
data is not available.
As discussed in Section 4.4.3, when the potential causal SNPs within a region have been
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Figure 4.14 Results from a haplotype analysis of MS-associated SNPs in the IL2RA
region. Two models perform well for MS, tagged by {rs2104286} (group B) and
{rs12722496, rs56382813} (groups A and D respectivly). This demonstrates that, while
the two SNP model is preferred, rs2104286 is selected by a univariate model, since it
tags the common disease susceptible haplotypes. Figure is taken from [Wallace et al,
2015].
narrowed down to a small set, my fine mapping approach, with a high Nγ , can be deployed
in order to distinguish between the fit of models containing subsets of these SNPs. After
discussion with a collaborator (Linda Wicker, an expert in IL2RA), I considered the following
SNPs as potential causal variants, selected from the MS and T1D fine mapping paper with
additional “top SNPs” in the region for other diseases, as found in ImmunoBase:
• rs4147359 (associated with UC)
• rs10795791 (most associated SNP in region for RA)
• rs3118470 (most associated SNP in region for Alopecia Areata)
• rs706779 (most associated SNP in region for Vitiligo and Thyroiditis)
• rs41295055 (Group D)
• rs11594656 (Group C)
• rs2104286 (Group B)
• rs61839660 (Group A)
• rs6602437 (Group E)
I considered models containing one, two, three, four or five of these SNPs. I did not consider
larger causal models, since with six or more causal SNPs, the search space of γ becomes
arduously large. In order to cut down upon the necessary computation, I also did not consider
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models containing two or more of rs4147359, rs10795791 and rs3118470; these SNPs are in
high LD (pairwise R2 ∼ 0.7) and hence little information would be added by these models.
I do not have p-values for rs3118470; it was not genotyped in all the GWAS whose results I
analysed. However, following the demonstration in Section 4.5 above that my method is able
to detect causal models containing non-genotyped SNPs, I left rs3118470 in the analysis.
In total, I considered 233 causal models. These I analysed for fit against the Z Scores
obtained from UK-only ImmunoChip studies for the seven diseases listed above; I also tested
them against the Z Scores obtained from international ImmunoChip studies (with all subjects
having self-reported European ancestry) for MS and RA. I sampled 1000 γ at a time until Nγ
was large enough that the 5-CV models converged to within 0.1 of their final minimum value.
I first explored the results for MS, using both the UK and the international data. Figure
4.15 gives heatmaps of the optimised γ for each of the 233 models, ordered by the resulting
minimum sumsq. The 2-SNP model, {rs12722496, rs56382813}, identified in [Wallace et al,
2015] is tagged by the SNPs {rs61839660, rs41295055} in my analysis. The 1 SNP model
identified in [Wallace et al, 2015] is {rs2104286}, which is included in my analysis.
Since all the models considered in the MS UK analysis have sumsq between 0.678 and 1.82,
the vast majority are within the bounds where we would expect the true causal model to fall.
The variation due to the inherent randomness of the observed Z Score is much greater than
the difference between many of the models. My choice of Nγ resulted in convergence within
only 0.1 of the best possible sumsq for a model containing five causal variants. Hence, on the
results of this analysis, it is not possible to come to strong conclusions about our preference for
a specific model. However, by viewing the heatmap of SNP effect sizes, arranged by goodness
of fit of model, some patterns emerge.
The top models appear to contain rs41295055, with a weaker secondary signal in rs11594656
or rs61839660; this effect is particularly strong in the international analysis. rs41295055 is the
SNP with most support for being individually causal; by contrast, rs2104286 does not appear
to adequately explain the pattern of association across all SNPs in this region.
Note that models perform differently between the analyses; for instance, model
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{rs61839660, rs41295055}, corresponding to the 2-SNP model identified in [Wallace et al,
2015], emerges more strongly in the international analysis. This may be due to the increase
in power achieved by analysing more samples, or an effect not found in the UK population.
However, it may also be due to the use of an inappropriate UK-only reference dataset; this
possibility is examined in more depth in Section 4.7.
For T1D, if I fit the preferred model from [Wallace et al, 2015] ({Group A, Group C, Group
E, Group F}, tagged in my analysis by SNPs {rs61839660, rs11594656, rs6602437, rs41295121
rs41295121 is from Group F), I get a sumsq of 1.61. However, the Group F signal appears
to be T1D-specific, and not associated with the other six diseases; by contrast, the effects of
Groups A-E appear to be cross-disease. Hence, the SNPs selected above are taken from groups
A-E only, and no models were fitted including Group F. By contrast with the UK analyses of
the other six diseases, each of which contained many models with sumsq consistent with being
the true causal variants, very few of the minimum sumsq obtained for the T1D analysis were
consistent with being the true model (Figure 4.16). This confirms that the signal found within
Group F is required to explain the T1D association in the region.
Nonetheless, all other diseases achieved sumsq below or close to 1 in the UK analysis using
only SNPs within Groups A-E, suggesting that the signal within Group F of SNPs is unique
to T1D (Figures 4.17, 4.18 and 4.19 give results for the other traits).
From these heatmaps, we see some patterns. The results from the CD analysis are
consistent with a single SNP, rs6602437, being causal; the presence of rs6602437 within the
model is a strong predictor of whether that model will have sumsq < 1. No other disease
displays this behaviour; indeed, in UC, where we would expect to see very similar behaviour
to CD due to the similarities in the disease processes, it is not possible to come to any strong
conclusions about preferred models. However, both ATD and JIA show evidence of being
associated with the same 2-CV model: {rs706779, rs6602437}; all top models in these
diseases contain these two SNPs, with rs706779 consistently having the larger effect size.
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Figure 4.15 Heatmap of optimised γ from the analysis of UK MS and international
MS summary data in the IL2RA region. The 233 models analysed have been sorted by
their goodness of fit (that is, the smallness of the resulting minimum sumsq, which is
given in the blue column to the left of the plot) so that the best fitting models are at
the top. Each row of the heatmap then shows the value of γ at which the model
obtained this minimum sumsq, with SNPs not present in the model having their
corresponding γ set to 0.
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Figure 4.16 Heatmap of optimised γ from the analysis of UK T1D summary data in
the IL2RA region. The 233 models analysed have been sorted by their goodness of fit
(that is, the smallness of the resulting minimum sumsq, which is given in the blue
column to the left of the plot) so that the best fitting models are at the top. Each row
of the heatmap then shows the value of γ at which the model obtained this minimum
sumsq, with SNPs not present in the model having their corresponding γ set to 0.
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Figure 4.17 Heatmap of optimised γ from the analysis of UK CD and UK UC
summary data in the IL2RA region. The 233 models analysed have been sorted by
their goodness of fit (that is, the smallness of the resulting minimum sumsq, which is
given in the blue column to the left of the plot) so that the best fitting models are at
the top. Each row of the heatmap then shows the value of γ at which the model
obtained this minimum sumsq, with SNPs not present in the model having their
corresponding γ set to 0.
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Figure 4.18 Heatmap of optimised γ from the analysis of UK ATD and UK JIA
summary data in the IL2RA region. The 233 models analysed have been sorted by
their goodness of fit (that is, the smallness of the resulting minimum sumsq, which is
given in the blue column to the left of the plot) so that the best fitting models are at
the top. Each row of the heatmap then shows the value of γ at which the model
obtained this minimum sumsq, with SNPs not present in the model having their
corresponding γ set to 0.
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Figure 4.19 Heatmap of optimised γ from the analysis of UK RA and International
RA summary data in the IL2RA region. The 233 models analysed have been sorted by
their goodness of fit (that is, the smallness of the resulting minimum sumsq, which is
given in the blue column to the left of the plot) so that the best fitting models are at
the top. Each row of the heatmap then shows the value of γ at which the model
obtained this minimum sumsq, with SNPs not present in the model having their
corresponding γ set to 0.
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4.7 The Impact of the Reference Dataset
The work done so far assumes that the reference dataset, which is used to estimate the
between-SNP relations P(GXi = x ∩ GWi = w), and as input to the LDAK algorithm to
estimate weightings, is a correct reflection of the correlations between SNPs in the control
samples analysed in the original GWAS. For the majority of work presented in this thesis,
this assumption is valid; most of my p-values come from ImmunoChip studies curated in
ImmunoBase, and the control data I have used as a reference is the common control data
used by the ImmunoChip consortium in their analyses. However, my method aims to enable
fine mapping of GWAS output in the absence of genotype data. Hence, in practice, the
reference dataset used will be at most population-matched to the true control data. This is a
requirement for all such fine mapping techniques using summary data; both methods
discussed in Section 1.5, PAINTOR and Caviar, suggest using 1000 Genomes data for this
purpose. However, it is not obvious how much impact the choice of reference dataset has
upon the results obtained.
The frequencies of, and correlations between, SNPs vary greatly across populations; their
presence or absence can be used in genetic ancestry testing. Hence, in order for my reference
dataset to give an accurate reflection of the SNP correlation structure found in the control
sample of the GWAS whose summary results I am fine mapping, it must come from the same
ethnic population. In the case of the analysis presented in this thesis, that population is
individuals of European descent in the UK.
Recall in Section 4.5, I analysed the 1p13.2 region containing candidate causal gene
PTPN22 using p-values obtained from a T1D UK-only ImmunoChip analysis, and from a
much downsampled T1D GWAS analysis where, while all the control samples were of
self-reported European ancestry, some were taken from a US study. There was a substantial
difference between the results. Although this may be explainable by the SNPs downsampled
including one in high LD with the likely causal SNPs, it may also be the effect of analysing
the GWAS output using an inappropriate reference dataset.
Similarly, in Section 4.6, I analysed the 10p15.1 region containing candidate causal gene
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IL2RA. Although the main body of my analysis was upon the p-values obtained from UK-
only ImmunoChip analyses, and I used UK-only reference datasets, for MS and RA I also
analysed the p-values from the ImmunoChip analysis of an international (although of self-
reported European ancestry) cohort. Comparison of the results obtained for MS can be found
in Figure 4.15 and for RA can be found in Figure 4.19. The MS results show similar patterns,
with the two-SNP model identified in a previous analysis of the region having more evidence
of association; any discrepancies could be the result of an increase in the power to detect
associated signals. However, there are no clear patterns of association in the RA results, and
our preferred models change greatly between the UK-only and international analysis. This
does not appear to be the result of a power difference (a concentration of the same pattern in
the larger sample), and suggests instead that this may reflect differences between the GWAS
and reference datasets.
The smaller the number of samples in our reference dataset, the greater the effect of
sampling variation will be on estimates of SNP structure computed from them. My method
requires computing the (m+ 1)-way correlation between each SNP and the m causal SNPs in
W. Thus, the largerm, the greater number of samples required to obtain an accurate estimate.
1000 Genomes, the reference dataset often suggested by summary statistic fine mapping papers,
contains only 91 British samples; this is surely too small to accurately estimate the relationships
between any but the most common SNPs. One solution would be to integrate 1000 Genomes
data from across Europe, taking us up to 503 samples, and hope that the reduction in sampling
variance outweighs any bias due to different population structures.
In order to assess the potential effect of choice of reference dataset upon the results
presented in this chapter, I reran them using five different reference datasets, to see whether
my conclusions might be changed. In order to disentangle the effects of down sampling and
different populations, I used the following reference datasets:
1. All UK ImmunoChip controls, as discussed in Section 2.6
2. UK ImmunoChip controls, downsampled to 503 samples
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3. UK ImmunoChip controls, downsampled to 91 samples
4. EUR cohort from 1000 Genomes, containing 503 samples
5. GBR cohort from 1000 Genomes, containing 91 samples
4.7.1 Analysis of the PTPN22 Region
Recall that the 1p13.2 region containing candidate causal gene PTPN22 has strong evidence of
being a single-CV region for T1D, with two disease associated SNPs (rs6679677 and rs2476601
with r2 of 0.995) outperforming all other models in my fine mapping analysis (Section 4.5).
Figure 4.20 shows the results from using my five reference datasets to analyse all one-CV
models in the region. Each line gives the minimum sumsq obtained for one model under the
different reference datasets. The bold blue line corresponds to rs6679677, while the bold red
line corresponds to rs2476601. Regardless of reference datasets chosen, we conclude that these
are the top pair of SNPs. In the ImmunoChip downsampled to 91 analysis, however, they
obtain a minimum sumsq of > 2.4, which is too high to be consistent with being the true
causal model.
The bold green line on Figure 4.20 corresponds to SNP rs1230666. This is in LD with the
top SNPs (R2 = 0.61 with each of them), and on a Manhattan plot of the region (Figure 4.5)
it is clearly the third most associated SNP (p-value= 1.64× 10−54 in the ImmunoChip study),
with a substantial gap between it and the next SNPs. When a standard single CV summary
statistic fine mapping analysis is performed upon this region with rs6679677 and rs2476601
excluded (figure 4.6), rs1230666 is clearly the preferred SNP, with a posterior probability of
being causal = 1. In my fine mapping analysis, using the correct reference dataset, rs1230666
is the third preferred model (although its minimum sumsq of 2.21 is not consistent with being
the true causal model). By contrast, in the analyses using 1000 Genomes data, a set of SNPs
with (r2 ∼ 0.41 with rs6679677 and rs2476601) outperform rs1230666.
This analysis shows that, even in a highly associated region with a clear causal SNP,
changing the reference dataset can affect the resulting minimum sumsq, although not our
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Figure 4.20 The impact of choice of reference dataset on single CV models for T1D
association in the 1p13.2 region containing PPTPN22. Each line corresponds to the
minimum sumsq obtained for each model when the five different reference datasets,
represented by position on the horizontal axis, are used. The bold blue, red and green
lines correspond to the results for rs6679677, rs2476601 and rs1230666 respectively,
which are the three most strongly associated SNPs in the region. The dotted line
denotes log10(sumsq) = 0, which corresponds to sumsq = 1.
conclusions about the best performing models. Looking at the models overall, while
downsampling the reference dataset does have some effects upon the results in this region,
the largest change occurs when we switch to a different population of samples.
4.7.2 Analysis of the FASLG Region
Recall that the 1q24.3 region containing candidate causal gene FASLG has a potential causal
variant, rs78037977, which was not genotyped in the original CEL ImmunoChip analysis.
However, my fine mapping approach, using the complete ImmunoChip reference dataset,
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identifies this variant as performing well in the T1D analysis (Figure 4.10) and as the top
model in the CEL analysis (Figure 4.11). Here, I investigate the effect of choice of reference
dataset upon my conclusions for this region.
Figure 4.21 shows the T1D analysis, giving the minimum sumsq obtained for each model/
reference dataset pair. The bold red line corresponds to rs78037977, which performs well
regardless of the reference dataset; for all analyses, its minimum sumsq is within the bounds
where we would expect the sumsq from the true causal model to lie.
Looking over all models tested for T1D analysis, the choice of reference dataset appears to
have affected their relative rankings much more than was the case for the PTPN22 region. This
is not surprising. The observed Z Score for this region is relatively low (it has a maximum value
of 4.45; T1D association in this region is not genome-wide significant). While we would expect
the true causal model to perform well upon this region, we would also expect some models with
expected Z Scores clustered around the origin to do well by random chance. Which models
have this spurious low sumsq will be heavily dependent upon their MAF and LD structure; our
estimate of this varies with choice of reference dataset, and hence our well performing near-zero
models will also vary. Consider for instance rs74844118 (r2 of 0.00319 with rs78037977), which
is denoted in Figure 4.21 by the bold green line. While it performed poorly in four of the
analyses, it is the top model when the reference dataset is the ImmunoChip data downsampled
to 91.
Figure 4.22 shows the CEL analysis, giving the minimum sumsq obtained for each model/
reference dataset pair. The bold red line corresponds to rs78037977. This SNP is ranked highly
regardless of reference dataset, however, it is no longer the top model in the ImmunoChip
downsampled to 91, 1000 Genomes EUR and 1000 Genomes GBR analyses; these are the
reference datasets whose estimates are likely to be furthest from the true values. Looking over
all models analysed, both downsampling and changing to the 1000 Genomes population change
our conclusions, and the rankings, of many of the models. The CEL association in this region
is GWAS significant (maximum Z Score = 7.38), and we see fewer potentially spurious top
models than in the T1D analysis.
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Figure 4.21 The impact of choice of reference dataset on single CV models for T1D
association in the 1q24.3 region containing FASLG. Each line corresponds to the
minimum sumsq obtained for each model when the five different reference datasets,
represented by position on the horizontal axis, are used. The bold red line corresponds
to the results for rs78037977. The dotted line denotes log10(sumsq) = 0, which
corresponds to sumsq = 1.
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Figure 4.22 The impact of choice of reference dataset on single-CV models for CEL
association in the 1q24.3 region containing FASLG. Each line corresponds to the
minimum sumsq obtained for each model when the five different reference datasets,
represented by position on the horizontal axis, are used. The bold red line corresponds
to the results for rs78037977.
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4.7.3 Analysis of the IL2RA Region
Recall that while the 10p15.1 region containing candidate causal gene IL2RA is associated with
many autoimmune diseases the patterns of association are complex and vary between diseases.
A fine mapping analysis of this region [Wallace et al, 2015] found a 4-CV model for T1D,
whereas in MS there were two competing causal models, one with 1 CV ({rs2104286}) and one
with 2 CV (tagged in my analysis by {rs61839660, rs41295055}). In Section 4.6 I compared
models containing a subset of nine SNPs with evidence of being causal; the results of my T1D
and MS analyses were consistent with [Wallace et al, 2015]. In this section, I investigated the
effect of choice of reference dataset on all 1-CV and 2-CV models for T1D and MS association
in this region.
Figure 4.23 shows the results of these analyses, giving the minimum sumsq obtained for
each model/reference dataset pair. This shows that while changing the reference data does
change the sumsq values for individual models, it does not appear to change our conclusions
in this region. None of the models in the T1D analysis have sumsq ∼ 1; from this, we conclude
that this region is not consistent with having only 1 or 2 CVs, as found in [Wallace et al, 2015].
By contrast, in the MS analysis, a great many of the models fall within the sumsq bounds
where we would expect to see the true causal model. The two models identified in [Wallace
et al, 2015] for MS association are denoted by the bold yellow and red lines in Figure 4.23.
Regardless of choice of reference dataset, while neither is ever the top performing model, both
have sumsq consistent with being causal; the exact ordering of potentially causal models with
sumsq < 1 is likely due to random chance.
However, although Figure 4.23 gives an overview of our inference for the region, the number
of models being analysed makes it difficult to see the effect of changing the reference dataset
on a specific choice of W.
Figure 4.24 uses a heatmap to represent the sumsq for each of the five reference datasets
in the T1D analysis. Each row and column of each heatmap corresponds to a SNP. SNPs have
been ordered according to their minimum sumsq in the single causal variant models when
analysed using the complete ImmunoChip reference dataset, starting from the bottom left
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T1D Analysis
MS Analysis
Figure 4.23 The impact of choice of reference dataset on T1D and MS 1-CV and
2-CV models in the 10p15.1 region containing IL2RA. Each line corresponds to the
minimum sumsq obtained for each model when the five different reference datasets,
represented by position on the horizontal axis, are used. In the MS plot, the bold
yellow line corresponds to the results for {rs2104286}. The bold red line corresponds to
the results for {rs61839660, rs41295055}. The dotted line denotes log10(sumsq) = 0,
which corresponds to sumsq = 1.
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hand corner. Each cell is coloured according to the minimum sumsq obtained at the model
where W contains the two SNPs corresponding to the cell’s row and column; the diagonals
give the minimum sumsq obtained by the 1-CV model containing that SNP. Shading goes from
blue (low sumsq for this region) to red (high sumsq for this region).
There are notable differences between each of the five heatmaps. However, the most striking
effect is how much of a difference the choice of reference population makes. The trend is for
sumsq computed using the correlation structures from 1000 Genomes reference datasets to
be higher than those computed using ImmunoChip reference datasets. However, in the 1000
Genomes analysis, a subset of SNPs, corresponding to the thin blue lines visible upon the right
hand heatmaps, form an exception. Despite not performing well in the original, ImmunoChip
reference dataset, analysis, with the 1000 Genomes data, these SNPs have among the lowest
sumsq in the region when included in W. This effect is consistent in both the EUR and GBR
datasets. This demonstrates that choice of reference population can dramatically change the
ranking of models in this analysis.
Figure 4.25 gives the same five heatmaps, but for the MS analysis. Here, the effect of choice
of reference dataset is not so dramatic as it was for the T1D analysis. However, in all four
of the smaller reference datasets, we do see a number of cases of SNPs which perform much
better than in the original analysis. Consider for instance, rs41294917, corresponding to the
blue line seen towards the top right of the ImmunoChip 503 heatmap. WhileW = rs41294917
has minimum sumsq = 2.96 when using the complete ImmunoChip genotypes for reference
data, when this is downsampled to 503, the minimum sumsq obtained is 1.45. When the 1000
Genomes GBR reference data is used, rs41294917 has minimum sumsq = 1.32. As in the T1D
case, such differences affect the relative ranking of the models. In addition, a change of sumsq
from 2.96 to 1.32 is large enough that it moves the model from unlikely to be causal to the
region where we would expect to see the true causal model. This highlights that changing
the reference dataset may change our inferences about where the causal model is likely to be
found.
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Figure 4.24 Heatmaps showing the impact of choice of each of the five reference
datasets used upon T1D association found in the 10p15.1 region containing IL2RA.
Each row and column of each heatmap corresponds to a SNP. SNPs have been ordered
according to their minimum sumsq in the single causal variant models when analysed
using the complete ImmunoChip reference dataset, starting from the bottom left hand
corner. Each cell is coloured according to the minimum sumsq obtained at the model
where W contains the two SNPs corresponding to the cell’s row and column; the
diagonals give the minimum sumsq obtained by the 1-CV model containing that SNP.
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Figure 4.25 Heatmaps showing the impact of choice of each of the five reference
datasets used upon MS association found in the 10p15.1 region containing IL2RA.
Each row and column of each heatmap corresponds to a SNP. SNPs have been ordered
according to their minimum sumsq in the single causal variant models when analysed
using the complete ImmunoChip reference dataset, starting from the bottom left hand
corner. Each cell is coloured according to the minimum sumsq obtained at the model
where W contains the two SNPs corresponding to the cell’s row and column; the
diagnoals give the minimum sumsq obtained by the 1-CV model containing that SNP.
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4.8 Discussion
In this chapter, I demonstrate a method for fine mapping which builds upon the algorithm
for computing the expected output of a GWAS presented in Chapter 3. Using a publicly
available reference dataset to estimate the between-SNP correlation structure, I can compute
the expected summary statistics under a given causal model. By comparing this to the
(unsigned) summary statistics reported by a GWAS, I am able to compute a measure of
model-fit. Using an ABC-like framework, I sample from many such models, and am able to
rank them. With an appropriate threshold, it may also be possible to determine a set which
is likely to contain the true model, if the true model has been sampled.
Note that this method for fine mapping could also be employed when the direction of effect
at each SNP is known; the observed signed Z Score can be directly compared to the expected
signed Z Score. However, in such a case, the likelihood is tractable, and hence other fine
mapping approaches, such as those discussed in Section 1.5 may be used instead.
4.8.1 Comparisons to other Fine Mapping Approaches
The simplest techniques for performing fine mapping using summary data use only the
results of the single-SNP tests. They do not require the use of a reference dataset, and are
computationally very quick to perform. However, since they approximate the complete data
likelihood under a single-CV model, they are restricted to testing single CV models only.
They also assume all possible CVs have been genotyped, and hence require imputation if the
summary data is not known for all SNPs. In the absence of complete genotyping they have
the potential to give incorrect results with high confidence; Figure 4.6 shows an example of a
region with the likely causal variants removed; a standard single-CV summary statistic fine
mapping results in a posterior probability of being causal of 1 for a SNP which mostly likely
represents only LD with the CV. By contrast, my method allows for the analysis of
arbitrarily large (subject to restrictions on computation time) potential causal models. It is
able to recover causal variants even when those SNPs have been trimmed from the output
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presented.
Other tests do exist which enable fine mapping of multiple CV models from summary data.
I summarise two, PAINTOR and CAVIAR, in Section 1.4. However, both these approaches
are likelihood based; as I discussed in Section 4.2.1, this requires knowing the signed p-values;
that is, knowing the direction of effects for each SNP. However, many GWAS which report
only summary data also fail to report these values or fail to clearly state which allele the
direction corresponds to. Without these directions of effect, directly computing the likelihood
is computationally intractable. By sampling from the prior distribution of causal models, I
measure model fit by distance between absolute Z scores rather than by probability of observed
data under full likelihood, and hence am able to perform fine mapping from the unsigned p-
values.
In addition, both PAINTOR and CAVIAR assume that the effect at any SNP can be
represented as a linear sum over the effects upon the causal variants (see Equations 1.2 and
1.3). However, this assumes that only pairwise LD affects the interaction between any SNP and
the causal SNPs, and there are not any higher order effects. This is not a realistic assumption;
if SNPs X1, X2 and X3 are in LD, it is not possible to decompose P(GX1i = x1 ∩ GX2i =
x2 ∩ GX3i = x3) into second-order terms. In the extreme case when SNP X occurs only in
the presence of two or more of the causal SNPs, then Equations 1.2 and 1.3 will not be valid
models for the effect at X. For this reason, rather than assuming linear sums, I have computed
the complete probability P(GXi = x ∩GWi = w) for all possible w ∈ Zm3 . This will result in a
more accurate estimate of the expected Z Score, however it also increases the computational
time required, since I must compute the result in all 3m cases.
4.8.2 Impact of the Reference Dataset
In common with any summary statistic fine mapping algorithm which does more than single
SNP analysis, my method requires a reference dataset of genotype information to infer
correlation structure in the control data. In practice, this data will not precisely match the
control population used in the GWAS. In addition, in order to calculate the expected Z
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Score, we must first compute P(GXi = x ∩GWi = w), the joint probability of the genotype at
which we wish to compute the Z Score, X and the genotypes of the causal SNPs, W. This
has a multivariate binomial distribution, and is estimated from the reference dataset of
control samples. However, this reference dataset is of finite size, n. For a univariate binomial
distribution, Bin(2, π), the standard error is
√
2π(1−π)
n . Similarly, in the multivariate case,
the standard error is proportional to
√
1
n , and becomes large as the joint probabilities of
events become small. Hence, in models with many causal SNPs, or where causal SNPs have
low MAF, many samples are required in order to accurately estimate the reference
probabilities.
I show in Section 4.7 above that changing the reference dataset (whether that be by
downsampling, or by using data from a subtly different population) has the potential to
change my conclusions about a region. Although a strongly preferred model will remain the
top model, its minimum sumsq value is dependant on the reference dataset. Whether any
models fall within the sumsq bounds where we would expect to see a true causal model, and
the relative rankings of models, is also subject to change.
This variability is to be expected, and is almost certainly present to some extent in all
similar fine mapping algorithms. The Z Score at a non-causal SNP X must be some function
of its correlation with the causal SNPsW. Even within a relatively similar population, taking
different samples as references will result in different estimated relationships betweenX andW,
and hence different expected Z Scores. A common source suggested for a reference dataset is the
1000 Genomes project. However, this contains only 91 samples from the GBR population; this
is insufficient power to accurately estimate the MAF of a rare SNP, let alone the correlations
between a group of rare SNPs. Aggregating 1000 Genomes datasets across many populations
would increase the power to estimate such variables, but at a cost of the estimates no longer
being appropriate to the population in the original GWAS. I therefore suggest the use of larger
reference datasets, such as UK10K [Walter et al, 2015] if UK specific samples are sought, for
this class of methods.
It is likely that the results of my method are more sensitive to choice of reference dataset
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than either PAINTOR and CAVIAR. As discussed in 4.8.1 above, these methods require only
estimation of the LD matrix. By contrast, my method requires the estimation of the correlation
between the SNP at which we are currently estimating the Z Score and all causal SNPs in the
model. For large models, the sampling variance in this estimation, and hence the variance in
my results, will be much larger than the sampling variance when merely computing LD.
4.8.3 Extensions to my Fine Mapping Method
I have so far applied my fine mapping method to the analysis of results from a single population.
Due to the difference in LD structures between populations, cross-ethnic studies cannot be
performed simply by concatenating samples into a single large dataset, and instead a meta-
analysis must be performed. However, the results from such a multi-population meta-analysis
are simply a function of the Z Scores from the individual GWAS. It will be theoretically simple
to apply my method to simulate the output of each of these GWAS and then combine them
to estimate the expected meta-analysis output under a causal model of interest (which can
potentially include population-specific causal SNPs or effect sizes), and hence perform cross-
population fine mapping.
Similarly, I have so far applied this method to the fine mapping of a single disease. In
Chapter 2, however, I discuss colocalization techniques, which disentangle whether two related
diseases share causal variants or whether apparent common association to a region is a result
of distinct causal variants. I extend existing approaches to the case of a shared control dataset;
this is a common study design, since it increases power, but the resulting correlation between
the analysis of the two diseases makes it more difficult to analyse. My colocalization techniques
require complete genotype data for both sets of cases and controls; as is discussed in this
chapter, such information is often not available.
It would be possible to extend my fine mapping approach to fine mapping two diseases
simultaneously, and hence providing information about regions where colocalization occurs.
Rather than considering causal models {W,γ}, the fit of joint models
{Wtrait 1,Wtrait 2,γtrait 1,γtrait 2} would be analysed. In the case of separate controls, no
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additional method development would be required, and the expected output for each trait under
the model being considered would be computed independently. However, methods already exist
to perform colocalization from summary data only [Giambartolomei et al, 2014] (although they
often assume at most one causal variant per trait per region, an assumption not required in my
approach). There would be greater value in extending my method to allow for colocalization
from summary statistic data when the control data is shared, which could be done by extending
the algebra in Section 3.2 to the case where disease status is modelled by multinomial, rather
than binomial, logistic regression.
Note, however, that due to the number of γ which must be sampled in order to converge to
the minimum sumsq at a set of potential causal SNPs W (particularly in the case where the
size of W is large), my fine mapping method is computationally expensive even when applied
to a single population or disease. This effect will be magnified by the number of studies being
simulated, and the size of the models being analysed.
Chapter 5
Discussion
In this thesis, I develop methods for the analysis of causal variants and causal processes in
complex diseases. I extend methods which investigate whether variants within a region are
shared between related diseases or are distinct. I also develop a method which enables the
simulation of the output from a GWAS; this can be used to estimate the null distribution in
a SNP set enrichment analysis, or to provide the backbone of a technique for fine mapping
causal variants from only summary statistic data, using an approach similar to ABC.
5.1 Future Relevance of Methods Presented Here
In Chapter 2, I present extensions of colocalization algorithms to the study design where disease
case samples are compared to a common control. Such a study design is common, especially by
consortia which are analysing many diseases. Genotyping is expensive, and by genotyping only
a single control set, the power of the study can be maximised. However, with data increasingly
becoming cheaper to generate, or even being made freely available from repositories, will this
design be less used?
The UK Biobank (www.ukbiobank.ac.uk) is a biorepository containing health
information, including genotypes and disease statuses from 500,000 participants. It was
designed to study multiple diseases with onset in later age, but such a large publicly available
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resource is obviously an attractive source of population controls for many studies, including
colocalization. However, there are complicating factors. For instance, unlike the ImmunoChip
for autoimmune-associated regions, Biobank samples are not densely genotyped. In
colocalization tests, the likelihood is partitioned according to the probability that each
included variant is causal; an implicit assumption in interpreting the results is that, if there is
a causal variant, it is genotyped. Hence, these tests require densely genotyped controls, and,
by downsampling to the density found in Biobank, we would lose accuracy.
One solution might be to impute genotype data for those SNPs not genotyped by
Biobank, using resources such as the Haplotype Reference Consortium to estimate haplotype
probabilities (www.haplotype-reference-consortium.org/). This is not desirable, since it
is preferable to avoid having to compare an imputed control dataset to a non-imputed case
set. However, the use of imputation in the control data alone will result in differential
measurement error; in addition, the choice of reference dataset used for imputation can lead
to bias, particularly in SNPs with low MAF. This has the potential to cause an inflated Type
1 error rate in the subsequent analysis. While additional QC steps may be able to control
this, they will likely result in the exclusion of many of the SNPs we wish to study [Sinnott
and Kraft, 2012]. However, in such a case, the only other option is to downsample the
ImmunoChip cases and then impute them back up to full density; a needless loss of
information.
More fundamentally, methods for comparing case/control cohorts assume that there is no
systematic difference other than disease status between the datasets being analysed. With large
sample sizes taken from similar populations, extracted and stored in similar conditions, and
genotyped upon the same chip, at the same centre, this assumption is probably valid, although
detecting variants with systematically different errors between cases and controls remains a key
step in every GWAS. When comparing an ImmunoChip case group to a Biobank control group
such similarity conditions do not hold, and any results obtained might easily be artefacts of
the differences in chips used for genotyping. Even when comparing two Biobank groups (which
might not be possible for a sufficiently rare disease) care must be taken, since two different
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arrays have been used for genotyping.
Hence it is likely that, particularly in the case of rare diseases or diseases where a specialised
chip is appropriate, the common control design will continue to be used. Regardless of data
availability, even though this design does make the downstream analysis more difficult due
to the correlation structure induced, it does have a number of methodological advantages. It
increases the power to detect associations (if only marginally as control data sizes increase
relative to case data sizes) and negates the issue of error due to systematic differences between
finite samples of separate controls.
Another common design likely to see continued use is that of overlapping controls. This
may come about due to varying choice of standard reference cohorts, or even due to substantial
difference in QC, between two studies. Just as in the common control case, the partial sharing
of controls between studies leads to correlations which must be accounted for in comparative
analyses. For instance, [Pickrell et al, 2016] estimate the correlation between effect sizes under
the null model and use this to correct effect size estimates. The methods I present in Chapter
2 could also be extended to the case of overlapping controls.
In Chapter 4, I developed a technique which fine maps a genetic region given only summary
data. Even if the use of freely available genotypes from biorepositories becomes standard within
the field, there will still be a requirement for summary statistic methods. For instance, we may
wish to analyse the results from a historical GWAS for which full genotype data is not available,
or to integrate such a study into a meta-analysis. Making genotype data available requires
ethical approval and consent from the donors: due to patient privacy concerns, summary data
may be all it is possible to release from a study.
As datasets become increasingly large, using full genotype data becomes computationally
infeasible. In such cases, a divide-and-conquer approach may be employed; genotype data is
segmented, and the analysis is done within these segments, all outputs then being merged to
obtain a final result. An approach using even a fraction of the true genotype data is likely to be
more accurate than a summary statistic approach, which unavoidably relies upon a reference
dataset to estimate SNP correlations. However, if a summary statistic approach could be
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developed which is sufficient for the analysis in question, it might increase computational
efficiency in such cases.
5.2 Future Directions
In Section 5.1 above, I discuss the issues with integrating data (for example, a case cohort
and a control cohort) which have come from different sources. A fundamental assumption of
the methods used to analyse such data is that there are no systematic differences between
the cohorts other than that being studied. As the amount of data available increases, and
sample sizes become larger, the statistical theory behind these methods will assume that the
only source of error, sampling variation, becomes negligible, and will find differences between
cohorts which would not be expected by random chance. However, practically in analysis
of biological data, there are invariably errors which are systemic, and which do not decrease
as sample size increases; for instance the cases and controls will frequently be genotyped at
different centres. There is a need for the development of fine mapping analyses which allow
for such errors.
However, the ultimate aim of disease analysis is for the results to translate to clinical
impact. By finding the true causal variants, linking these to a gene or gene network and
hence identifying a target, such as a protein or RNA molecule, we may be able to find a
therapeutic which modulates this target and hence, potentially, treats the disease. This requires
collaboration between many different disciplines, and projects such as Open Targets (https:
//www.targetvalidation.org/) aim to assist target validation by integrating information
about potential drug targets.
GWAS, while they identify disease associated regions, are not able to perform causal variant
identification. Instead, fine mapping is run as a secondary analysis, often on an ad-hoc basis,
and with incomplete input data, possibly only on summary statistics, as reported from the
GWAS. In order to better understand disease aetiology, I believe fine mapping should be part
of the initial aim of a GWAS, with a causal variant identification technique run systematically
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upon each region which shows significant evidence of disease association.
In addition, once these causal variants have been found, it still remains to characterise the
effect they have upon genes. By integrating GWAS and fine mapping results with functional
annotation data, we hope to identify such effects and hence also novel candidate causal genes.
There are many effects which could potentially have a role in disease processes; variants in
coding regions may affect the function of a protein, or a variant might result in splicing errors.
However, in the case of complex traits such as autoimmune disease, one of the largest effects is
expected to be from variants changing gene expression; hence, many approaches focus on eQTL
data to identify causal genes. These effects may well be cell-type specific, or even cell-state
specific (in autoimmune disease, for instance, we might look for differences in gene expression
between non-activated and activated CD4+ T Cells).
Although I extended it to the analysis of two traits in the case of a common control
dataset, the Bayesian colocalization method described in Section 1.4.1 can be used to infer
whether disease associated variants appear to colocalize with eQTL signals by simultaneously
fine mapping disease and eQTL signals, and integrating the likelihood of shared versus distinct
causal variants over the two probabilistic maps. This is illustrated in Section 2.3, where I ran
this method upon the region containing candidate causal gene FADS2. I found strong evidence
of colocalization between Crohn’s Disease and an eQTL for FADS2 in five cell types (CD4+,
CD8+, CD14+, CD16+, CD19+), implicating FADS2 in the aetiology of CD. Functional data
such as eQTLs can also be directly analysed for disease association. In a Transcription Wide
Association Study (TWAS) [Gusev et al, 2016] the eQTLs are mapped in a separate dataset,
and then used to impute the gene expression for a set of control samples and for a set of
case samples (thus increasing the power available, since the cost of measuring gene expression
would lead to small samples sizes without imputation). A GWAS-like analysis of dependence
between expression and disease status is then performed in order to identify genes which
have significant differential expression between cases and controls. Alternatively, [Zhu et al,
2016] uses Mendelian Randomisation style techniques to test for association between disease
expression and disease status, taking as input summary data from GWAS and eQTL studies.
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Studies combining eQTLs with autoimmune disease GWAS have found evidence of disease-
associated genes. [Guo et al, 2015] identified evidence of disease association at six genes in
monocytes and/or B cells, including some cell-type specific effects. However, out of the 125
genes showing evidence of potential overlapping disease association and eQTL signals, only 28
showed some support for colocalization. [Huang et al, 2015] performed a fine mapping of 94 loci
associated with IBD, and found that the overlap between eQTLs and disease associated credible
sets of SNps was no more than would be expected by random chance. While enrichment of
eQTLs in the disease credible sets were found in cell types including CD4+ and ileum cells,
the majority of cell types tested, all of which were plausibly associated with IBD, showed no
significant overlap. Based upon our current understanding of gene expression as an important
mechanism in the aetiology of complex diseases, we would expect to see overlap of causal
variants and eQTLs more frequently than these studies suggest is the case. What is causing
these studies to be less successful than we might expect?
One explanation might be that, while the effects of eQTLs upon disease status are present,
they are so tissue-context specific that, unless a study surveys precisely the correct tissue, in
the correct state, no association will be found. However, the space of potential tissue contexts
is large; for instance, gene expression differs between a T-cell which has just been activated,
and that same T-cell an hour post activation, as well as depending on the means of T-cell
activation, so it may not be appropriate to consider a single analysis of eQTLs in activated
T-cells. This suggests that, for any study into the effect of gene expression upon disease,
care must be taken to select the appropriate analysis, and a range of cell types in a range of
conditions should probably be considered.
In addition, the odds ratios of effect found in GWAS for complex diseases tend to be small;
see Section 3.3.3 for an empirical distribution of effects sizes reported in the GWAS catalog.
Due to the expense, many eQTL studies have low sample sizes; it could simply be that they
are underpowered to detect the effects which are present. As technology becomes cheaper, and
larger datasets become available, it is to be hoped that studies will become powered to detect
smaller effects due to gene expression.
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However, a single gene will have many eQTLs, and there is evidence that their effect upon
the expression of their target is additive. Hence, it is also possible that we do not tend to
see significant association between individal eQTLs and disease status since genes are able to
compensate for a variant affecting a single enhancer via the actions of their other eQTLs.
While I believe that the development of methods which identify differential gene
expression in disease is important in the search for potential drug targets, there is still an
important place for fine mapping techniques such as those presented in this thesis. Although
gene expression being associated with disease status is suggestive of a causal role, it does not
constitute verification of causal status. eQTL studies are unable to distinguish between
“driver” genes, which contribute to the disease process, and “passenger” genes, where the
differential expression is a downstream effect of the disease. It is by investigating the genetic
variants which cause the disease that we can determine in which direction this causality runs.
Appendix A
Regions Analysed in Chapter 2
This Appendix gives a list of all 126 regions analysed by my colocalization analyses in Chapter
2, their locations and the candidate causal genes within them. Also given are which of the four
diseases (T1D, RA, CEL, MS) have existing associations with the region, and which of the
four diseases my colocalization analysis found to be associated with the region. Novel disease
associations are indicated by the use of a bold font, while distinct signals are indicated by a
“|”.
Locus (hg18) Band Existing
associations
Associations
found
Candidate causal genes and genes in
region
chr1:2353185-2786479 1p36.32 RA, CEL,
MS
RA, CEL,
MS
PLCH2 TNFRSF14 FAM213B
MMEL1 TTC34
chr1:25096906-25180863 1p36.11 CEL None RUNX3
chr1:85376325-85713887 1p22.3 MS None BCL10 DDAH1
chr1:92023171-93311800 1p22.1 MS MS EVI5
chr1:100982239-101455699 1p21.2 MS MS EXTL2 SLC30A7
chr1:113619999-114460000 1p13.2 T1D, RA T1D, RA PTPN22
chr1:116831830-116911865 1p13.1 MS MS CD58
chr1:152574287-152933315 1q21.3 RA RA ATP8B2 IL6R
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Locus (hg18) Band Existing
associations
Associations
found
Candidate causal genes and genes in
region
chr1:155746666-156085174 1q23.1 MS None FCRL3 FCRL1
chr1:158947387-159200000 1q23.3 MS None CD48 SLAMF7 CD244 ITLN1
chr1:170882016-171208336 1q24.3 CEL T1D, CEL FASLG
chr1:190728935-190815166 1q31.2 CEL, MS CEL, MS RGS1
chr1:199110000-199320000 1q32.1 T1D, CEL,
MS
CEL, MS C1orf106 KIF21B
chr1:204869062-205116454 1q32.1 T1D T1D MAPKAPK2 IL10 IL19 IL20
chr2:24539944-25341162 2p23.3 T1D, MS None CENPO ADCY3 EFR3B DNMT3A
chr2:43165703-43240464 2p21 MS MS
chr2:60722116-61952276 2p16.1 RA, CEL,
MS
CEL|MS AC010733.4 REL PUS10 KIAA1841
C2orf74 AHSA2
chr2:65246601-65570598 2p14 RA RA, MS SPRED2
chr2:68388948-68711822 2p14 CEL, MS None PLEK
chr2:99883120-100415547 2q11.2 T1D, RA T1D, RA,
CEL
AFF3
chr2:102169652-102670082 2q12.1 CEL CEL IL1RL2 IL1RL1 IL18R1 IL18RAP
chr2:162669118-163101007 2q24.2 T1D T1D IFIH1 KCNH7
chr2:181022069-181977071 2q31.3 CEL CEL UBE2E3
chr2:191412527-191739472 2q32.2 T1D, RA,
CEL, MS
RA,
CEL|MS
STAT1 STAT4
chr2:202920548-204528303 2q33.1 T1D, RA,
CEL
T1D,
CEL|RA
CD28 CTLA4 ICOS
chr2:230758228-230962304 2q37.1 MS CEL, MS SP140
chr3:18582795-18831864 3p24.3 MS MS
chr3:27656007-27811049 3p24.1 MS None EOMES
chr3:28015774-28105476 3p24.1 MS MS
chr3:32873208-33063377 3p22.3 CEL, MS None CCR4
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Locus (hg18) Band Existing
associations
Associations
found
Candidate causal genes and genes in
region
chr3:45812888-46633741 3p21.31 T1D, CEL T1D|CEL CCR3 CCR1 CCR5 LTF
chr3:120581991-120788414 3q13.33 CEL, MS MS ARHGAP31 TMEM39A POGLUT1
TIMMDC1 CD80
chr3:122818149-123329522 3q13.33 MS MS IQCB1 SLC15A2 CD86
chr3:160950948-161389020 3q25.33 CEL, MS CEL|MS IL12A
chr3:189504161-189629875 3q28 CEL CEL
chr4:25637284-25745871 4p15.2 T1D, RA RA
chr4:103607587-104383056 4q24 MS None NFKB1 MANBA
chr4:106143093-106702164 4q24 MS None TET2
chr4:123121079-124497235 4q27 T1D, RA,
CEL
T1D|CEL KIAA1109 ADAD1 IL2 IL21
chr5:35831493-36107254 5p13.2 MS T1D, MS SPEF2 IL7R CAPSL UGT3A1
chr5:40322722-40723788 5p13.1 MS MS PTGER4
chr5:55450712-55492884 5q11.2 RA, MS DRM ANKRD55
chr5:102062861-102777130 5q21.1 RA RA GIN1 C5orf30
chr5:141392811-141620603 5q31.3 MS None NDFIP1
chr5:158451344-158758888 5q33.3 MS None IL12B
chr5:176439335-176780625 5q35.2 MS None RGS14
chr6:315547-412533 6p25.3 CEL CEL IRF4
chr6:36452190-36721790 6p21.31 MS MS PXT1
chr6:90863554-91103018 6q15 T1D, CEL,
MS
T1D, RA,
MS
BACH2
chr6:126479721-127461527 6q22.32 T1D T1D CENPW
chr6:127876526-128385456 6q22.33 CEL, MS CEL THEMIS PTPRK
chr6:135630625-136228061 6q23.3 MS None AHI1
chr6:137348296-137587799 6q23.3 MS MS IL22RA2
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Locus (hg18) Band Existing
associations
Associations
found
Candidate causal genes and genes in
region
chr6:137914792-138345363 6q23.3 RCM T1D, RA,
CEL|MS
TNFAIP3
chr6:159237498-159464567 6q25.3 T1D, RA,
CEL, MS
CEL, MS TAGAP
chr6:167268496-167467944 6q27 RA RA RNASET2 FGFR1OP CCR6
chr7:26624486-27436525 7p15.2 T1D, MS T1D, MS SKAP2
chr7:28086237-28228851 7p15.1 MS None JAZF1
chr7:37323488-37406978 7p14.2 CEL, MS RA, CEL,
MS
ELMO1
chr7:50222360-50335957 7p12.2 MS T1D, MS IKZF1
chr7:50337180-50662811 7p12.2 T1D T1D IKZF1 FIGNL1
chr7:50866661-51640000 7p12.2 T1D T1D COBL
chr7:128338975-128564756 7q32.1 RA RA IRF5 TNPO3
chr8:11375792-11389894 8p23.1 RA None BLK
chr8:79575897-79914680 8q21.12 MS MS PKIA ZC2HC1A
chr9:4218549-4311558 9p24.2 T1D T1D GLIS3
chr9:34638417-34986014 9p13.3 RA CEL CCL21
chr10:6068495-6237542 10p15.1 T1D, RA,
MS
T1D|MS IL2RA
chr10:6428075-6585110 10p15.1 T1D, RA,
CEL
None PRKCQ
chr10:31172479-31520710 10p11.23 MS None ZNF438
chr10:35080006-35590006 10p11.21 T1D None CREM CCNY
chr10:80658841-80774414 10q22.3 CEL, MS CEL ZMIZ1
chr10:89998026-90268360 10q23.31 T1D T1D RNLS
chr10:94189315-94491883 10q23.32 MS None HHEX
chr11:2024999-2264880 11p15.5 T1D T1D INS
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associations
Associations
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Candidate causal genes and genes in
region
chr11:46304899-49088571 11p11.2 MS None AGBL2
chr11:60482183-60617465 11q12.2 MS MS CD6
chr11:63600519-63980103 11q13.1 MS None FLRT1 TRPT1 ESRRA PRDX5
CCDC88B RPS6KA4
chr11:117805448-118403529 11q23.3 RA, CEL,
MS
CEL|MS TREH DDX6 CXCR5
chr11:127754640-128010703 11q24.3 CEL CEL ETS1
chr12:6291754-6334123 12p13.31 MS MS TNFRSF1A SCNN1A
chr12:6353046-6393510 12p13.31 MS None SCNN1A LTBR
chr12:9407874-9867423 12p13.31 T1D, MS CEL CLECL1 CD69
chr12:54637612-55091576 12q13.2 T1D T1D IKZF4 ERBB3 IL23A STAT2
chr12:56127370-56774934 12q13.3 T1D, MS MS AGAP2 CYP27B1 TSFM
chr12:109772108-111723111 12q24.11 T1D, RA,
CEL
T1D|CEL SH2B3 ATXN2 BRAP
chr12:121926103-122574026 12q24.31 MS MS PITPNM2
chr13:98723872-99034738 13q32.3 T1D, MS T1D GPR183
chr14:68231082-68387815 14q24.1 T1D, CEL,
MS
MS RAD51B ZFP36L1
chr14:75012674-75107858 14q24.3 MS None BATF
chr14:87372049-87716867 14q31.3 MS MS GALC GPR65
chr14:97427666-97601359 14q32.2 T1D T1D
chr14:100357783-100398492 14q32.2 T1D T1D
chr15:36603999-36786000 15q14 T1D ,RA T1D RASGRP1
chr15:72389033-73270664 15q24.1 CEL None CLK3 CSK
chr15:76773859-77050416 15q25.1 T1D, MS T1D, CEL CTSH
chr15:88612805-89221004 15q26.1 MS None IQGAP1 CRTC3
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chr16:10831557-11408130 16p13.13 T1D, CEL,
MS
T1D,
MS|CEL
CIITA DEXI CLEC16A RMI2 SOCS1
PRM3 PRM2 PRM1
chr16:28191235-28944416 16p11.2 T1D T1D IL27 NUPR1 SULT1A2 SULT1A1
EIF3C SH2B1 RABEP2 CD19 LAT
chr16:29753185-30627501 16p11.2 MS None MAPK3 ITGAL
chr16:66887501-67407338 16q22.1 MS None ZFP90 CDH3
chr16:73760230-74086012 16q23.1 T1D T1D
chr16:84539746-84581605 16q24.1 RA, MS RA, MS
chr17:34629755-35508018 17q12 T1D, RA,
MS
T1D PNMT RP11-94L15.2 IKZF3 ZPBP2
GSDMB ORMDL3 GSDMA
chr17:35990899-36132000 17q21.2 T1D None
chr17:37562258-38298988 17q21.2 MS MS STAT5B STAT5A STAT3 PTRF MLX
chr17:42664102-43231021 17q21.32 MS MS NPEPPS TBKBP1 TBX21
chr18:12407903-12919721 18p11.21 T1D, CEL T1D|CEL PTPN2
chr18:65630494-65722590 18q22.2 T1D None CD226
chr19:6564831-6636304 19p13.3 MS MS TNFSF14
chr19:10081000-11019034 19p13.2 T1D, RA,
MS
T1D, RA,
MS|CEL
PPAN-P2RY11 PPAN ICAM1
ICAM3 TYK2 CDC37 SLC44A2
ILF3 CARM1
chr19:16300497-16612240 19p13.11 MS MS
chr19:17905598-18272802 19p13.11 MS MS IFI30 MPV17L2
chr19:51843217-52015224 19q13.32 T1D T1D PRKD2 STRN4
chr19:53784241-53969894 19q13.32 T1D T1D SPHK2 DBP FUT2 MAMSTR
RASIP1 IZUMO1
chr20:1444472-1707590 20p13 T1D T1D
chr20:43965660-44217558 20q13.12 RA, MS CEL, MS PLTP MMP9 NCOA5 CD40
chr20:47840533-48095989 20q13.13 MS None SLC9A8 RNF114
Continued on next page
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chr20:52207832-52256247 20q13.2 MS None CYP24A1
chr20:61650000-61959471 20q13.33 MS None STMN3 RTEL1 RTEL1-TNFRSF6B
TNFRSF6B ZGPAT LIME1
SLC2A4RG ZBTB46
chr21:42681877-42771181 21q22.3 T1D, RA,
CEL
T1D|RA|CELUBASH3A
chr21:44414408-44528088 21q22.3 CEL None ICOSLG
chr22:20042414-20686540 22q11.21 RA, CEL,
Ms
CEL UBE2L3 YDJC CCDC116 MAPK1
chr22:28137854-28999883 22q12.2 T1D T1D MTMR3 LIF OSM
chr22:35898615-35996732 22q12.3 T1D T1D IL2RB C1QTNF6
Appendix B
Results from Colocalization Analysis
for Regions Mentioned in Chapter 2
This Appendix gives the results from my colocalization analysis, for 24 of the 126 regions
tested. Included are regions which were discussed in detail in Chapter 2, regions which were
given in Table 2.3 (regions showing evidence of seperate SNP effects) and regions which were
given in Table 2.4 (regions showing strong evidence of novel association).
For each region is given the location, the candidate causal genes within the region, which
of the four autoimmune diseases (T1D, RA, CEL, MS) it had existing associations with, and
which of the four autoimmune diseases my analysis concluded it has associations with. For each
of the six pairwise analyses of the diseases, from the Bayesian approach, I give the posterior
probabilities of H0, H1, H2, H3, H4. From the proportional approach I give the posterior
predictive p-value, and the estimate ηˆ, the constant of proportionality.
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Location Candidate Causal Genes Existing Associations Associations Found
1q24.3 FASLG CEL T1D, CEL
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 8.30E-01 1.64E-01 2.15E-03 3.98E-04 2.66E-03 1.04E+00 3.13E-01
T1D-CEL 5.21E-08 8.72E-09 2.51E-01 3.49E-02 7.14E-01 1.88E+00 6.22E-01
T1D-MS 5.87E-01 4.11E-01 1.05E-03 7.33E-04 1.56E-05 3.33E+00 6.87E-02
RA-CEL 1.28E-06 2.17E-09 9.88E-01 1.58E-03 1.00E-02 2.18E+00 5.00E-01
RA-MS 9.96E-01 2.64E-03 1.85E-03 4.91E-06 7.00E-07 8.18E-01 5.44E-02
CEL-MS 4.19E-08 9.98E-01 7.35E-11 1.74E-03 6.65E-05 2.65E-01 5.43E-02
Location Candidate Causal Genes Existing Associations Associations Found
2p16.1 REL RA, CEL, MS CEL | MS
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 9.43E-01 1.87E-03 5.54E-02 1.10E-04 4.13E-05 2.87E+00 2.01E-01
T1D-CEL 1.28E-02 1.76E-05 9.86E-01 1.35E-03 3.01E-04 3.21E+00 1.11E-01
T1D-MS 2.57E-01 5.31E-04 7.41E-01 1.53E-03 4.11E-04 4.02E+00 2.67E-01
RA-CEL 6.25E-03 7.12E-04 8.86E-01 1.01E-01 6.48E-03 3.16E+00 3.61E-02
RA-MS 3.21E-01 2.33E-02 5.87E-01 4.25E-02 2.63E-02 1.15E+00 1.58E-01
CEL-MS 1.52E-04 2.72E-01 3.60E-04 6.45E-01 8.19E-02 6.34E-01 1.42E-02
Location Candidate Causal Genes Existing Associations Associations Found
2p14 SPRED2 RA RA, MS
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 6.25E-02 1.28E-04 9.35E-01 1.91E-03 1.68E-04 3.58E+00 2.23E-01
T1D-CEL 9.97E-01 1.11E-03 1.80E-03 2.00E-06 3.28E-07 5.75E-01 3.77E-01
T1D-MS 4.33E-01 7.06E-04 5.66E-01 9.22E-04 7.38E-05 3.08E+00 7.48E-01
RA-CEL 5.59E-02 9.42E-01 9.72E-05 1.63E-03 7.77E-04 3.98E-01 6.13E-01
RA-MS 6.91E-03 1.22E-01 1.41E-02 2.43E-01 6.14E-01 9.89E-01 4.07E-01
CEL-MS 7.54E-01 2.00E-03 2.43E-01 6.42E-04 1.92E-04 3.14E+00 2.69E-01
Location Candidate Causal Genes Existing Associations Associations Found
2q11.2 AFF3 T1D, RA T1D, RA, CEL
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 1.18E-06 7.69E-05 1.94E-03 1.18E-01 8.80E-01 1.25E+00 3.84E-01
T1D-CEL 1.33E-04 1.18E-02 4.76E-03 4.19E-01 5.65E-01 9.43E-01 1.38E-01
T1D-MS 4.28E-02 9.43E-01 4.33E-04 9.49E-03 4.50E-03 5.57E-01 2.09E-01
RA-CEL 1.89E-07 5.25E-04 4.01E-05 1.02E-01 8.97E-01 8.00E-01 2.37E-01
RA-MS 5.88E-04 9.58E-01 2.50E-05 4.07E-02 6.90E-04 2.85E-01 2.06E-01
CEL-MS 2.59E-02 9.53E-01 5.16E-04 1.90E-02 1.20E-03 7.34E-01 2.77E-01
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2q32.2 STAT1 STAT4 T1D, RA, CEL, MS RA, CEL | MS
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 2.86E-01 2.45E-02 6.26E-01 5.34E-02 1.03E-02 9.73E-01 5.25E-01
T1D-CEL 4.73E-01 4.71E-02 3.53E-01 3.42E-02 9.22E-02 1.05E+00 2.95E-01
T1D-MS 3.80E-02 5.01E-03 8.45E-01 1.11E-01 2.07E-04 -7.32E-01 3.38E-02
RA-CEL 2.68E-01 2.99E-01 1.85E-01 2.07E-01 4.08E-02 1.22E+00 2.56E-01
RA-MS 1.32E-02 1.50E-02 4.51E-01 5.11E-01 9.23E-03 -1.04E+00 5.74E-02
CEL-MS 1.99E-02 1.99E-02 4.79E-01 4.79E-01 1.57E-03 -7.08E-01 1.51E-03
Location Candidate Causal Genes Existing Associations Associations Found
2q33 CD28, CTLA4, ICOS T1D, RA, CEL T1D, RA, CEL
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 1.18E-11 1.29E-02 8.97E-10 9.85E-01 2.52E-03 5.10E-01 1.69E-01
T1D-CEL 1.10E-14 2.47E-05 5.67E-11 1.18E-01 8.82E-01 7.32E-01 1.62E-02
T1D-MS 1.78E-09 9.99E-01 1.01E-12 5.69E-04 6.22E-05 -4.72E-02 2.71E-01
RA-CEL 7.77E-07 9.94E-06 7.12E-02 9.12E-01 1.66E-02 1.62E+00 1.47E-01
RA-MS 2.68E-01 7.31E-01 1.26E-04 3.44E-04 1.02E-04 1.79E-01 1.72E-01
CEL-MS 4.24E-05 9.99E-01 1.88E-08 4.42E-04 7.52E-05 -1.09E-01 2.44E-01
Location Candidate Causal Genes Existing Associations Associations Found
2q37.1 SP140 MS CEL, MS
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 6.64E-01 3.36E-01 1.02E-04 5.13E-05 2.34E-05 -1.74E-01 1.93E-01
T1D-CEL 3.76E-01 2.07E-02 3.73E-01 1.84E-02 2.12E-01 9.96E-01 5.16E-01
T1D-MS 2.61E-05 2.29E-06 6.71E-01 5.62E-02 2.73E-01 1.57E+00 3.37E-01
RA-CEL 4.40E-01 9.94E-05 5.60E-01 1.25E-04 9.60E-05 -3.18E+00 2.58E-01
RA-MS 1.00E-07 9.44E-11 9.99E-01 9.40E-04 7.34E-05 -1.48E+01 2.67E-01
CEL-MS 3.18E-09 5.12E-09 6.19E-02 9.13E-02 8.47E-01 1.76E+00 6.54E-01
Location Candidate Causal Genes Existing Associations Associations Found
3p21.31 CCR3, CCR1, CCR5 T1D, CEL T1D | CEL
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 1.68E-01 8.29E-01 3.63E-04 1.79E-03 2.18E-04 1.43E+00 2.81E-01
T1D-CEL 2.13E-09 2.70E-08 7.29E-02 9.22E-01 4.87E-03 2.12E+00 2.65E-01
T1D-MS 6.45E-01 3.46E-01 5.51E-03 2.95E-03 3.08E-04 1.54E+00 4.75E-01
RA-CEL 9.01E-08 3.15E-10 9.96E-01 3.47E-03 3.68E-04 2.13E+00 3.74E-01
RA-MS 9.90E-01 3.23E-03 7.18E-03 2.33E-05 1.03E-05 1.23E+00 1.61E-01
CEL-MS 1.63E-08 8.53E-01 2.61E-09 1.36E-01 1.04E-02 6.42E-01 8.07E-01
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3q25.33 IL12A CEL, MS CEL | MS
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 9.99E-01 4.56E-04 3.34E-04 1.51E-07 1.16E-07 -1.22E-01 2.04E-01
T1D-CEL 5.01E-15 2.01E-18 9.99E-01 3.97E-04 1.51E-04 8.00E+01 4.97E-01
T1D-MS 9.52E-03 7.73E-06 9.90E-01 8.03E-04 7.37E-05 -1.76E+01 1.14E-01
RA-CEL 1.26E-14 5.83E-18 9.99E-01 4.60E-04 2.72E-04 -5.54E+00 4.09E-01
RA-MS 1.08E-02 4.67E-06 9.89E-01 4.26E-04 4.79E-05 8.84E+00 3.01E-01
CEL-MS 3.05E-18 3.30E-02 8.86E-17 9.59E-01 7.59E-03 -4.75E-01 1.10E-01
Location Candidate Causal Genes Existing Associations Associations Found
4q27 IL2 IL21 T1D, RA, CEL T1D | CEL
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 1.31E-05 8.15E-01 2.83E-06 1.77E-01 8.85E-03 4.74E-01 1.61E-01
T1D-CEL 9.46E-26 1.89E-20 5.01E-06 1.00E+00 4.50E-08 2.05E+00 6.40E-09
T1D-MS 1.19E-05 1.00E+00 1.82E-09 1.52E-04 5.35E-05 1.94E-01 2.27E-01
RA-CEL 5.51E-22 1.03E-22 5.84E-01 1.06E-01 3.09E-01 3.07E+00 2.91E-02
RA-MS 8.25E-01 1.75E-01 2.68E-04 5.62E-05 5.96E-05 5.71E-01 4.83E-01
CEL-MS 2.23E-21 9.99E-01 4.72E-25 2.08E-04 3.20E-04 2.70E-01 4.02E-01
Location Candidate Causal Genes Existing Associations Associations Found
5q11.2 ANKRD55 RA, MS T1D, RA, MS
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 1.40E-07 3.41E-09 2.91E-01 4.56E-131 7.09E-01 2.30E+00 5.01E-01
T1D-CEL 9.51E-01 4.88E-02 3.15E-04 1.52E-05 1.01E-04 8.36E-01 4.09E-01
T1D-MS 8.26E-06 2.00E-07 2.94E-01 6.76E-05 7.06E-01 2.09E+00 3.43E-01
RA-CEL 1.43E-07 9.98E-01 4.49E-11 2.93E-04 1.98E-03 2.82E-01 2.61E-01
RA-MS 9.30E-14 2.94E-07 3.17E-09 8.08E-05 1.00E+00 8.64E-01 2.39E-01
CEL-MS 3.48E-05 9.04E-09 9.98E-01 2.40E-04 1.96E-03 2.75E+00 1.41E-01
Location Candidate Causal Genes Existing Associations Associations Found
6q23.3 TNFAIP3 RA, CEL, MS T1D, RA, CEL | MS
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 1.45E-04 3.83E-05 1.99E-01 4.50E-02 7.56E-01 1.43E+00 3.74E-01
T1D-CEL 2.22E-21 6.14E-22 2.32E-01 5.70E-02 7.11E-01 2.06E+00 1.14E-01
T1D-MS 3.51E-02 2.09E-02 5.88E-01 3.50E-01 6.50E-03 -1.47E+00 1.59E-03
RA-CEL 2.16E-25 3.27E-22 3.19E-05 3.88E-02 9.61E-01 1.56E+00 2.48E-01
RA-MS 7.38E-04 2.44E-01 2.26E-03 7.49E-01 3.47E-03 -4.24E-01 1.70E-02
CEL-MS 2.06E-21 1.51E-01 1.16E-20 8.48E-01 1.32E-03 -7.76E-02 1.04E-03
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6q25.3 TAGAP T1D, RA, CEL, MS CEL, MS
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 9.36E-01 4.43E-03 5.82E-02 2.67E-04 7.75E-04 1.13E+00 7.94E-01
T1D-CEL 2.78E-09 1.32E-11 9.83E-01 4.54E-03 1.23E-02 -2.97E+00 2.59E-01
T1D-MS 1.22E-02 3.21E-05 9.77E-01 2.50E-03 8.09E-03 1.76E+00 6.15E-01
RA-CEL 3.44E-08 2.12E-09 9.28E-01 5.71E-02 1.44E-02 -5.23E+00 4.27E-01
RA-MS 1.42E-02 1.03E-03 8.59E-01 6.18E-02 6.43E-02 2.93E+00 1.98E-01
CEL-MS 1.97E-12 1.66E-03 8.56E-11 6.26E-02 9.36E-01 -5.42E-01 4.59E-02
Location Candidate Causal Genes Existing Associations Associations Found
7p14.2 ELMO1 CEL, MS RA, CEL, MS
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 6.45E-01 2.59E-03 3.49E-01 1.39E-03 1.52E-03 1.77E+00 4.25E-01
T1D-CEL 8.95E-10 2.17E-11 9.22E-01 2.18E-02 5.57E-02 2.01E+00 3.00E-01
T1D-MS 3.45E-09 1.37E-10 8.49E-01 3.24E-02 1.18E-01 2.22E+00 3.57E-01
RA-CEL 3.02E-10 1.95E-10 1.99E-01 1.23E-01 6.78E-01 1.32E+00 5.59E-01
RA-MS 1.11E-07 6.71E-08 2.31E-01 1.34E-01 6.35E-01 1.34E+00 5.84E-01
CEL-MS 1.58E-17 1.08E-08 4.89E-11 2.40E-02 9.76E-01 1.01E+00 2.93E-01
Location Candidate Causal Genes Existing Associations Associations Found
7p12.2 IKZF1 MS T1D, MS
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 1.85E-01 8.10E-01 2.17E-04 9.17E-04 3.31E-03 8.08E-01 4.34E-01
T1D-CEL 5.44E-01 4.53E-01 1.38E-03 1.14E-03 1.48E-04 3.27E-01 9.53E-02
T1D-MS 4.52E-03 3.82E-03 2.65E-01 2.19E-01 5.08E-01 1.08E+00 1.96E-01
RA-CEL 9.97E-01 7.78E-04 2.34E-03 1.82E-06 9.76E-07 9.37E-01 1.02E-01
RA-MS 7.11E-03 5.17E-06 9.90E-01 7.02E-04 1.88E-03 1.57E+00 1.57E-01
CEL-MS 1.65E-02 2.82E-05 9.81E-01 1.66E-03 1.14E-03 2.12E+00 1.56E-01
Location Candidate Causal Genes Existing Associations Associations Found
7p12.2 IKZF1, FIGNL1 T1D T1D
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 2.84E-02 9.71E-01 6.51E-06 2.20E-04 2.03E-04 -2.31E-01 2.74E-01
T1D-CEL 2.68E-02 9.72E-01 1.78E-05 6.37E-04 6.46E-04 3.26E-01 3.24E-01
T1D-MS 3.44E-02 9.64E-01 4.57E-05 1.28E-03 5.20E-05 -1.45E-01 1.30E-01
RA-CEL 9.99E-01 2.58E-04 5.93E-04 1.52E-07 1.46E-07 -5.75E-01 4.94E-01
RA-MS 9.98E-01 2.55E-04 1.31E-03 3.30E-07 4.15E-07 1.90E-01 1.98E-01
CEL-MS 9.99E-01 5.51E-04 9.11E-04 5.01E-07 2.03E-07 -1.64E+00 4.11E-01
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10p15.1 IL2RA T1D, RA, MS T1D|MS
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 6.69E-27 6.85E-01 1.69E-27 1.72E-01 1.43E-01 4.27E-01 7.38E-01
T1D-CEL 1.06E-25 8.64E-01 1.65E-26 1.35E-01 1.13E-03 9.41E-02 6.50E-04
T1D-MS 5.84E-33 8.94E-08 6.57E-26 1.00E+00 2.54E-07 4.38E-01 5.04E-09
RA-CEL 6.18E-01 3.18E-01 3.61E-02 1.85E-02 9.32E-03 9.66E+00 1.93E-01
RA-MS 9.79E-08 4.72E-08 5.41E-01 2.58E-01 2.00E-01 2.10E+00 3.93E-01
CEL-MS 2.35E-09 9.60E-10 7.10E-01 2.90E-01 1.52E-04 -6.52E+00 9.38E-03
Location Candidate Causal Genes Existing Associations Associations Found
11q23.3 CXCR5 RA, CEL, MS CEL | MS
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 9.92E-01 1.40E-03 6.75E-03 9.42E-06 1.34E-05 -4.08E-01 4.77E-01
T1D-CEL 1.53E-03 2.31E-06 9.97E-01 1.50E-03 1.20E-04 1.70E+01 2.70E-01
T1D-MS 2.85E-01 7.53E-04 7.12E-01 1.88E-03 1.08E-04 -2.36E+00 2.93E-01
RA-CEL 5.33E-03 7.83E-05 9.57E-01 1.38E-02 2.33E-02 4.14E+00 4.25E-01
RA-MS 2.41E-01 5.59E-03 7.29E-01 1.68E-02 8.02E-03 -1.34E-01 4.88E-01
CEL-MS 4.06E-05 1.70E-01 1.98E-04 8.27E-01 2.61E-03 3.06E-01 2.34E-02
Location Candidate Causal Genes Existing Associations Associations Found
13q32.3 GPR183 T1D, MS T1D | CEL
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 4.70E-02 9.53E-01 3.40E-06 6.71E-05 1.84E-04 -3.51E-01 4.05E-01
T1D-CEL 7.97E-03 3.04E-01 1.75E-02 6.70E-01 3.92E-05 -2.68E-01 1.40E-05
T1D-MS 1.22E-02 8.14E-01 2.50E-03 1.67E-01 4.55E-03 -3.19E-02 4.12E-03
RA-CEL 4.47E-01 2.95E-05 5.53E-01 3.63E-05 2.97E-05 5.29E+00 3.79E-01
RA-MS 8.61E-01 8.06E-05 1.39E-01 1.29E-05 1.04E-05 3.56E+01 4.66E-01
CEL-MS 3.57E-01 4.97E-01 5.87E-02 8.16E-02 6.01E-03 1.20E-02 1.33E-02
Location Candidate Causal Genes Existing Associations Associations Found
15q25.1 CTSH T1D, MS T1D | CEL
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 3.35E-07 1.00E+00 1.14E-10 3.38E-04 1.50E-04 1.00E-01 4.55E-01
T1D-CEL 2.99E-08 1.83E-01 3.00E-09 1.02E-02 8.06E-01 -7.55E-01 4.33E-01
T1D-MS 1.36E-07 9.46E-01 6.47E-09 4.51E-02 9.03E-03 -3.51E-02 4.36E-02
RA-CEL 8.94E-01 1.98E-04 1.06E-01 2.33E-05 1.60E-05 -2.43E+01 3.17E-01
RA-MS 9.31E-01 1.56E-04 6.93E-02 1.16E-05 5.61E-06 5.45E+00 4.24E-01
CEL-MS 6.09E-01 3.49E-01 2.43E-02 1.38E-02 3.53E-03 2.05E-01 9.44E-02
180 Results from Colocalization Analysis for Regions Mentioned in Chapter 2
Location Candidate Causal Genes Existing Associations Associations Found
16p13.13 DEXI, SOCS1 T1D, CEL, MS T1D, MS | CEL
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 3.92E-07 9.99E-01 3.77E-10 9.60E-04 7.42E-05 -4.26E-02 4.02E-01
T1D-CEL 1.36E-10 4.88E-01 1.43E-10 5.12E-01 6.66E-05 -3.75E-01 1.85E-03
T1D-MS 6.28E-15 7.85E-06 3.29E-10 4.05E-01 5.95E-01 8.21E-01 2.47E-01
RA-CEL 4.65E-01 3.48E-04 5.34E-01 3.99E-04 3.16E-05 3.83E+00 1.39E-01
RA-MS 3.86E-05 2.38E-08 9.99E-01 6.17E-04 5.30E-05 5.56E+00 2.18E-01
CEL-MS 4.53E-06 2.58E-06 6.37E-01 3.63E-01 1.93E-04 -1.48E+00 3.76E-03
Location Candidate Causal Genes Existing Associations Associations Found
18p11.21 PTPN2 T1D, CEL T1D | CEL
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 1.43E-10 9.99E-01 8.81E-14 6.10E-04 6.33E-04 4.54E-01 2.62E-02
T1D-CEL 1.83E-11 2.10E-02 5.11E-10 5.83E-01 3.96E-01 6.18E-01 8.90E-01
T1D-MS 2.93E-09 1.00E+00 4.79E-13 1.63E-04 6.45E-05 -2.38E-03 7.84E-01
RA-CEL 2.41E-02 1.18E-04 9.71E-01 4.78E-03 1.53E-04 1.41E+00 1.34E-02
RA-MS 9.99E-01 6.40E-04 8.46E-05 5.34E-08 7.96E-08 2.03E-01 3.24E-01
CEL-MS 1.76E-02 9.82E-01 1.99E-06 1.11E-04 5.60E-05 5.64E-02 2.30E-01
Location Candidate Causal Genes Existing Associations Associations Found
19p13.2 ICAM1, ICAM3, TYK2 T1D, RA, MS T1D, RA, CEL, MS
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 2.63E-14 2.11E-07 1.21E-09 8.99E-146 1.00E+00 1.00E+00 8.22E-01
T1D-CEL 7.62E-09 1.28E-01 3.13E-08 5.25E-01 3.47E-01 8.84E-01 3.16E-03
T1D-MS 2.75E-11 1.50E-03 2.72E-10 5.22E-03 9.93E-01 6.57E-01 5.08E-01
RA-CEL 1.26E-06 1.25E-01 4.72E-06 4.69E-01 4.05E-01 8.91E-01 6.93E-02
RA-MS 7.23E-09 1.54E-03 7.36E-08 6.01E-03 9.92E-01 7.18E-01 4.78E-01
CEL-MS 7.51E-03 3.76E-02 7.61E-02 3.77E-01 5.01E-01 5.06E-01 2.80E-03
Location Candidate Causal Genes Existing Associations Associations Found
21q22.3 UBASH3A T1D, RA, CEL T1D | RA | CEL
Analysis PP.H0 PP.H1 PP.H2 PP.H3 PP.H4 eta.hat P-Value
T1D-RA 1.12E-07 2.00E-01 4.33E-07 7.70E-01 3.00E-02 5.13E-01 2.24E-02
T1D-CEL 1.77E-10 7.78E-04 2.25E-07 9.88E-01 1.11E-02 8.16E-01 6.93E-03
T1D-MS 2.20E-07 1.00E+00 2.70E-11 1.22E-04 7.31E-05 1.26E-03 1.71E-01
RA-CEL 3.49E-04 8.43E-04 2.87E-01 6.93E-01 1.92E-02 1.53E+00 4.80E-02
RA-MS 4.29E-01 5.71E-01 3.79E-05 4.99E-05 6.12E-05 2.27E-01 4.84E-01
CEL-MS 2.37E-04 1.00E+00 1.83E-08 7.69E-05 3.51E-05 -1.96E-02 3.66E-01
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